Download SHORT CV - Diabetes Research Institute

JAY S. SKYLER, MD, MACP
CURRICULUM VITAE
Professor of Medicine, Pediatrics & Psychology
Division of Endocrinology, Diabetes, & Metabolism – Department of Medicine
University of Miami Leonard M. Miller School of Medicine
Deputy Director for Clinical Research and Academic Programs, Diabetes Research Institute, University of Miami
Member, Interdisciplinary Stem Cell Institute, University of Miami
Adjunct Professor of Pediatrics, Barbara Davis Center for Childhood Diabetes, University of Colorado
BIOGRAPHICAL INFORMATION
1. PERSONAL
a.
b.
c.
d.
e.
f.
g.
Date:
Full Name:
Home Phone:
Office Phone:
Fax Numbers:
E-Mail:
Office Address:
h.
Office Location:
i.
Home Address:
j.
k.
l.
m.
n.
o.
p.
Status:
Current Rank:
Citizenship:
Health:
Born:
Marital Status:
Children:
September 2015
Jay Samuel Skyler
(305) 361-8035
(305) 243-6146
(305) 243-4484; (425) 988-9818
[email protected]
University of Miami Diabetes Research Institute
P.O. Box 016960 (D-110)
Miami, Florida 33101-6960
Diabetes Research Institute, Suite 3061
1450 N.W. 10th Avenue
Miami, Florida 33136-1011
445 Grand Bay Drive #1206
Key Biscayne FL 33149-1910
Full-time Tenured
Professor of Medicine, Pediatrics & Psychology
United States of America
Excellent
February 14, 1947 - Philadelphia Pennsylvania
Married – Mercedes Armas Bach – 8/9/03
Jennifer Anne Skyler, Born: 2/12/81
Alexandra Regina Bach, Born: 4/23/81
Marcus Richard Bach, Born 8/22/83
2. EDUCATION
Primary and Secondary Schools, Philadelphia, Pennsylvania
B.A., Central High School: June 1964 (222nd Graduating Class)
B.S. in Science (Magna Cum Laude), Pennsylvania State University: September 1967
(Cooperative Five-Year Program in Medicine, Pennsylvania State University and Jefferson Medical College)
M.D., Jefferson Medical College: June 1969
Visiting Student, Department of Cardiology, University of Glasgow at the Royal Infirmary, Glasgow, Scotland:
Summer 1967
Alliance for Academic Internal Medicine Executive Leadership Program,
Cambridge, Massachusetts: Summer 2003
Harvard Business School Executive Education Program,
Making Corporate Boards More Effective: Winter 2006
Stanford Law School
Directors Course: June 2009
Jay S. Skyler
Page 2
Curriculum Vitae
3. POST-DOCTORAL EDUCATION
Intern and Resident, Department of Medicine (James B. Wyngaarden, M.D., Chairman), Duke University Medical
Center: July 1969-June 1971
Fellow in Endocrinology and Metabolism (Harold E. Lebovitz, M.D., Division Chief), Department of Medicine,
Duke University Medical Center: February 1971-June 1973
Fellow in Medicine, Medical Research Training Program (Nicholas M. Kredich, M.D., Program Director), in the
Laboratory of Molecular Animal Virology (Hans J. Zweerink, Ph.D., Laboratory Director), Department of
Microbiology and Immunology (Wolfgang K. Joklik, Ph.D., Chairman), Duke University: September 1971September 1972
Staff Associate, Section on Biochemical Pharmacology (Walter M. Lovenberg, Ph.D., Laboratory Chief),
Hypertension-Endocrine Branch (Frederic C. Bartter, M.D., Branch Chief), National Heart and Lung Institute
(Donald S. Fredrickson, M.D., Scientific Director), National Institutes of Health: July 1973-June 1975
4. BOARD CERTIFICATION AND LICENSURES
National Board of Medical Examiners - Diplomate: July 1, 1970
American Board of Internal Medicine - Diplomate, Internal Medicine: June 21, 1972
American Board of Internal Medicine - Diplomate, Endocrinology and Metabolism: October 6, 1973
Pennsylvania Board of Medical Examiners (Inactive)
North Carolina Board of Medical Examiners (Inactive)
District of Columbia Board of Medical Examiners (Inactive)
Florida Board of Medical Examiners
5. PROFESSIONAL EXPERIENCES
Academic Appointments
Associate in Medicine, Duke University School of Medicine: July 1972-August 1975
Associate in Community Health Sciences, Duke University School of Medicine: September 1972-June 1975
(**Leave of Absence from Duke University: July 1973-June 1975)
Clinical Investigator, Hypertension-Endocrine Branch, National Heart and Lung Institute, National Institutes of
Health: July 1973-June 1975
Attending Physician, Clinical Center, National Institutes of Health: July 1973-June 1975
Visiting Lecturer, Department of Medicine, George Washington University Medical Center: November 1973-June
1974
Assistant Clinical Professor of Medicine, George Washington University School of Medicine and Health Sciences:
June 1974-June 1975
Assistant Professor of Medicine, Duke University School of Medicine: September 1975-October 1976
Associate Professor of Medicine, University of Miami School of Medicine: November 1976-May 1985
Associate Professor of Pediatrics, University of Miami School of Medicine: November 1976-May 1986
Professor of Medicine, University of Miami School of Medicine: June 1985-Present
Professor of Pediatrics, University of Miami School of Medicine: June 1986-Present
Professor of Psychology, University of Miami College of Arts and Sciences: October 1986-Present
Professor, Graduate School, University of Miami: February 1996-Present
Adjunct Professor of Pediatrics, Barbara Davis Center for Childhood Diabetes, University of Colorado at Denver:
July 2009-Present
Administrative Appointments
Medical Director, Physician's Associate Program, Duke University: July 1972-June 1973
Director, Diabetes and Nutrition Clinics and Education Program, Division of Endocrinology and Metabolism,
Department of Medicine, Duke University: July 1975-October 1976
Associate Director, Diabetes Research Institute, University of Miami School of Medicine: November 1976November 1986
Director, Diabetes/Metabolic Unit, Division of Endocrinology and Metabolism, Department of Medicine, University
of Miami School of Medicine: January 1977-November 1986
Jay S. Skyler
Page 3
Curriculum Vitae
Project Director, University of Miami/Southeastern Florida Regional Diabetes Program: September 1979-November
1986
Co-Director, NHLBI Behavioral Medicine Research Center, University of Miami: July 1986-June 2009
Chief, Section of Behavioral Internal Medicine, Division of Endocrinology, University of Miami School of
Medicine: July 1987-March 2000
Director, Operations Coordinating Center, and Study Chairman, NIDDK Diabetes Prevention Trial for Type 1
Diabetes (DPT-1): August 1993-August 2001
Chairman, NIDDK Diabetes Prevention Trial for Type 1 Diabetes (DPT-1): August 1993-August 2001
Chairman, NIDDK Type 1 Diabetes TrialNet Study Group: August 2001-June 2015
Director, Division of Endocrinology, Diabetes, & Metabolism, Department of Medicine, University of Miami School
of Medicine: July 2000-August 2004
Program Director, General Clinical Research Center, University of Miami: August 2000-March 2006
Associate Director for Academic Programs, Diabetes Research Institute, University of Miami School of Medicine:
April 2001-June 2011
Area Leader, Immunomodulation & Tolerance, Diabetes Research Institute, University of Miami School of
Medicine: March 2008-June 2011
Deputy Director for Clinical Research and Academic Programs, Diabetes Research Institute, University of Miami
School of Medicine: June 2011-Present
Hospital Appointments
Attending Physician, Clinical Center, National Institutes of Health: July 1973-June 1975
Attending Physician, Duke University Medical Center: July 1975-October 1976
Consulting Physician, Durham Veterans Administration Medical Center: July 1975-October 1976
Attending Physician, University of Miami/Jackson Memorial Medical Center: November 1976 - Present
Attending Physician, University of Miami Hospital and Clinics/Sylvester Cancer Center: November 1976 - Present
Consulting Physician, Miami Veterans Affairs Medical Center: November 1976 - Present
Consulting Physician, Mount Sinai Medical Center of Miami Beach: August 1983-July 2001
Attending Physician, University of Miami Hospital: March 2008-Present
Military Service
Assistant Surgeon (Reserve Corps), United States Public Health Service: October 1969-June 1973; July 1975-June
1980
Surgeon, United States Public Health Service: July 1973-June 1975
6. GRANTS RECEIVED
Active
“Mesenchymal Precursor Cell Therapy in Type 2 Diabetes” (JS Skyler, PI). Mesoblast, Ltd. Project Period –
6/13/12-6/12/16.
“Prospective, Multicenter, Open-Label, First-in-Human Phase 1/2 Study with Two Cohorts to Evaluate the Safety,
Tolerability, and Efficacy of Various Doses of VC-01TM Combination Product in Subjects with Type 1 Diabetes
Mellitus” (JS Skyler, PI). Viacyte Inc. Project Period – 10/1/15-12/31/17
Major Previous Grant Support
“Type 1 Diabetes TrialNet Chairman’s Office” (JS Skyler, PI). NIDDK, NIH. U01. Project Period – 9/1/01 –
6/30/15
“Diabetes Prevention Trial for Type 1 Diabetes (DPT-1)” (Operations Coordinating Center for Multi-Center
National Clinical Trial) (JS Skyler, PI). NIDDK, NIH. U01. Project Period - 9/1/93-8/31/03.
“General Clinical Research Center” (John Clarkson, P.I.; Jay S. Skyler, Program Director). NCRR, NIH. M01.
Project Period – 7/1/02 – 3/31/06
Jay S. Skyler
Page 4
Curriculum Vitae
“Diabetes Mellitus: Pathogenesis and Immune Intervention” (JS Skyler, PI). NIDDK, NIH. R01. Project Period 9/20/85-8/31/89.
“Clinical Islet Transplantation Center” (C Ricordi, PI; JS Skyler, Co-Investigator). NIDDK, NIH. U01. Project
Period – 9/30/04-9/29/09
“Biobehavioral Bases of Coronary Heart Disease Risk and Management” (N Schneiderman, PI; JS Skyler, Co-PI &
Core Leader). NHLBI, NIH. P01. Project Period 7/1/96-6/30/01. [Continuation of Program Project
“Psychophysiology of Cardiovascular Reactivity”] (Program Project Grant), (N Schneiderman, PI; JS Skyler, CoPI). NHLBI, NIH. Project Period 7/1/86-6/30/96. Subprojects: “Diabetes: Reactivity, Stress, Glycemia, & Blood
Pressure” (JS Skyler, Project Leader) 7/1/86-6/30/91. “Insulin Sensitivity, Blood Pressure, and Glucose Tolerance”
(JS Skyler, Project Leader) 7/1/91-6/30/96. Co-Investigator, 7/1/97-7/31/12.
“Biobehavior, Ethnicity, Hormones, & Blood Pressure” (RJ Prineas, PI; JS Skyler, Investigator). NHLBI, NIH.
R01. Project Period 12/1/90-11/30/95
“Stress and Immune Function in Control and Complications of Diabetes” (MW Linn, PI; JS Skyler, Co-PI). NIMH.
R01. Project Period - 7/1/80-6/30/85.
“Dynamic Autonomic Assessment in Diabetic Neuropathy” (BE Hurwitz, PI; JS Skyler, Co-PI). NHLBI, NIH. R01.
Project Period 9/1/95-8/31/99.
“Diabetes, Metabolism, and Endocrinology Training Grant” (DH Mintz, PI; JS Skyler, Co-PI). NIADDK, NIH.
T32. Project Period - 9/01/79-6/30/87.
“Behavioral Medicine Research in Cardiovascular Disease Training Grant” (N Schneiderman, PI; JS Skyler,
Investigator). NHLBI, NIH. T32. Project Period 7/1/84-5/31/09.
“Drug abuse, HIV, Selenium Supplementation, & Cardiovascular Disease Risk” (B Hurwitz, PI; JS Skyler, CoInvestigator). NIDA. R01. Project Period - 7/01/00-6/30/06
“HAART, & Cardiovascular Disease Risk” (B Hurwitz, PI; JS Skyler, Co-Investigator). NIDA. R01. Project
Period - 7/01/00 to 6/30/06
“University of Miami Diabetes Education, Treatment and Research Center” (JS Skyler, PI). Florida Department of
Health and Rehabilitative Services. Project Period - 9/1/79-6/30/87.
“Southeastern Florida Regional Diabetes Program for Children and Youth” (JS Skyler, PI). Florida Department of
Health and Rehabilitative Services. Project Period 7/1/77-6/30/87.
“Pharmacokinetics of Peritoneal Insulin and Implantable Insulin Delivery Systems” (JS Skyler, PI). Cordis Research
Corporation. Project Period 1/1/82-6/30/84.
“Tolrestat Use in Diabetic Neuropathy” (JS Skyler, PI). Ayerst Laboratories. Project Period 4/1/83-12/31/85.
“Pharmacokinetics of Long-Acting Insulin” (JS Skyler, PI). Lilly Research Laboratories and Novo Research
Institute. Project Period - 9/1/83-12/31/85.
“Insulin in Type II Diabetes” (JS Skyler, PI). Lilly Research Laboratories. Project Period - 1/1/84-2/28/87.
“Cyclosporine in Type I Diabetes - A Controlled Clinical Trial” (JS Skyler, PI). Sandoz Research Institute. Project
Period 2/1/84-7/31/87.
“Studies of Captopril in Diabetic Patients with Proteinuria or Microalbuminuria” (JS Skyler, PI). Squibb Institute
for Research. Project Period - 11/01/87-12/30/90.
“Immune Intervention in Type I Diabetes with XomaZyme-H65” (JS Skyler, PI). Xoma Corporation. Project Period
- 4/01/89-6/30/90.
Jay S. Skyler
Page 5
Curriculum Vitae
“Studies with a New Insulin Sensitizer in Type II Diabetes Mellitus” (JS Skyler, PI). Boehringer Mannheim
Pharmaceuticals. Project Period - 9/01/89-12/30/90.
“Dose Timing Study of CI-991, An Insulin Sensitizer” (JS Skyler, PI). Parke-Davis Pharmaceutical Research.
Project Period - 1/01/92-05/31/92.
“Human Insulin Analog: Premeal Therapy in Type I Diabetes” (JS Skyler, PI). Eli Lilly & Company. Project Period
- 1/01/93-12/31/93.
“Acetyl-L-Carnitine in Diabetic Peripheral Neuropathy” (JS Skyler, PI). Hoffman-LaRoche. Project Period 10/1/93-3/31/96.
“Effects of BTS 67 582 in Patients with Type II Diabetes Uncontrolled on Diet Therapy”
(JB Marks, PI; JS Skyler, Co-PI). Boots Pharmaceuticals. Project Period - 10/1/94-9/30/96.
“Effects of Tolrestat on Peripheral Nerve Morphology and Biochemistry in Patients with Diabetic Peripheral
Neuropathy” (JS Skyler, PI). Wyeth-Ayerst Clinical Research. Project Period - 6/1/91-12/31/96.
“The Effects of Inhaled Insulin in Patients with Diabetes Mellitus” (JS Skyler, PI; JB Marks, Co-PI). Pfizer Central
Research. Project Period - 10/1/96-12/31/08.
“Viaject Insulin in Type 1 and Type 2 Diabetes Mellitus” (JS Skyler, PI; JB Marks & C Hernandez-Cassis, Co-PIs).
Biodel, Inc. Project Period – 5/1/07-6/30/08.
“Prandial Insulin-PH20 NP Compared to Insulin Lispro in Type 1 Diabetes” (JS Skyler, PI). Halozyme
Therapeutics, Inc. Project Period - 7/1/09-6/30/10.
“Prandial Insulin-PH20 Type 1 and Type 2 Diabetes” (JS Skyler, PI). Halozyme Therapeutics, Inc. Project Period
- 7/1/10-6/25/14.
“BHT-3021 in Type 1 Diabetes Mellitus” (JS Skyler, PI; JB Marks, Co-PI). Bayhill Therapeutics, Inc. Project
Period – 7/1/07-12/30/10.
“Mesenchymal Human Stem Cells in Type 1 Diabetes Mellitus” (JS Skyler, PI). Osiris Therapeutics, Inc. Project
Period – 7/1/08-12/30/10.
“Assessment of All in One Blood Glucose Device – Pogo” (JS Skyler, PI). Intuity Medical. Project Period - 7/1/106/30/11.
“The Effects of Recombinant Human IGF-1 (rhIGF-1) in Patients with Diabetes Mellitus” (JS Skyler, PI; JB Marks,
Co-PI). Genentech, Inc. Project Period - 10/1/96-9/30/97.
“Studies with Doxazosin and Insulin Resistance” (JS Skyler, PI). Roerig Division, Pfizer Pharmaceuticals. Project
Period - 4/1/92-7/31/98.
“Aminoguanidine in Diabetic Nephropathy” (JS Skyler, PI). Marion Merrell Dow and Alteon Corporation. Project
Period - 10/1/93-12/31/98.
“Effects of Zopolrestat in Patients with Diabetic Peripheral Neuropathy” (JS Skyler, PI). Pfizer Central Research.
Project Period - 3/1/96-10/31/99.
“Effects of Repaglinide on First Phase Insulin Secretion” (JS Skyler, PI). Novo-Nordisk Pharmaceuticals. Project
Period - 9/1/98-12/31/99.
“Effects of Insulin Aspart in Continuous Subcutaneous Insulin Infusion in Types 1 & 2 Diabetes” (JS Skyler, PI; JB
Marks, Co-PI). Novo-Nordisk Pharmaceuticals. Project Period - 3/1/99-3/31/00.
Jay S. Skyler
Page 6
Curriculum Vitae
“The Effects of Trans-Dermal Insulin in Human Subjects” (JS Skyler, PI; JB Marks, Co-PI). Vector Medical.
Project Period - 11/1/99-12/31/00.
“Protein Kinase C  Inhibitor – Studies in Diabetic Retinopathy & Diabetic Macular Edema” (WE Smiddy, PI; JS
Skyler, Co-PI). Lilly Research Laboratories. Project Period - 5/1/98-9/30/02.
7. DEPARTMENTAL ADMINISTRATIVE AND COMMITTEE RESPONSIBILITIES
Director, Diabetes/Metabolic Unit, University of Miami Hospital & Clinics: 1977-1986
Chief, Endocrinology & Metabolism Section, Department of Medicine, Jackson Memorial Hospital: 1979-1981
Director, Division of Endocrinology Diabetes & Metabolism: 2000-2004
Finance Committee: 1979-1981
Patient Care Committee: 1979-1980
Internship Selection Committee: 1979-1981
Committee on Clinical Competence: 1980-1982, 1985-1986
Department of Medicine Promotions & Tenure Advisory Committee: 2002-2004
Research Task Force: 2004-2005
8. EXTRA-DEPARTMENTAL APPOINTMENTS & RESPONSIBILITIES
University of Miami School of Medicine
Sophomore Promotions Committee: 1977-1981
Mechanisms of Disease Coordinator Committee: 1977-1981, 1988-1989
Governance Committee, Professional Income Plan: 1977-1979
Governing Board, Professional Income Plan: 1979-1981
Committee for Honors Program in Medical Education (B.S.-M.D.): 1985-1988
Ad Hoc Committee on Faculty Consulting Policy: 1987
General Clinical Research Center (GCRC) Advisory Committee:
Member: 1990-1996; Chairman: 1995-1996
Chairman, GCRC Protocol Review Subcommittee: 1990-1994
Chairman, Faculty Council Committee on Mission of the School of Medicine: 1993
Member, Biotechnology Development Committee: 1993
Member, Clinical Research Advancement Group: 1997-1998
Member, Curriculum Revision Subcommittee on Endocrinology & Reproduction: 1999-2001
Program Director, General Clinical Research Center: 2000-2006
Member, Committee on Clinical Research Development & Health Outcomes: 2000-2001
Member, Search Committee for Chair, Department of Pediatrics: 2001-2003
Member, Faculty Council Research Task Force: 2001-2002
Chairman, Search Committee for Chief of Medical Services at Miami Veterans Affairs Medical Service and
Vice-Chairman, Department of Medicine: 2002-2003
Chairman, Search Committee for Director, Center for Research Design & Clinical Outcomes: 2003-2004
Center Director, Federation of Clinical Immunology Societies Center of Excellence at the University of Miami:
2004-2007
Chairman, Clinical Research Institute Operations Planning Committee: 2004-2006
Member, Executive Research Council: 2004-2006
Member, Search Committee for Chief, Division of Cardiology: 2005-2006
Chairman, Lawrence M. Fishman Endocrinology Visiting Professorship Committee: 2004-2010
Member, Center on Aging Assessment Committee: 2008
Member, Interdisciplinary Stem Cell Institute, University of Miami: 2012-Present
Jackson Memorial Hospital
Clinical Nutrition Committee: 1977-1979
Chairman, Diabetes Care Committee: 1979-1982
Diabetic Ketoacidosis Audit Committee: 1979
Chief, Endocrinology Diabetes & Metabolism: 2000-2004
Jay S. Skyler
Page 7
Curriculum Vitae
University of Miami Hospitals and Clinics
Fire and Safety Committee: 1979-1981
Executive Committee, Medical Staff: 1979-1981
Pharmacy & Therapeutics Committee: 1986-2002
Vice-Chairman: 1988-2002
University of Miami Diabetes Research Institute
Associate Director: November 1976-November 1986
Investigator: June 2000-Present
Associate Director for Academic Programs: April 2001-June 2011
Area Leader, Immunomodulation & Tolerance: 2008-June 2011
Deputy Director for Clinical Research & Academic Programs: June 2011-Present
University of Miami
Lowe Art Museum Advisory Committee: 1980-1982
Member, Patent and Copyright Committee: 2013-2015
University of Miami/Miami Veterans Administration Medical Center
Consultant Physician: 1977-Present
Geriatric Research, Education, & Clinical Center
Affiliate Member: 1992-Present
Clinical Protocol Development Committee: 1992-2000
9. HONORS AND AWARDS, CONSULTANTSHIPS, LECTURES, ETC.
a. HONORS AND AWARDS
Philadelphia Board of Education Scholarship: 1964-1968
Phi Delta Epsilon Student Scholarship Award
Jefferson Medical College: 1968
Hobart Amory Hare Honorary Medical Society
Jefferson Medical College: 1967-1969
President: 1968-1969
Solomon Solis-Cohen Memorial Prize for Excellence in Clinical Medicine
Jefferson Medical College: 1969
Lowell Ashton Erf Prize for Seriousness of Purpose, Aptitude, and Ability in Medicine
Jefferson Medical College: Honorable Mention: 1969
Honorary Physician's Associate - In Recognition of Distinguished Teaching
Duke University Medical Center: 1973
Award of Special Distinction for Outstanding Dedication, Personal Commitment and Personal Service
American Diabetes Association, Florida Affiliate: 1979
Invited Lecturer
International Diabetes Federation Eighth Congress, Vienna, Austria: 1979
Resolution of Gratitude for the Creation of DIABETES CARE
Board of Directors, American Diabetes Association: 1982
Invited Lecturer
International Diabetes Federation Ninth Congress, Nairobi, Kenya: 1982
Honorary Life Member
South African Society for Endocrinology, Metabolism and Diabetes: 1982
Fellow - All India Institute of Diabetes: 1983
Achievement Award “for Distinguished Contributions to the Knowledge of Diabetes Mellitus”
American Society of Contemporary Medicine & Surgery: 1985
First “Leon Mow Visiting Professor”, Lions International Diabetes Institute & Monash University, Melbourne,
Australia: July 1986
Plenary Lecturer & Medal Recipient
International Diabetes Federation Thirteenth Congress, Sydney, Australia: 1988
Twentieth Reunion Lecturer
Jefferson Medical College: 1989
Jay S. Skyler
Page 8
Curriculum Vitae
Celal Oker Memorial Lecturer
Turkish Diabetes Association, Istanbul, Turkey: 1991
Swedish Diabetes Foundation Honorary Lecturer
Swedish Medical Association, Stockholm, Sweden: 1991
Banting Medal for Service
American Diabetes Association: 1992
Novo-Nordisk Lecturer
Australian Diabetes Society: 1992
Plenary Lecturer
Asociacion Latinoamericana de Diabetes: 1992 (Mar del Plata, Argentina), 1998 (Cartegena, Columbia),
2001 (Punta de este, Uruguay), 2010 (Santiago, Chile), 2013 (Cancun, Mexico)
Commencement Speaker
Physicians Assistant Program, University of Oklahoma: 1994
Plenary Lecturer & Plaque Recipient
International Diabetes Federation Fifteenth Congress, Kobe, Japan: 1994
Honorary Plenary Lecturer
Norwegian Diabetes Association: 1995
Best Doctors in America - First Edition 1992-1993; Second Edition 1994-1995; Continuously through 2015
Meritorious Research Award
American Diabetes Association - Florida Affiliate: 1996
Invited Lecturer
International Diabetes Federation Fourteenth Congress, Helsinki, Finland: 1997
Invited Lecturer
Israel Diabetes Association, Tel Aviv: 1998
Glassman Memorial Lecturer
Hadassah Medical Center, Hebrew University, Jerusalem, Israel: 1998
First Annual Dean’s Senior Clinical Research Award
University of Miami School of Medicine: 1999
Invited Lecturer
German Diabetes Association, Munich: 2000
Invited Lecturer
Canadian Diabetes Association, Halifax, Nova Scotia: 2000
Invited Lecturer
International Diabetes Federation Fifteenth Congress, Mexico City: 2000
America’s Top Doctors - Listed 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012,
2013, 2014, 2015
Eric Reiss Memorial Lecturer
University of Miami School of Medicine: 2003
Provost’s Award for Scholarly Activity
University of Miami: 2003
Simon Gratz Prize for Jefferson Medical College Alumni in recognition of “outstanding contributions to medical
research having real practical value to the care of patients”
Jefferson Medical College: 2003
Invited Lecturer
International Diabetes Federation Sixteenth Congress, Paris: 2003
Julio Santiago Memorial Lecturer
Washington University of St. Louis: 2003
Invited Lecturer
Turkish Diabetes Association – 40th National Congress, Antalya, Turkey: 2004
Marvin Levin Visiting Professor/Lecturer
Washington University of St. Louis: 2004
Master of the American College of Physicians (MACP): 2005
Invited Lecturer, Diabetes India, Jaipur, India: 2005
David Rabin Memorial Lecturer
Vanderbilt University: 2005
Eric Reiss Memorial Lecturer
University of Miami School of Medicine: 2006
Eastern-Atlantic Student Research Forum Awards Banquet Speaker: 2006
Jay S. Skyler
Page 9
Curriculum Vitae
Invited Lecturer
Opening of Clinical Research Center at Malmo, Lund University, Sweden: 2006
Invited Lecturer
International Diabetes Federation 17th Congress, Cape Town, South Africa: 2006
Who's Who in Science and Medicine: 2007-Present
Hall of Fame, Physician Assistant Program
Duke University Medical Center: 2008
Keynote Lecturer
American Association of Diabetes Educators, Atlanta, Georgia: 2009
Establishment of the Jay S. Skyler Visiting Professorship in Diabetes
University of Miami Miller School of Medicine: 2009
John Ensinck Visiting Professor
University of Washington, Seattle: October 2010
Donnell D. Etzwiler Memorial Lecturer
International Diabetes Center, Minneapolis: April 2013
Invited Speaker
Joslin Diabetes Center/Harvard Medical School Symposium – Challenges and Opportunities in Type 1
Diabetes Research: May 2013
Invited Lecturer
International Diabetes Federation 20th Congress, Melbourne, Australia: 2013
First George Eisenbarth Memorial Lecturer
Immunology of Diabetes Society, Lorne, Australia: December 2013
2014 Distinction in Endocrinology Award
American College of Endocrinology: May 2014
Mildred “Barrie” Friedman Memorial Lecturer
State University of New York Downstate Medical Center: April 2015
2015 Distinguished Faculty Scholar Award
Faculty Senate, University of Miami: April 2015
2015 JDRF Mary Tyler Moore and S. Robert Levine Excellence in Clinical Research Award
Juvenile Diabetes Research Foundation, New York: September 2015
Brownlee Lectureship
Harvard Medical School Longwood Campus/Joslin Diabetes Center: December 2015
b. EXAMINING BOARD MEMBERSHIPS
American Board of Internal Medicine
Subspecialty Board on Endocrinology and Metabolism
Member: 1985-1991
Chairman, Subcommittee on Assessment of Competency in Diabetes: 1987-1988
Subspecialty Board on Endocrinology Diabetes and Metabolism
Chairman, Committee on Re-certification (Self Evaluation Process): 1992-1995
c. SOCIETY MEMBERSHIPS AND OFFICES
Academy of Behavioral Medicine Research (Fellow)
American Association of Clinical Endocrinologists (AACE)
American College of Clinical Pharmacology (Fellow)
American College of Physicians (Master)
Delegate, Council on Subspecialty Societies: 1993-1999
Chair, Council on Subspecialty Societies: 1996-1999
Member, Board of Regents: 1996-1999
Chair, Research Center Advisory Committee: 1997-1999
Member, Subspecialist/Generalist Interface Oversight Group: 1997-1999
Master of the American College of Physicians (MACP): 2005
American Diabetes Association
Board of Directors: 1978-1984, 1989-1993
Executive Committee: 1989-1992
Jay S. Skyler
Page 10
Curriculum Vitae
Vice President: 1989-1990
President-Elect: 1990-1991
President: 1991-1992
American Federation of Medical Research
(formerly American Federation of Clinical Research)
American Society of Hypertension
Association of Subspecialty Professors
British Diabetic Association / Diabetes UK
Council of Biology Editors / Council of Science Editors
Endocrine Society
European Association for the Study of Diabetes
Federation of American Societies for Experimental Biology
Federation of Clinical Immunology Societies (FOCiS)
Council, Centers of Excellence: 2003-2006
Immune Tolerance Network
Special Member, Network Steering Committee: 2002-2008
Member, Network Steering Committee: 2008-2014
Immunology of Diabetes Society
Councilor: 1999-2001
International Diabetes Federation
Member 1977
Life Member 1990
Special Consultant to the President: 1982
Organizing Committee, 14th Congress (June 1991)
Governing Council: 1989-2000
Executive Board: 1991-2000
Financial Planning Task Force: 1992-1993
Vice-President: 1994-2000
International Diabetes Immunotherapy Group
Executive Committee: 1986-1990, 1993-2001
President-Elect: 1996-1999
President: 1999-2001
International Society of Pediatric & Adolescent Diabetes
(formerly International Study Group for Diabetes in Children & Adolescents)
New York Academy of Sciences
Society of Behavioral Medicine (Fellow)
Society of Clinical Trials
Society of the Sigma Xi
Southern Society for Clinical Investigation
Councilor: 1989-1994
Chairman, Publications Committee: 1990-1992
President-Elect: 1991-1992
President: 1992-1993
d. EDITORIAL RESPONSIBILITIES
DIABETES CARE (A Publication of the American Diabetes Association)
Founding Editor-in-Chief: 1977-1982
Advisory Editor: 1983-1987
Associate Editor, DIABETES CARE REVIEWS: 1990-1992
Associate Editor for Reviews: 1999-2001
AMERICAN JOURNAL OF MEDICAL SCIENCES
Editorial Board: 1990-2002
AMERICAN JOURNAL OF MEDICINE
Board of Consulting Editors: 1981-1986
CANADIAN JOURNAL OF DIABETES CARE
Editorial Board: 1994-1997
Jay S. Skyler
Page 11
Curriculum Vitae
CLINICAL DIABETES (A Publication of the American Diabetes Association)
Editorial Board: 1983-1986
CURRENT DIABETES REPORTS
Editorial Board: 2012-Present
DIABETES METABOLISM REVIEWS
Board of Consulting Editors: 1984-1998
DIABETES METABOLISM RESEARCH & REVIEWS (Successor to Diabetes Metabolism Reviews)
Board of Consulting Editors: 1999-Present
DIABETES, NUTRITION, & METABOLISM: CLINICAL & EXPERIMENTAL
Associate Editor: 1987-1993
Editorial Board: 1987-2004
DIABETES, OBESITY AND METABOLISM
Editorial Board: 1998-Present
DIABETES RESEARCH AND CLINICAL PRACTICE (Journal of the International Diabetes Federation)
Editorial Board: 1993-2014
Regional Editor, Western Hemisphere: 1996-2005
DIABETES REVIEWS (A Publication of the American Diabetes Association)
Associate Editor: 1993-1997
Editor: 1998-1999
DIABETES SPECTRUM (A Publication of the American Diabetes Association)
Editorial Board: 1987-1990
DIABETES TECHNOLOGY & THERAPEUTICS
Associate Editor: 2006-2009
Senior Editor: 2009-Present
DIABETES & METABOLIC SYNDROME: CLINICAL RESEARCH & REVIEWS
Associate Editor: 2005-2014
DIABETIC MEDICINE (Journal of the British Diabetic Association)
Editorial Board: 1990-2007
DIABETOLOGIA (Journal of the European Association for the Study of Diabetes)
Advisory Board: 2005-2010
EXCERPTA MEDICA/CORE JOURNALS IN CLINICAL ENDOCRINOLOGY
Editorial Advisory Committee: 1982-1987
EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM
Editorial Board: 2006-2010
INTERNATIONAL DIABETES FEDERATION BULLETIN
Editorial Board: 1983-1985
INTERNATIONAL DIABETES MONITOR
Scientific Editor: 1989-2010
JOURNAL OF DIABETES
Editorial Board: 2008-Present
JOURNAL OF DIABETES AND ITS COMPLICATIONS
Editorial Board: 1991-2011
JOURNAL OF DIABETES INVESTIGATION
Editorial Board: 2009-2013
JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY
Editorial Board: 2007-2012
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Editorial Board: 2003-2006
PRACTICAL CARDIOLOGY
Editorial Board: 1981-1985
PSYCHOSOMATIC MEDICINE
Editorial Board: 2002-2005
THE ENDOCRINOLOGIST
Editorial Board: 1997-1999
Reviewer for the Following Journals (*Reviewer During Past Year):
Advances in Therapeutics
American Journal of Epidemiology
Jay S. Skyler
Page 12
American Journal of Medical Sciences
American Journal of Medicine
American Journal of Obstetrics & Gynecology
American Journal of Transplantation
American Psychologist
Analytical Biochemistry
Annals of Internal Medicine
Archives of Internal Medicine
Autoimmunity
British Medical Bulletin
British Medical Journal
Canadian Medical Association Journal
Circulation
Circulation Research
Clinical Endocrinology
Clinical Immunology
Clinical Therapeutics
Diabete et Metabolisme
Diabetes*
Diabetes Care*
Diabetes Educator
Diabetes Metabolism Research and Review
Diabetes, Nutrition, & Metabolism: Clinical & Experimental
Diabetes Research
Diabetes Research and Clinical Practice
Diabetes Technology & Therapeutics*
Diabetic Medicine
Diabetologia
Endocrine Practice
Endocrine Research Communications
Endocrinology
European Journal of Immunology
Expert Review of Endocrinology and Metabolism
Health Affairs
Health Psychology
International Journal of Behavioral Medicine
Islet
JAMA*
Journal of Autoimmunity
Journal of Biochemical and Biophysical Methods
Journal of Biological Chemistry
Journal of Diabetes & Its Complications
Journal of Chronic Diseases
Journal of Clinical Endocrinology and Metabolism
Journal of Clinical Investigation*
Journal of Internal Medicine
Journal of Laboratory and Clinical Medicine
Journal of Pediatrics
Journal of Pharmacology & Experimental Therapeutics
Journal of the Florida Medical Association
Journal of Transplantation
Lancet
Lancet Diabetes Endocrinology
Life Sciences
Metabolism
Nature Biotechnology
Nature Clinical Practice Endocrinology & Metabolism
Nature Reviews Drug Discovery
Curriculum Vitae
Jay S. Skyler
Page 13
New England Journal of Medicine*
Nutrition Metabolism & Cardiovascular Disease
Pediatrics
Pediatric Diabetes*
PLoS ONE
Proceedings of the National Academy of Sciences USA*
Proceedings of Society of Experimental Biology & Medicine
Psychophysiology
Psychosomatic Medicine
Science
Science Translational Medicine
Stem Cells*
The Physician and Sports Medicine
Curriculum Vitae
e. STUDY SECTION AND COUNCIL MEMBERSHIPS
National Commission on Diabetes, 1975-1976
Consultant, Committee on Education and Treatment
Chairman, Workgroup on Current Status & Future Directions of Therapy
State of Florida
Governor's Diabetes Advisory Council: 1979-1990, 1994-2002
Joint Food and Drug Administration/United States Pharmacopeia
International Workshop on Drugs and Reference Standards for Insulins, Somatotropins and Thyroid
Axis Drugs
Chairman, Consensus Panel on Insulin, May 1982
National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases
Diabetes Control and Complications Trial
Policy Advisory Group: 1982-1986, 1993
National Diabetes Information Clearinghouse
Advisory Board: 1983-1986
National Institute of Diabetes, Digestive and Kidney Diseases
Long Term Planning Panel
Member: 2000, 2002
Special Review Committee for Type 2 Diabetes Mellitus Studies in Children
Chairman: 2002
Diabetes Strategic Plan – Clinical Research and Trials Sub-Group
Member: 2009
Special Review Committee
Member: 2009
National Institute of Child Health and Human Development
Special Review Panel, Genetic Linkage Analysis of Juvenile Diabetes Mellitus
Member: 1978
Chairman: 1979, 1980
Special Review Panel, Primary Prevention of Type I Diabetes
Chairman: 1995
National Institutes of Health
Behavioral Medicine Study Section
Ad Hoc Reviewer: 1979, 1986
Metabolism Study Section
Ad Hoc Reviewer: 1980, 1981, 1982, 1984
Special Emphasis Research Career Award Program
(NHLBI/NIADDK) - Ad Hoc Reviewer: 1982
Epidemiology and Chronic Disease Study Section
Ad Hoc Reviewer: 1986
Advisory Committee on Type 1 Diabetes
Member: 2000, 2002
Jay S. Skyler
Page 14
Curriculum Vitae
Advisory Committee for Restructuring NIH Clinical Research
Member: 2003
Special Emphasis Panel
Member: 2007, 2008, 2009
National Heart Lung and Blood Institute
Special Policy Advisory Review Committee – ACCORD Study
Member: 2002
National Institute of Mental Health
Treatment Development & Assessment Research Review Committee
Ad Hoc Reviewer: 1979
National Center for Research Resources
General Clinical Research Centers Review Committee
Ad Hoc Reviewer: 2000
Canadian Medical Research Council
Ad Hoc Reviewer: 1978, 1983, 1984, 1985, 1988, 2000, 2010
Canadian Institutes of Health Research
Ad Hoc Reviewer: 2009
Food and Drug Administration
Orphan Drug Program - Ad Hoc Reviewer: 1984, 1989
Endocrinologic & Metabolic Drugs Advisory Committee: 1984-1986
Centers for Disease Control
Community Health Care Models for Diabetes Prevention & Control Advisory Committee Member: 19901992
World Health Organization
Study Group on Prevention of Diabetes
Member: 1992
Juvenile Diabetes Research Foundation (JDRF)
Data Safety & Monitoring Board, Anti-CD3 European Trials
Chairman: 2002-2004
Special Review Panel
Member: 2005, 2006, 2008, 2011, 2012, 2013
Clinical Advisory Committee
Member: 2012-2013
Review Panel for International Centers for Type 1 Diabetes TrialNet
Member: 2014
European Union Program “Natural Immunomodulators as Novel Immunotherapies for Type 1 Diabetes
(NAIMIT)
External Advisory Board
Chairman: 2010-Present
United Kingdom Medical Research Council
Reviewer: 2010
Research Foundation Flanders
Reviewer: 2011, 2012
Diabetes UK
Reviewer: 2013-2014
Helmsley Charitable Trust
Reviewer: 2015
f. ADVISORY ACTIVITIES
Adocia
Advisor: 2015
Ajinomoto Pharmaceuticals
Advisor: 2004
Alinea Pharmaceuticals
Co-Chairman, Scientific Advisory Board: 2005-2008
Altea Therapeutics
Jay S. Skyler
Page 15
Advisor: 2001-2006
Member, Scientific Advisory Board: 2008-2009
American Academy of Physician's Assistants
Advisor for Continuing Education: 1973, 1976, 1977, 1979
Amgen, Inc.
Advisor: 2006
Amylin Pharmaceuticals, Inc.
Advisor: 1997-2003
Member, Board of Directors: 1999-2012
Andrx Corporation
Member, Scientific Advisory Board: 1996-1999
Animas Corporation
Member, Advisory Board: 2003-2006
Astra-Zeneca
Advisor: 2014-Present
AtheroGenics, Inc.
Advisor: 2007-2009
Aventis Pharmaceuticals
Advisor: 1999-2005
Bayer Corporation
Advisor: 1999
Bayer Diabetes Care
Advisor: 2008
Bayer/GSK
Levitra Advisory Board: 2003
Baxter Healthcare
Advisor: 2008
Becton-Dickinson
Advisor: 2004, 2009-2012
Berg Health
Advisor: 2014
Biodel, Inc.
Advisor: 2014
Biogenix Corporation/Exact Science, Inc.
Medical Advisor & Member, Board of Directors: 1987-1990
Chairman, Medical Advisory Board: 1988-1990
Biosite, Inc.
Advisor: 2005
Boehringer-Ingelheim Pharmaceuticals Inc.
Member, President’s Advisory Council: 2013
Advisor: 2014-Present
Boehringer-Mannheim Inc. (Corange Group)
Member, Global Diabetes Advisory Group: 1995-1998
Boehringer-Mannheim Pharmaceuticals, Inc.
Member, Diabetes Policy Advisory Group: 1988-1991
Boston Medical Technologies
Member, Scientific Advisory Board: 1999-2002
Bristol Myers Squibb
Diabetes Franchise Steering Committee: 1994-2003
Advisor: 1994-2005, 2008, 2013
Bristol Myers Squibb/Astra Zeneca Diabetes Franchise
Advisor: 2013
Cebix, Inc.
Member, Scientific Advisory Board: 2012
Centocor
Advisor: 2001
Chromium Information Bureau
Member, Scientific Advisory Board: 1995-2000
CIBC World Markets
Curriculum Vitae
Jay S. Skyler
Page 16
Advisor: 2007
Clinical Products, Ltd.
Chairman, Scientific Advisory Board: 1998-2005
CoGenesys, Inc.
Advisor: 2007
Converge, Inc.
Member, Scientific Advisory Board: 2006-Present
CPEX Pharmaceuticals, Inc.
Advisor: 2008
CV Therapeutics
Advisor: 2008
Daiichi-Sankyo
Advisor: 2008, 2010
Dance Biopharm, Inc.
Advisor: 2011-2013, 2015-Present
Member, Board of Directors: 2013-2015
Debiopharm
Advisor: 2003-2004, 2014-2015
Dexcom, Inc.
Member, Board of Directors: 2002-Present
Diabetes Centers, Inc.
External Advisory Board: 1985
Diabetes Support Systems, Inc.
Member, Board of Directors: 1995-1998
Diabetes Treatment Centers of America
Member, Scientific Advisory Council: 1990-2000
Diabetes Treatment Centers of America Foundation
National Medical Advisory Council: 1984-1990
Diabetogen Biosciences Inc.
Scientific Advisory Board: 2000-2002
diaDexus, Inc.
Diabetes Advisory Board: 2010
Diamedix, Inc.
Scientific Advisory Board: 1986-1988
Diasa, Inc.
Member, Board of Directors: 1998-2000
DiaVacs, Inc.
Scientific Advisory Board: 2013-Present
dLife Communications
Member, Advisory Board: 2005-2007
Domain Associates, L.L.C.
Special Advisor: 2002-2004, 2007-2008
Drexel, Burnham, Lambert
Advisor: 1984-1985
Elcelyx
Advisor: 2013-Present
Eli Lilly & Company
Advisor: 1982-1984, 2002, 2007-2008, 2012
Continuing Medical Education Advisory Committee: 1984-2003
Elizabeth Therapeutics
Founder; Chairman of the Board: 2014-present
Emisphere Technologies, Inc.
Member, Medical Advisory Board: 2007
Essentialis, Inc.
Advisor: 2011
Exocell, Inc.
Member, Medical Advisory Board: 1992
Exsulin, Inc.
Scientific Advisor: 2008-2011
Curriculum Vitae
Jay S. Skyler
Page 17
Curriculum Vitae
FABRUS, Inc.
Advisor: 2013
Florida Hospital Medical Center, Orlando
Chairman, Blue Ribbon Review Committee: 1990
Forest Laboratories
Advisor: 2002, 2005
GMP Companies, Inc
Member, Medical Advisory Board: 2000-2006
Genentech
Advisor: 1994, 2009
General Electric Corporation
Advisor, Medical Systems Division: 1971
Gilead
Advisor: 2011-Present
Glaxo-Wellcome
Diabetes Medical Advisory Board: 1999-2000
GlaxoSmithKline
Diabetes Medical Advisory Board: 2000-2001
Goldman-Sachs
Advisor: 2010, 2012, 2014
Halozyme, Inc.
Advisor: 2008, 2013-Present
HealthBanc, Inc.
Member, Board of Directors: 1998-2003
HealthScreenDirect, LLC.
Advisor: 2007-2008
Hoffman-LaRoche
Advisor: 1990, 2011
Member, Humanized Anti-TAC Advisory Board: 1993
Home Diagnostics, Inc.
Scientific Advisory Board: 1986-1992
Hyperion Therapeutics
Advisor: 2014
Ideal Life
Advisor: 2006-Present
Immunex
Advisor: 2001
Institute for Diabetes Discovery
Scientific Advisory Board: 1996-2005
Intarcia
Scientific Advisory Board: 2013-Present
IntraCellular Health, Inc.
Member, Medical and Scientific Advisory Board: 1995-1997
International Diabetes Institute, Monash University, Melbourne, Australia
Special Advisor: 1992-2000
IVAX Corporation (Previously Pharmedix, Inc.)
(including Baker-Norton Pharmaceuticals and Ivax Bioscience)
Scientific Advisory Board: 1986-1988
Business Advisory Board: 1992-1993
Chairman, Medical Food Advisory Board: 1996-1997
Advisor: 1998-2000, 2007
Johnson & Johnson
Advisor: 2008
Johnson & Johnson/Ortho-McNeil
Advisor: 2003-2004
JotMate, Inc.
Member, Board of Directors: 2008-Present
Kinexum, LLC
Advisor: 2003-2004
Jay S. Skyler
Page 18
Curriculum Vitae
Kos Pharmaceuticals
Advisor: 2002-2006
Kyowa Hakko Kirin Co., Ltd.
Advisor: 2010
Liberty Medical / Polymedica
Advisor: 2006
LifeGate. Inc.
Member, Board of Directors: 2007-Present
Lipha Pharmaceuticals/Merck KGaA/EMD Pharmaceuticals
Metformin Steering Committee: 1987, 1994
Diabetes Scientific Advisory Board: 1997-2005
MannKind Corporation
Advisor: 2002-2012
Mars Symbioscience
Advisor: 2009-2010
Medco/Merck
Diabetes Advisory Committee: 1994
Medingo Ltd.
Scientific Advisory Board: 2006-2010
MediSense, Inc. (Abbott)
Member, Advisory Panel: 1998
Mega Technologies, Inc.
Advisor: 1984-1990
Member, Board of Directors: 1984-1990
Mellitech S.A.S.
Advisor: 2011
Merck and Company
Advisor: 1997, 2009, 2012, 2015
Merrill, Lynch, Inc.
Advisor: 1985, 1996-2002
Mesoblast Limited
Advisor: 2013-Present
Miles Laboratories, Diagnostics Division
Advisor: 1989
Miles Laboratories, Pharmaceuticals Division
Advisor: 1991
MiniMed Corporation
Chairman, Medical Advisory Board: 1989-2000
Member, Board of Directors: 2000-2001
Moerae Matrix Inc.
Member, Board of Directors: 2009-Present
Moerae Vascular, LLC/VasoPrep Surgical
Member, Board of Directors: 2011-Present
Muttart Diabetes Research & Training Center, University of Alberta
Member, External Advisory Committee: 1992-2000
National Commission on Diabetes, 1975-1976
Consultant, Committee on Education and Treatment
National Heart and Lung Institute (Hypertension-Endocrine Branch) and National Institute of Mental
Health
Consultant: 1975-1977
Neurocrine Biosciences, Inc
Advisor: 2001
Nipro Medical Corporation
Advisor: 2004
Novartis Pharmaceuticals
Vildagliptin Medical Advisory Board: 2003-2005
Advisor: 2008
Novo Research Institute
International Diabetes Research Advisory Group (DRAG): 1985-1993
Jay S. Skyler
Page 19
Curriculum Vitae
Novo-Nordisk, A/S
External Peer Review Group: 1994
Advisor: 2013
Novo-Nordisk, Inc.
Senior Advisory Committee: 1997-2008
NPS Pharmaceuticals, Inc.
Advisor: 2014
Nutrio Technologies, Inc
Scientific Advisory Board: 2002-2005
Nutrition 21
Advisory Board: 2006-2008
Ono Pharmaceuticals
Advisor: 2010
Opko Health
Advisor: 2013
Orgenesis
Scientific Advisory Board: 2013-Present
Paean Therapeutics
Founder; Chairman of the Board: 2012-present
Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company
Advisor: 1990-1994
Patton Medical Devices
Scientific Advisory Board: 2005-2011
Pennsylvania Diabetes Academy
Scientific Advisory Board: 1985
Pfizer Pharmaceuticals Visiting Professorship Program in Diabetes
Academic Advisory Committee: 1991-1994
Pfizer Pharmaceuticals
Diabetes Advisory Board: 1991-1992, 1998-2008
Member, Zopolrestat Advisory Board: 1993-1998
Member, Inhaled Insulin Advisory Board: 1997-2007
PhaseBio Pharmaceuticals, Inc.
Advisor: 2013-Present
Philips Home Care Chronic Disease Project
Advisor: 2008
Physician's Associate Program, Duke University
Advisory Board: 1973-1974
Advisory Consultant: 1973-1976
Precision Medical Devices, Inc.
Member, Board of Directors: 1998-2005
Present Diabetes LLC.
Member, Scientific Advisory Board: 2006-2008
Regeneron Pharmaceuticals, Inc.
Advisor: 2015
REMD Biotherapeutics, Inc.
Advisor: 2015
Roche Diagnostics
Special Advisor: 2002, 2006
Advisor: 2013
Roche Pharmaceuticals
Diabetes Advisory Board: 2006, 2007
Rodman & Renshaw
Advisor: 2006-2008
Salutria Pharmaceuticals
Advisor: 2009
Sanofi-Synthelabo
Metabolism Advisory Board: 2004
Sanofi (Previously sanofi-aventis)
Metabolism Advisory Board: 2004-2007
Jay S. Skyler
Page 20
Advisor: 2004-Present
Chairman, Type 1 Diabetes Advisory Board: 2010-Present
Satiogen
Advisory Board: 2010
Searle
Member, Magnesium Advisory Board: 1993
Sekris
Advisory Board: 2012
Servier
Advisor: 2009
Smith Kline Beckman
Consultant: 1989
Smith Kline Beecham
Member, Rosiglitazone Advisory Board: 1998-2001
Smiths Medical / Deltec
Insulin Pump Advisory Board: 2003-2006
Squibb-Novo, Inc.
Medical Advisory Council: 1984-1986
SynAlpha Therapeutics LLC
Founder; Chairman of the Board: 2013-present
Takeda Pharmaceuticals
Advisor: 2010-2012
Takeda Pharmaceuticals North America
Diabetes Advisory Board: 1999-2003
Tethys Bioscience
Scientific Advisory Board: 2009
Teva
Advisor: 2008-2009
Tolerx, Inc.
Scientific Advisory Board: 2008
Transition Therapeutics
Scientific Advisory Board: 2003-2006
TransTech Pharma
Advisor: 2015
University of Minnesota Program Project: Pancreas Transplantation
External Advisory Committee: 1986
Università Campus Bio-Medico di Roma
Member, International Advisory Board: 2001-2005
Valeritas LLC
Diabetes Advisory Board: 2006-Present
VasoPrep Surgical, LLC
Member, Board of Directors: 2012-present
Veroscience LLC
Advisor: 2008
Viacyte (Previously Novocell)
Scientific Advisory Board: 2009-Present
Virginia Mason Medical Research Foundation
Consultant: 1983-1984
vTv Therapeutics (Previously TransTech Therapeutics)
Advisor: 2015-Present
Warburg Pincus
Advisor: 2014
William Warren Medical Research Institute
Consultant: 1986
Wyeth-Ayerst, Inc.
Tolrestat Commission: 1987-1988
Tolrestat Neuropathy Steering Committee: 1990-1996
Yamanouchi Pharmaceuticals
Advisor: 2004
Curriculum Vitae
Jay S. Skyler
Page 21
ZyCare, Inc. (Previously Health Ware, Inc.)
Member, Scientific Advisory Board: 1996-2000
Zylera Pharmaceuticals, Inc.
Advisor: 2006
Zymogenetics, Inc.
Advisor: 1996
Curriculum Vitae
g. VISITING PROFESSORSHIPS (Selected)
Portsmouth Naval Regional Medical Center, Portsmouth, Virginia - April 1979
State University of New York, Upstate Medical Center, Syracuse, NY - October 1979
Oakland Naval Regional Medical Center, Oakland, California - October 1979
George Hamwi Memorial Lecturer, Central Ohio Diabetes Association - October 1982
Leon Smelo Memorial Lecturer, American Diabetes Association, Alabama Affiliate - October 1982
Frederick Lind Memorial Lecturer, Bryn Mawr Hospital, Bryn Mawr, PA - October 1984
1984 “Steven Broidy Visiting Professor”, Cedars Sinai Medical Center, UCLA, Los Angeles, CA - March 1984
First “Leon Mow Visiting Professor”, Lions International Diabetes Institute & Monash University, Melbourne,
Australia - July 1986
Lennon Lecturer, Huron Road Meridia Hospital, Cleveland, Ohio - April 1988
DeWitt Burnham-Bernard Robson Visiting Professor, Pacific Presbyterian Medical Center, San Francisco, CA December 1988
Fourth Annual Samuel Levit Honorary Lecturer, Hahnemann University, Philadelphia, PA - March 1990
Leon Smelo Memorial Lecturer, Birmingham (Alabama) Society of Internal Medicine - April 1990
First Eli Lilly Visiting Professor, Muttart Diabetes Research and Training Center, University of Alberta,
Edmonton - May 1990
Phillip Sarver Visiting Professor, The Hospital of the Good Samaritan & University of Southern California, Los
Angeles, CA - October 1990
Barbara Scott Maroney Memorial Lecturer, Interstate Postgraduate Medical Association of North America, Lake
Buena Vista, FL – November 1990
Harry McPherson Symposium in Endocrinology, Duke University Medical Center, Durham, NC - November
1993
47th John Herr Musser Lecturer, Musser-Burch Society, Tulane University Medical Center, New Orleans, LA September 1994
Third Harold Rifkin Visiting Professor, Montefiore Medical Center and Albert Einstein College of Medicine,
Bronx, NY - April 1995
Tripler Army Medical Center, Honolulu, Hawaii – July 1998
George Hamwi Memorial Lecturer, Central Ohio Diabetes Association - November 1998
Walter Reed Army Medical Center, Washington – May 2002
Marvin Levin Visiting Professor at Washington University – November 2004
Barbara Davis Center for Childhood Diabetes, Denver – October 2005
Duke University Medical Center – October 2005
University of Texas Health Sciences Center, San Antonio – November 2005
David Rabin Visiting Professor, Vanderbilt University – November/December 2005
University of Colorado Keystone Diabetes Course – July 2006
University of Colorado Keystone Diabetes Course – July 2007
Great Plains Diabetes Center, Kansas City – March 2008
University of Colorado Keystone Diabetes Course – July 2008
La Jolla Institute of Allergy and Immunology – March 2009
University of Pittsburgh Medical Center – March 2009
Turney Lecture, Virginia Commonwealth University – April 2009
University of Colorado Keystone Diabetes Course – July 2009
Mayo Medical School, Rochester, Minnesota - September 2009
University of Colorado Keystone Diabetes Course – July 2010
University of Washington, Seattle – October 2010
University of Colorado Keystone Diabetes Course – July 2012
University of Florida, Gainesville – September 2012
Columbia University, New York – November 2012
Jay S. Skyler
Page 22
Curriculum Vitae
Donnell D. Etzwiler Memorial Lecture, International Diabetes Center, Minneapolis – April 2013
Columbia University, New York – April 2013
Joslin Diabetes Center, Boston – May 2013
University Children's Hospital, Ljubljana, Slovenia – June 2013
University of Colorado Keystone Diabetes Course – July 2013
University of Colorado Keystone Diabetes Course – July 2014
State University of New York Downstate Medical Center, Brooklyn – April 2015
h. SCIENTIFIC PRESENTATIONS: NATIONAL & INTERNATIONAL MEETINGS
Beilinson Diabetes Symposium; Natanya, Israel - October 1972
First International Workshop on Diabetes & Camping; Lake Saint Croix, Wisconsin - May 1974
First International Congress on Obesity; London, England - October 1974
American Federation of Clinical Research, Eastern Section; Boston, Massachusetts - January 1975
International Symposium on Growth Hormone & Related Peptides; Milan, Italy - September 1975
ADA National Postgraduate Course, New York - January 1978
Endocrine Society 30th Postgraduate Assembly; Miami Beach, FL - October 1978
Southern Sugar Club; Kiawah Island, SC - April 1979
International Symposium on New Approaches to the Management of the Patient with Diabetes Mellitus; New
York, N.Y. - May 1979
NIH Conference on Psychosocial & Behavioral Aspects of Diabetes; Madison, Wisconsin - May 1979
American Dietetic Association; Las Vegas, NV - October 1979
American Diabetes Association Conference on Gestational Diabetes; Chicago, IL - November 1979
ADA National Postgraduate Course, Atlanta, GA - January 1980
University of Nottingham Symposium on Home Blood Glucose Monitoring; Nottingham, England - March 1980
ADA National Postgraduate Course, Phoenix, AZ - January 1981
National Continuing Medical Education Television Network; Live from Cincinnati, Ohio - June 1981
International Study Group on Diabetes in Children and Adolescents; Les Collons, Switzerland, September 1981
International Symposium on Artificial Systems for Insulin Delivery; Assisi, Italy - September 1981
Beilinson Diabetes Symposium; Herzylia, Israel - November 1981
ADA National Postgraduate Course, Orlando, FL - January 1982
Steno Memorial Hospital 50th Anniversary Symposium; Gentofte, Denmark - May 1982
International Symposium on Insulin Delivery; Toronto - June 1982
International Symposium on Human Insulin of Recombinant DNA Origin; San Francisco, CA - June 1982
American Diabetes Association, Annual Meeting; San Francisco, CA - June 1982
International Diabetes Federation Congress; Nairobi, Kenya - November 1982
South African Society for Endocrinology, Metabolism, & Diabetes; Capetown, South Africa - November 1982
ADA National Postgraduate Course, Denver, CO - January 1983
Third Aberdeen Colloquium on Diabetes and Pregnancy; Aberdeen, Scotland - April 1983
Symposium on Intensive Insulin Therapy; Copenhagen, Denmark - April 1983
Second Japan-Korea Diabetes Symposium; Nagoya, Japan - September 1983
American Academy of Family Physicians, Annual Meeting; Miami Beach, FL - October 1983
British Diabetic Association Postgraduate Course; Nottingham, England - January 1984
4th Symposium on Diabetes Mellitus in Asia & Oceania; Melbourne, Australia - January 1984
International Symposium on Diabetes Education; Melbourne, Australia - January 1984
International Symposium on Human Insulin and Diabetes Epidemiology; Hobart, Tasmania - January 1984
International Symposium on Immunology in Diabetes; Rome, Italy - March 1984
ADA “Clinical Education Program” for Type II Diabetes (National Television Faculty) - April 1984
American College of Physicians Annual Meeting; Atlanta, GA - April 1984
2nd International Symposium on Insulin Delivery Devices; Toronto, Canada - June 1984
ADA National Postgraduate Course, New Orleans, LA - January 1985
American Society of Contemporary Medicine & Surgery; Orlando, FL - March 1985
American Academy of Pediatrics; Atlanta, Georgia - April 1985
Endocrine Society 37th Postgraduate Assembly; Bal Harbour, FL - October 1985
American College of Physicians Annual Meeting; San Francisco, CA - April 1986
American Academy of Pediatrics Annual Meeting; Washington, D.C. - November 1986
Jay S. Skyler
Page 23
Curriculum Vitae
American Diabetes Association Consensus Conference on Blood Glucose Monitoring, Opening Keynote
Address; Washington, D.C. - November 1986
National Heart, Lung, and Blood Institute Conference on Research in Cardiovascular Behavioral Medicine; Key
Biscayne, FL - December 1986
ADA National Postgraduate Course, Orlando, FL - January 1987
Juvenile Diabetes Foundation Conference on Immune Intervention in Type I Diabetes; Houston, TX - February
1987
American Association of Diabetes Educators, Annual Meeting, Keynote Address; Orlando - September 1987
Interstate Postgraduate Medical Association of North America (72nd Scientific Assembly); Hollywood, FL November 1987
Diabetic Renal-Retinal Symposium #4; New York - November 1987
ADA National Postgraduate Course, Palm Desert, CA - January 1988
4th Aberdeen Colloquium on Diabetes and Pregnancy; Aberdeen, Scotland - April 1988
Immunointervention in Autoimmune Diseases; Paris - June 1988
Cardiostim '88; Monaco - June 1988
Third International Symposium on Treatment of Diabetes Mellitus; Nagoya, Japan - July 1988
Eighth International Congress of Endocrinology; Kyoto, Japan - July 1988
International Diabetes Federation Congress, Plenary Lecture; Sydney, Australia - November 1988
American Academy of Pediatrics; Orlando, Florida - March 1989
Fifth Korea-Japan Diabetes Symposium; Cheju Island, Korea - April 1989
Endocrine Society of Thailand, Bangkok - April 1989
Hong Kong College of General Practicioners, Kowloon - April 1989
Philippine Society of Endocrinology & Metabolism, Manila - April 1989
Cebu Medical Society, Manila, Philippines - April 1989
American Diabetes Association, Annual Meeting; Detroit, Michigan - June 1989
Academy of Behavioral Medicine Research; Lake Mohank, NY - June 1989
American Association of Diabetes Educators, Annual Meeting; Seattle, Washington - August 1989
ADA National Postgraduate Course, Orlando, FL - January 1990
Turkish Diabetes Association, Istanbul, Turkey - March 1990
Tenth International Workshop, Immunology of Diabetes; Jerusalem, Israel - March 1990
American College of Physicians Annual Meeting; Chicago, Illinois - April 1990
NIH Workshop on Clinical Trials of Immunomodulation for Prevention of IDDM - April 1990
Endocrine Society Annual Meeting; Atlanta, Georgia - June 1990
Second International Symposium on Immunotherapy of Type I Diabetes; London, England - September 1990
Interstate Postgraduate Medical Association of North America (75th Scientific Assembly); Orlando, FL November 1990
Mexican Society of Endocrinology and Nutrition 30th Congress; Acapulco, Mexico - November 1990
American Diabetes Association Postgraduate Course, Keynote Address; San Diego, California - January 1991
Associazione Medici Diabetologi 8th National Congress; Giardini Naxos, Touramina, Sicily - April 1991
Turkish Diabetes Association; Istanbul, Turkey - May 1991
International Diabetes Federation Congress; Washington, DC – June 1991
Symposium on Diabetic Neuropathy; Melbourne, Australia - July 1991
American Association of Diabetes Educators, Annual Meeting; Baltimore, Maryland - September 1991
Eleventh International Workshop, Immunology of Diabetes; Nagasaki, Japan - November 1991
Swedish Medical Association; Stockholm, Sweden - November 1991
American Diabetes Association Postgraduate Course; Orlando, Florida - January 1992
American Diabetes Association, Annual Meeting; San Antonio, TX - June 1992
Australian Diabetes Society; Adelaide, South Australia - September 1992
XIV Congreso Chileno de Medicina Interna; Santiago, Chile - October 1992
VIII Congreso de la Asociacion Latinoamericana de Diabetes; Mar del Plata, Argentina - October 1992
Sociedad Venezolana de Endocrinologia y Metabolismo - Simposio Sobre Diabetes Mellitus; Caracas, Venezuela
- October 1992
JDF/Joslin Nice Neuropathy Circles Meeting; Nice, France - November 1992
Egyptian Diabetes Care Association/American Diabetes Association Postgraduate Course on Diabetes Mellitus;
Giza, Egypt - November 1992
Twelfth International Workshop, Immunology of Diabetes; Orlando, Florida – March 1993
American Academy of Pediatrics; Chicago, Illinois - March 1993
American Association of Clinical Endocrinologists; San Francisco, California - May 1993
Jay S. Skyler
Page 24
Curriculum Vitae
Endocrine Society Annual Meeting; Las Vegas, Nevada - June 1993
American Diabetes Association, Annual Meeting; Las Vegas, Nevada - June 1993
International Business Communications Conference on Diabetes Mellitus; Miami – January 1994
I Congresso Português de Diabetes, Sociedade Portuguesa de Diabetologia; Porto, Portugal - February 1994
Juvenile Diabetes Foundation Workshop on Islet Specific Antigens; San Francisco, California - March 1994
International Business Communications Conference on Diabetes Mellitus; London, England - April 1994
Eastern Regional Osteopathic Convention; Atlantic City, New Jersey - April 1994
Thirteenth International Workshop, Immunology of Diabetes; Paris, France – 1994
Endocrine Fellows Foundation Annual Meeting; New Orleans, Louisiana - June 1994
American Diabetes Association, Annual Meeting; New Orleans, Louisiana - June 1994
Endocrine Society Annual Meeting; Anaheim, California - June 1994
Third International Congress of Behavioral Medicine; Amsterdam, Netherlands - July 1994
21st Meeting of Brazilian Society of Endocrinology; Curitiba, Brazil - October 1994
Society of Diabetes of Argentina; Buenos Aires, Argenina - October 1994
American Academy of Pediatrics; Dallas, Texas - October 1994
International Diabetes Federation Congress, Plenary Lecture; Kobe, Japan - November 1994
International Symposium on Type I Diabetes Mellitus; Nagasaki, Japan - November 1994
American Psychosomatic Society; New Orleans, Louisiana - March 1995
Paraguay Society of Internal Medicine; Asuncion, Paraguay - May 1995
Norwegian Diabetes Association; Oslo, Norway - May 1995
American Society of Hypertension; New York, NY - May 1995
American Diabetes Association, Annual Meeting; Atlanta, GA - June 1995
International Pancreas and Islet Transplantation Society; Miami Beach, FL - June 1995
ADA Research Symposium on Prediction & Prevention of Type I Diabetes, Estes Park, Colorado - September
1996
Immunology of Diabetes Society; Orvieto, Italy – October 1995
Foundation for Innovation in Medicine; Washington, DC - November 1995
8th Congress of the ASEAN Federation of Endocrine Societies; Manila, Philippines - December 1995
Hong Kong Society of Endocrinology & Metabolism; Hong Kong - December 1995
Steno Memorial Hospital 75th Anniversary of Insulin Symposium; Gentofte, Denmark - May 1996
American Diabetes Association, Annual Meeting; San Francisco, CA - June 1996
International Diabetes Federation Diabetes Declaration of Americas Conference; San Juan, Puerto Rico - August
1996
Foundation for Innovation in Medicine; New York, NY - November 1996
Immunology of Diabetes Society; Canberra, Australia – December 1996
Carribean Diabetes Association; Ocho Rios, Jamaica – March 1997
General Clinical Research Centers Annual Meeting; Crystal City, Virginia - March 1997
American College of Physicians Annual Meeting; Philadelphia, PA - March 1997
American Diabetes Association, Annual Meeting; Boston, MA - June 1997
Endocrine Society Annual Meeting; Minneapolis, Minnesota - June 1997
International Diabetes Federation Congress; Helsinki, Finland – July 1997
International Business Communications Conference on Obesity; Miami – November 1997
Israel Diabetes Association; Tel Aviv – January 1998
American College of Physicians Annual Meeting; San Diego, CA – April 1998
Immunology of Diabetes Society; Oak Brook, Illinois – June 1998
American Diabetes Association, Annual Meeting; Chicago, IL - June 1998
European Association for the Study of Diabetes; Barcelona, Spain – September 1998
Visiting Professor in China; Beijing, Shanghai, Xian – September 1998
X Congreso de la Asociacion Latinoamericana de Diabetes; Cartagena, Colombia – October 1998
American Diabetes Association Postgraduate Course; Orlando, FL - January 1999
American College of Physicians Annual Meeting; New Orleans, LA – April 1999
American Diabetes Association, Annual Meeting; San Diego, CA - June 1999
Endocrine Society Annual Meeting; San Diego, CA – June 1999
EASD Postgraduate Course; Kaunas, Lithuania – September 1999
European Association for the Study of Diabetes; Brussels, Belgium – September 1999
Endocrine Society Postgraduate Assembly; Los Angeles, CA – October 1999
Immunology of Diabetes Society; Fiuggi, Italy – October 1999
American Diabetes Association Postgraduate Course; Honolulu, Hawaii - January 2000
Jay S. Skyler
Page 25
Curriculum Vitae
Southern Society of Clinical Investigation; New Orleans, LA – February 2000
American College of Physicians Annual Meeting; Philadelphia, PA – April 2000
German Diabetes Association; Munich, Germany – May 2000
American Diabetes Association, Annual Meeting; San Antonio, TX - June 2000
Endocrine Society Annual Meeting; Toronto, Ontario, Canada – June 2000
European Association for the Study of Diabetes; Jerusalem, Israel – September 2000
EASD Postgraduate Course; Jerusalem, Israel – September 2000
Juvenile Diabetes Foundation Workshop on Prevention of Diabetes; Snow Mountain, Colorado – October 2000
Canadian Diabetes Association; Halifax Nova Scotia – October 2000
International Society of Pediatric and Adolescent Diabetes; Los Angeles – November 2000
International Diabetes Federation Congress; Mexico City – November 2000
American Diabetes Association, Annual Meeting; Philadelphia, PA – June 2001
Ashland Endocrine Conference; Ashland, Oregon – August 2001
American Association of Clinical Endocrinologists Consensus Development Conference; Washington, DC –
August 2001
European Association for the Study of Diabetes; Glasgow, Scotland – September 2001
XI Congreso de la Asociacion Latinoamericana de Diabetes; Punte de Este, Uruguay – November 2001
American Diabetes Association Postgraduate Course; San Francisco, CA – January 2002
Visiting Professor in China; Beijing, Shanghai, Xiamen, Guangzhou – February-March 2002
American Diabetes Association, Annual Meeting; San Francisco, CA – June 2002
European Association for the Study of Diabetes; Budapest, Hungary – September 2002
Immunology of Diabetes Society; Copper Mountain, Colorado – October 2002
IDF Conference: Type 2 Diabetes in the Adolescent: The Evolving Epidemic; Los Angeles – February 2003
American Chemical Society; New Orleans, LA – March 2003
American Diabetes Association, Annual Meeting; New Orleans, LA – June 2003
International Diabetes Federation Congress; Paris, France – August 2003
Endocrine Society Postgraduate Assembly; Miami Beach, FL – October 2003
New York Academy of Sciences; New York City – October 2003
Immunology of Diabetes Society; Cambridge, UK – March 2004
American Diabetes Association, Annual Meeting; Orlando, FL – June 2004
Juvenile Diabetes Research Foundation – European Association for the Study of Diabetes Workshop; Oxford,
UK – August 2004
European Association for the Study of Diabetes; Munich, Germany – September 2004
EASD/ADA/IDF Postgraduate Course; Nairobi Kenya & Yaounde Cameroon – April 2005
Diabetes Technology Society Clinical Meeting; San Francisco – April 2005
American Association of Clinical Endocrinologists; Washington DC – May 2005
Endocrine Society, Annual Meeting ENDO 05; San Diego, CA – June 2005
American Diabetes Association, Annual Meeting; San Diego, CA – June 2005
European Association for the Study of Diabetes; Athens, Greece – September 2005
Diabetes India; Jaipur, India – November 2005
International Symposium on Prevention of Type 1 Diabetes: The New Frontier; Rome, Italy – March 2006
First International Conference on Diabetes Cell Therapy; Tel Aviv, Israel – March 2006
American Association of Clinical Endocrinologists; Chicago – April 2006
Endocrine Society Annual Meeting; Boston - June 2006
European Congress of Immunology; Paris – September 2006
European Association for the Study of Diabetes; Copenhagen – September 2006
Cardiometabolic Health Congress; Boston – October 2006
International Diabetes Federation Congress; Cape Town, South Africa – December 2006
American Diabetes Association Postgraduate Course; New York, NY – February 2007
Amsterdam Diabetes Forum; Amsterdam, Netherlands – March 2007
Endocrine Society, Annual Meeting ENDO 07; Toronto, Ontario – June 2007
American Diabetes Association, Annual Meeting; Chicago – June 2007
European Association for the Study of Diabetes; Amsterdam – September 2007
Cardiometabolic Health Congress; Boston – September 2007
Aspen Institute Health Forum; Aspen, Colorado – October 2007
Immunology of Diabetes Society; Miami Beach – November 2007
International Diabetes Summit; Columbus, Ohio – November 2007
American Diabetes Association Postgraduate Course; San Francisco – January/February 2008
Jay S. Skyler
Page 26
Curriculum Vitae
American College of Physicians Annual Meeting; Washington DC – April 2008
American Association of Clinical Endocrinologists; Orlando – April 2008
American Diabetes Association, Annual Meeting; San Francisco – June 2008
American Association of Diabetes Educators Annual Meeting; Washington DC – August 2008
Cardiometabolic Health Congress; Boston – October 2008
EASD/ADA/IDF Postgraduate Course; Hanoi, Viet Nam – November 2008
University of Miami Global Business Forum; Coral Gables, FL – January 2009
Clinical Diabetes & Endocrinology in 2009; Snowmass, CO – January 2009
American Diabetes Association Postgraduate Course; New York, NY – February 2009
PriMed; Fort Lauderdale, FL – February 2009
International Conference on Advanced Technologies and Treatments for Diabetes; Athens Greece – February
2009
American Diabetes Association, Annual Meeting; New Orleans – June 2009
Endocrine Society, Annual Meeting ENDO 09; Washington – June 2009
Aspen Institute Health Forum; Aspen, Colorado - July 2009
American Association of Diabetes Educators Annual Meeting; Atlanta, GA – August 2009
European Association for the Study of Diabetes; Vienna – September/October 2009
Cardiometabolic Health Congress; Boston – October 2009
International Diabetes Federation Congress; Montreal – October 2009
9th International Conference on New Trends in Immunosuppression & Immunomodulation; Geneva, Switzerland
– February 2010
International Conference on Advanced Technologies and Treatments for Diabetes; Basel, Switzerland – February
2010
10th Annual Rachmiel Levine Diabetes and Obesity Symposium - Advances in Diabetes Biology, Immunology &
Cell Therapy; Las Vegas, Nevada – March 2010
6th World Congress on Prevention of Diabetes; Dresden, Germany – April 2010
Egyptian Pediatric Diabetes Association; Cairo, Egypt – April 2010
American Diabetes Association, Annual Meeting; Orlando, FL - June 2010
European Association for the Study of Diabetes; Stockholm – September 2010
Cardiometabolic Health Congress; Boston – October 2010
XIV Congreso de la Asociacion Latinoamericana de Diabetes; Santiago, Chile – November 2010
Spanish Federation of Internal Medicine; Granada, Spain – January 2011
International Conference on Advanced Technologies and Treatments for Diabetes; London – February 2011
90th Anniversary of Insulin Conference, Beijing University; Beijing, China – May 2011
European Association for the Study of Diabetes; Lisbon – September 2011
Juvenile Diabetes Research Foundation Workshop on Immmunotherapy; Lisbon – September 2011
Cardiometabolic Health Congress; Boston – October 2011
International Society of Pediatric and Adolescent Diabetes; Miami – October 2011
International Conference on Advanced Technologies and Treatments for Diabetes; Barcelona – February 2012
12th Annual Rachmiel Levine Diabetes and Obesity Symposium; Pasadena, California – February 2012
Sociedad Española de Endocrinología y Nutrición; Oveido – May 2012
Immunology of Diabetes Society; Victoria, British Columbia – June 2012
European Association for the Study of Diabetes; Berlin – October 2012
Cardiometabolic Health Congress; Boston – October 2012
International Diabetes Summit; Columbus, Ohio – November 2012
Frontiers in Diabetes, Naomi Berrie Diabetes Center at Columbia University; New York, NY – November 2012
90th Anniversary of Insulin Symposium; Barcelona, Spain – February 2013
International Conference on Advanced Technologies & Treatments for Diabetes; Paris – February 2013
Diabetes UK Type 1 Immunotherapy Symposium; London, UK – May 2013
VII Konferenca Slovenskih Zdravnikov Iz Sveta In Slovenue; Ljubljana, Slovenia – June 2013
Diabetes Education Program; Potorož, Slovenia – June 2013
European Association for the Study of Diabetes; Barcelona – September 2013
Cardiometabolic Health Congress; Boston – October 2013
XV Congreso de la Asociacion Latinoamericana de Diabetes; Cancun, Mexico – November 2013
International Diabetes Federation Congress; Melbourne, Australia – December 2013
Immunology of Diabetes Society; Lorne, Australia – December 2013
International Conference on Advanced Technologies & Treatments for Diabetes; Vienna – February 2014
2nd African Diabetes Congress; Yaounde, Cameroon – February 2014
Jay S. Skyler
Page 27
Curriculum Vitae
American Diabetes Association, Annual Meeting; San Francisco - June 2014
Endocrine Society Fellows Program; Chicago – June 2014
European Association for the Study of Diabetes; Vienna – September 2014
Peruvian Diabetes Association; Lima – October 2014
Cardiometabolic Health Congress; Boston – October 2014
International Conference on Advanced Technologies & Treatments for Diabetes; Paris – February 2015
Cardiometabolic Health Congress; Boston – October 2015
10. THESIS AND DISSERTATION ADVISING
Member, Ph.D. Dissertation Committee - Clarissa S. Scott
Degree Awarded, 1980
Member, Ph.D. Dissertation Committee - Donna Follansbee
Degree Awarded, 1982
Member, M.S. Thesis Committee - Adelle Platina
Degree Awarded, 1985
Member, Ph.D. Dissertation Committee - Suzanne Klemp
Degree Awarded, 1986
Member, M.S. Thesis Committee - Arnold Peckerman
Degree Awarded, 1989
Member, Ph.D. Dissertation Committee - Rosemary D. Pasin
Degree Awarded, 1989
Member, Ph.D. Dissertation Committee - Richard Nelesen
Degree Awarded, 1989
Member, Ph.D. Dissertation Committee - Patricia Wick
Degree Awarded, 1990
Member, M.S. Thesis Committee - Peggy Greco
Degree Awarded, 1990
Member, Ph.D. Dissertation Committee - Dante Spetter
Degree Awarded, 1991
Member, Ph.D. Dissertation Committee - Jane Ansley
Degree Awarded, 1991
Member, M.S. Thesis Committee - Ruth Quillian
Degree Awarded, 1991
Member, M.S. Thesis Committee - Julie Landel
Degree Awarded, 1993
Member, Ph.D. Dissertation Committee - Clifford A. Massie
Degree Awarded, 1993
Member, Ph.D. Dissertation Committee - Julie Landel
Degree Awarded, 1995
Member, Ph.D. Dissertation Committee - Alissa Sheldon
Degree Awarded, 1995
Member, Ph.D. Dissertation Committee - Catherine Davis
Degree Awarded, 1997
Member, Ph.D. Dissertation Committee – Rita Goldstein
Degree Awarded, 1998
Member, Ph.D. Dissertation Committee – Jeffrey Kibler
Degree Awarded, 1998
Member, Ph.D. Dissertation Committee, University of Leuven – Kristia Casteels
Degree Awarded, 1998
Member, Ph.D. Dissertation Committee – Carol Gallaher
Degree Awarded, 1999
Member, M.S. Thesis Committee – Johanna Klaus
Degree Awarded, 2001
Member, Ph.D. Dissertation Committee – Johanna Klaus
Degree Awarded, 2004
Jay S. Skyler
Page 28
Member, Ph.D. Dissertation Committee – Candace Hart
Degree Awarded, 2005
Member, MPH Thesis Committee – Carlos Hernandez-Cassis
Degree Awarded, 2008
Curriculum Vitae
11. CURRENT AND PAST TEACHING RESPONSIBILITIES
Organizational
Coordinator, Zoology 198.81, Man and Disease, Duke University Trinity College of Arts and Sciences: Spring
1972; Spring 1973
Coordinator, Division of Endocrinology Basic Seminar Series, Duke University Medical Center: Spring 1972;
Fall 1972; Spring 1973
Co-Coordinator, Medicine 262, Diabetes Mellitus: A Camping Experience, Duke University School of Medicine:
Summers of 1972 to 1976
Coordinator, Medicine 110-111, Clinical Medicine I & II; Medicine 120-121, Patient Evaluation I & II;
Physician's Associate Program, Duke University: Fall 1972; Spring 1973
Co-Coordinator, Nursing 187, Patient Assessment, Duke University School of Nursing: Fall 1972; Spring 1973
Coordinator, Medicine and Community Health Sciences Clinical Courses, Physician's Associate Program, Duke
University: July 1972 - June 1973
Lecturer, Sex Education, Immaculata School, Durham, NC: 1972 - 1973
Coordinator, Endocrinology Conferences, Department of Medicine, George Washington University: November
1973 - June 1974
Coordinator, Mechanisms of Disease: Endocrinology and Metabolism, University of Miami School of Medicine:
1978 - 1981
Coordinator, Diabetes Clinical Electives, Department of Medicine, University of Miami School of Medicine:
1978 - 1986
Director, “Optimizing Diabetes Management”, Recurring 5-Day Postgraduate Course (4-8 times yearly),
University of Miami: 1979 - 1986
Director, “Diabetes Therapy in the 1980s”, University of Miami & Pfizer Laboratories, Miami, FL: December
1979
Chairman, “Symposium on Diabetes Mellitus”, University of Miami & Upjohn Co., Doral Country Club, Miami,
FL: March 1980
Director, Postgraduate Course “Diabetes Mellitus: Update 1980”, University of Miami & Eli Lilly Co., Bal
Harbour, FL: November 1980
Chairman, Symposium “Insulin Update 1982”, University of Miami & Eli Lilly Co., Key Biscayne, FL:
December 1981
Director, American Diabetes Association Twenty-Ninth National Postgraduate Course, Orlando, FL: January
1982
Co-Chairman, “International Symposium on Type I Diabetes”, University of Miami & Squibb-Novo, Inc.,
Copenhagen, Denmark: September 1984
Director, Postgraduate Course “Diabetic Complications 1987”, University of Miami & Roerig/Pfizer, Miami, FL:
November 1986
Director, American Diabetes Association Thirty-Fourth National Postgraduate Course, Orlando, FL: January
1987
Director, Postgraduate Course “Diabetes & Its Vascular Complications”, University of Miami & HoechstRoussel, Miami, FL: February 1987
Coordinator, Mechanisms of Disease: Endocrinology and Metabolism, University of Miami School of Medicine:
1989
Chairman, Cardiovascular Teaching Symposium, University of Miami & Merck Sharp & Dohme, Fort
Lauderdale, FL - May 1989
Director, Postgraduate Course “Diabetic Complications: Update 1992”, University of Miami, Miami, FL: April
1992
Chairman, Diabetology Consultant Meeting on Magnesium Supplementation, Las Vegas, Nevada: June 1993
Coordinator, Combined Grand Rounds, Divisions of Endocrinology and of Diabetes & Metabolism, Department
of Medicine, University of Miami and Miami Veterans Administration Medical Center: 1993-2000
Jay S. Skyler
Page 29
Curriculum Vitae
Chairperson, Insulin Dependent Diabetes - Recent Developments in Prediction, Prevention, and Treatment,
International Business Communications (IBC-USA), Miami, FL: January 1994
Director, Postgraduate Course “The Insulin Resistance Syndrome”, University of Miami & Bristol-Myers
Squibb, Miami, FL: June 1995, January 1996
Director, Postgraduate Course “Hypertension Update”, University of Miami & Merck Human Health, Miami, FL:
November 1995
Director, Special Course for Korean Physicians “Diabetes and Its Complications: Realistic Expectations For
Effective Therapies”, University of Miami & Wyeth-Ayerst International, Miami, FL: February 1996
Director, Postgraduate Course “Diabetes In The Primary Care Setting”, University of Miami & Bristol-Myers
Squibb, Miami, FL: August 1997, October 1997, May 1998; November 1998; June 1999
Director, Diabetes Pre-Session Course, American College of Physicians Annual Meeting; San Diego, CA: April
1998
Chairman, Organizing Committee, NIH Workshop on Future Directions for Prevention of Type 1 Diabetes,
Miami, FL: January 2000
Director, American Diabetes Association Forty-Seventh National Postgraduate Course, Honolulu, Hawaii:
January 2000
Co-Chairman, American Diabetes Association Clinical Education Program “Insulin Therapy in the 21 st Century”:
2002-2003
Chairman, Organizing Committee, TrialNet Retreat on Immunologic Mechanisms & Animal Models for Type 1
Diabetes, Washington, DC: September 2003
Co-Chairman, NovoNordisk Diabetes Summit
Dallas: April 2005
Co-Chairman, Cardiometabolic Health Congress
Boston: October 2006
Director, American Diabetes Association Fifty-Fourth National Postgraduate Course, New York City: February
2007
Co-Chairman, NovoNordisk Diabetes Summit
Orlando: March 2007
Co-Chairman, Cardiometabolic Health Congress
Boston: September 2007
Director, American Diabetes Association Fifty-Fifth National Postgraduate Course, San Francisco:
January/February 2008
Co-Chairman, Cardiometabolic Health Congress
Boston: October 2008
Co-Chairman, Cardiometabolic Health Congress
Boston: October 2009
Co-Chairman, University of Colorado Keystone Diabetes Conference
Keystone, Colorado: July 2010
Co-Chairman, Cardiometabolic Health Congress
Boston: October 2010
Co-Chairman, University of Colorado Keystone Diabetes Conference
Keystone, Colorado: July 2011
Director, Rising Stars Program at the University of Miami: July 2011
Co-Chairman, International Society of Pediatric and Adolescent Diabetes; Miami – October 2011
Co-Chairman, Cardiometabolic Health Congress
Boston: October 2011
Co-Chairman, University of Colorado Keystone Diabetes Conference
Keystone, Colorado: July 2012
Director, Rising Stars Program at the University of Miami: July-August 2012
Co-Chairman, Cardiometabolic Health Congress
Boston: October 2012
Co-Chairman, University of Colorado Keystone Diabetes Conference
Keystone, Colorado: July 2013
Director, Rising Stars Program at the University of Miami: August 2013
Co-Chairman, Cardiometabolic Health Congress
Boston: October 2013
Co-Chairman, University of Colorado Keystone Diabetes Conference
Keystone, Colorado: July 2014
Jay S. Skyler
Page 30
Co-Chairman, Cardiometabolic Health Congress
Boston: October 2014
Co-Chairman, Cardiometabolic Health Congress
Boston: October 2015
Curriculum Vitae
Teaching (University of Miami)
General Internal Medicine, Third & Fourth Year Medical Students, and House Staff: 1976 - 2005
Mechanisms of Disease, Endocrinology and Metabolism, Second Year Medical Students: 1977 - 2003
Mechanisms of Disease, Endocrinology and Metabolism, Ph.D.-M.D. Students: 1977 - 1989
Endocrinology and Metabolism, and Diabetes Clinical Electives, Fourth Year Medical Students and House Staff:
1976 - 2012
Introduction to the Patient, First Year Medical Students: 1981 - 1983
Endocrinology Core Course, First Year Medical Students: 1984 – 2001
Endocrinology Diabetes & Metabolism Core Course, Second Year Medical Students: 2004 - 2012
13. PATENTS ISSUED
United States Patent # 5,422,125
Skyler, Jay S.; Frost, Phillip; Hahn, Elliot F.
Method and composition for treatment of insulin resistance syndromes
Filed: October 12, 1994; Issued: June 6, 1995
13. OTHER PROFESSIONAL ACTIVITIES (Selected)
Florida Department of Health & Rehabilitative Services Division of Children's Medical Services
Director, Southeast Florida Regional Diabetes Program for Children and Youth: 1977-1986
North Carolina Camp for Children with Diabetes
Physician & Medical Director: 1970-1980, 1982
Consultant: 1981, 1983-1985
International Workshops on Diabetes and Camping
Planning Committee, First Three Workshops: 1974-1976
Chairman, Planning Committee, Second Workshop: 1975
Eagles Nest Camp Foundation
Board of Trustees: 1976-2000; Emeritus Trustee: 2000-Present
Chairman, Committee on Diabetes Camping: 1976-1979
Executive Committee: 1978-1981
The National Foundation - March of Dimes
Grant Reviewer: 1979
Washington University Diabetes Research and Training Center
Ad Hoc Reviewer: 1980, 1989
The Educational Foundation of America
Ad Hoc Reviewer: 1980
The Kroc Foundation
Ad Hoc Reviewer: 1982
Canadian Diabetes Association
Ad Hoc Reviewer: 1984, 1986, 1987
The John D. & Catherine T. MacArthur Foundation
Grant Reviewer: 1985
Diabetes and Behavioral Medicine Study Group Member, 1986-1988
University of Massachusetts Diabetes/Endocrinology Research Center
Ad Hoc Reviewer: 1985
University of Pennsylvania Diabetes/Endocrinology Research Center
Ad Hoc Reviewer: 1990, 1991
Jay S. Skyler
Page 31
Curriculum Vitae
Sansum Research Foundation
Consultant: 1997
National Multiple Sclerosis Society
Consultant: 2006
National Institutes of Diabetes Digestive & Kidney Diseases Intramural Program
Ad Hoc Reviewer: 2006
Netherlands Organisation for Health Research and Development
Ad Hoc Reviewer: 2007
Australian National Health and Medical Research Council
Ad Hoc Reviewer: 2007
US Civilian Research & Development Foundation
Ad Hoc Reviewer: 2007
National Institutes of Health Clinical Center
Ad Hoc Reviewer: 2008
University of Washington Diabetes/Endocrinology Research Center
Ad Hoc Reviewer: 2008
University of Leuven (K.U.Leuven)
Ad Hoc Reviewer: 2008, 2012, 2013
Leiden University Medical Center
Ad Hoc Reviewer: 2009
Harvard Medical School
Promotions & Tenure Committee: Special Member: 2014, 2015
Jay S. Skyler
Page 32
Curriculum Vitae
BIBLIOGRAPHY
1. SCIENTIFIC ARTICLES
1) Kredich NM, Skyler JS, Foote LJ: A Rapid and Quantitative Method for Determination of Antibodies to DNA in Systemic Lupus
Erythematosus. Archives of Internal Medicine 1973; 131:639-644
2) Skyler JS, Ellis GJ, Delcher HK: Carolinas' Camp for Diabetic Children. I. Report of First Five Years of Operation. North
Carolina Medical Journal 1973; 34:935-938
3) Skyler JS, Ellis GJ, Bivins CH: Carolinas' Camp for Diabetic Children. II. Descriptive Features of a Camper Population with
Emphasis on Complications. North Carolina Medical Journal 1974; 35:29-32
4) Skyler JS, Neelon FA, Arnold WG, Kelley WN, Lebovitz HE: Growth Retardation in the Lesch-Nyhan Syndrome. Acta
Endocrinologica 1974; 75:3-10
5) Lebovitz HE, Skyler JS, Boyd AE: L-DOPA and Growth Hormone Secretion in Man. Advances in Neurology 1974; 5:461-469
6) Chrambach A, Skyler JS: The Application of Steady State Stacking to Macromolecular Fractionation by Polyacrylamide Gel
Electrophoresis. Protides of the Biological Fluids 1975; 22:701-713
7) Skyler JS: Camping for Youths with Diabetes Mellitus: Results and Analysis a Survey of Camps, 1973. In: Etzwiler DD, Robb J
(Eds), Proceedings of the First International Workshop on Diabetes and Camping, Diabetes Education Center, Minneapolis, 1974,
pp 27-42
8) Skyler JS, Newborg, BC, Peschel RL, Kempner W: Treatment of Massive Obesity. In: Howard A (Ed), Recent Advances in
Obesity Research, Newman Press, London, 1975; 1:284-285
9) Feldman JM, Bivins CH, Skyler JS, Lebovitz HE: Effects of Cyproheptadine on Insulin and Growth Hormone Secretion in
Acromegalic, Diabetic and Normal Subjects. Hormone and Metabolic Research 1975; 7:279-283
10) Kempner W, Newborg BC, Peschel RL, Skyler JS: Treatment of Massive Obesity with Rice/Reduction Diet Program: An Analysis
of 106 Patients with at Least 45 Kilograms Weight Lost. Archives of Internal Medicine 1975; 135:1575-1584
11) Knazek RA, Skyler JS: Polypeptide Hormone Production by Cells Cultured on Artificial Capillaries. In: Pecile A, Mueller E
(Eds), Growth Hormone and Related Peptides, Excerpta Medica, Amsterdam, 1976, pp 386-395
12) Knazek RA, Skyler JS: Secretion of Human Prolactin In Vitro. Proceedings of the Society of Experimental Biology and
Medicine 1976; 151:561-564
13) Jimmerson DC, Post RM, Skyler JS, Bunney WE: A Preliminary Report: Neuroendocrine Effects of Dopamine and
Norepinephrine Receptor Stimulators. Psychopharmacology Bulletin 1976; 12 (4):24-26
14) Slater S, De La Vega CE, Skyler JS, Murphy DL: Plasma Prolactin Stimulation by Fenfluramine and Amphetamine.
Psychopharmacology Bulletin 1976; 12 (4):26-27
15) Zweerink HJ, Morgan EM, Skyler JS: Reovirus Morphogenesis: Characterization of Subviral Particles in Infected Cells.
Virology 1976; 73:442-453
16) Jimmerson DC, Post RM, Skyler JS, Bunney WE: Prolactin in Cerebrospinal Fluid and Dopamine Function in Man. Journal of
Pharmacy and Pharmacology 1976; 28:845-847
17) Skyler JS, Rogol AD, Lovenberg W, Knazek RA: Characterization of Growth Hormone and Prolactin Produced by Human
Pituitary in Culture. Endocrinology 1977; 100:283-291
18) Skyler JS, Baumann G, Chrambach A: A Catalogue of Isohormones of Human Growth Hormone Based on Quantitative
Polyacrylamide Gel Electrophoresis. Acta Endocrinologica Supplementum 1977; 211:1-40
19) Skyler JS, Chrambach A, Li CH: Quantitative Polyacrylamide Gel Electrophoresis and Specific Activities of Human Growth
Hormone and Its Derivatives. Biochimica et Biophysica Acta 1977; 491:566-572
20) Lebovitz FL, Ellis GJ, Skyler JS: Increased Independence in Management of Diabetes Mellitus After Attending Summer Camp.
Diabetes Care 1978; 1:23-26
Jay S. Skyler
Page 33
Curriculum Vitae
21) Skyler JS, Lasky IA, Skyler DL, Robertson EG, Mintz DH: Home Blood Glucose Monitoring As An Aid In Diabetes
Management. Diabetes Care 1978; 1:150-157
22) Skyler JS, Ellis GJ, Skyler DL, Lasky IA, Lebovitz FL: Instructing Patients in Making Alterations in Insulin Dosage. Diabetes
Care 1979; 2:39-45
23) Skyler JS, O'Sullivan MJ, Robertson EG, Skyler DL, Lasky IA, Holsinger KK, McLeod AGW, Burkett G, Mintz DH: Blood
Glucose Control During Pregnancy. Diabetes Care 1980; 3:69-76
24) Skyler JS, Alberti KGMM: Clinical Assessment of Metabolic Control in Insulin-Dependent Diabetes Mellitus. Diabetes Care
1980; 3:369-370
25) Skyler JS, O'Sullivan MJ, Holsinger KK: The Relationship Between Maternal Glycemia and Macrosomia. Diabetes Care 1980;
3:433-434
26) Linn MW, Linn BS, Skyler JS, Harris R: The Importance of Self-Assessed Health in Patients with Diabetes. Diabetes Care 1980;
3:599-606
27) Jimmerson DC, Post RM, Van Kammen DP, Skyler JS, Brown GL, Bunney WE: Cerebrospinal Fluid Cortisol Levels in
Depression and Schizophrenia. American Journal of Psychiatry 1980; 137:979-980
28) Skyler JS, Skyler DL, Seigler DE, O'Sullivan MJ: Algorithms for Adjustment of Insulin Dosage by Patients Who Monitor Blood
Glucose. Diabetes Care 1981; 4:311-318
29) Reeves M, Forhan SE, Skyler JS, Peterson CM: Comparison of Methods for Blood Glucose Monitoring. Diabetes Care 1981;
4:404-406
30) Skyler JS, Seigler DE, Reeves ML: Optimizing Pumped Insulin Delivery. Diabetes Care 1982; 5:135-139
31) Reeves M, Seigler DE, Ryan EA, Skyler JS: Glycemic Control in Insulin-Dependent Diabetes Mellitus: Comparison of Outpatient
Intensified Conventional Therapy with Continuous Subcutaneous Insulin Infusion. American Journal of Medicine 1982; 72:673-680
32) Harris R, Skyler JS, Linn MW, Pollack L, Tewksbury D: Relationship Between the Health Belief Model and Compliance As a
Basis for Intervention in Diabetes Mellitus. Pediatric and Adolescent Endocrinology 1982; 10:123-132
33) Lieberman LS, Rosenbloom AL, O'Malley B, Malone JI, Skyler JS: Institutionally-Based Diabetes Educational Services for
Patients and their Families in Florida. Journal of the Florida Medical Association 1982; 69:23-31
34) Seigler DE, Reeves ML, Skyler JS: Lack of Effect of Improved Glycemic Control on C-Peptide Secretion in Patients Without
Residual B-Cell Function. Diabetes Care 1982; 5:334-336
35) Seigler DE, LaGreca A, Citrin WS, Reeves ML, Skyler JS: Psychological Effects of Intensification of Diabetic Control. Diabetes
Care 1982; 5 (Suppl. 1):19-23
36) Linn MW, Linn BS, Skyler JS, Jensen J: Stress and Immune Function in Diabetes Mellitus. Clinical Immunology and
Immunopathology 1983; 27:223-233
37) Ryan EA, Miller J, Skyler JS: Finger Sepsis - A Possible Complication of Self-Monitoring of Blood Glucose. British Medical
Journal 1983; 286:1614-1615
38) Duncan BB, Schmidt MI, Skyler JS, Ellis GJ, Keller A, Rathjens M: The Flashlight Test Lacks Validity As a Screen for Nocturnal
Hypoglycemia. Diabetes Care 1984; 7:269-272
39) Reeves ML, Seigler DE, Ayyar DR, Skyler JS: Medical Plantar Sensory Response: A Sensitive Indicator of Peripheral Nerve
Dysfunction in Patients with Diabetes Mellitus. American Journal of Medicine 1984; 76:842-846
40) Goldberg RB, Reeves ML, Seigler DE, Ryan EA, Miller N, Hsia SL, Skyler JS: Lack of a Persistent Reduction in Serum Lipid &
Apoprotein Levels in Insulin-Dependent Diabetic Patients Receiving Intensified Insulin Treatment. Acta Diabetologia Latina 1985;
22:93-101
41) Ryan EA, O'Sullivan MJ, Skyler JS: Insulin Action During Pregnancy: Studies with the Euglycemic Clamp Technique. Diabetes
1985; 34:380-389
Jay S. Skyler
Page 34
Curriculum Vitae
42) Boulton AJM, Bowker JH, Gadia M, Lemerman R, Caswell K, Skyler JS, Sosenko JM: The Use of Plaster Casts in the
Management of Diabetic Neuropathic Foot Ulcers. Diabetes Care 1986; 9:149-152
43) Boulton AJM, Cutfield RG, Abouganem D, Angus E, Flynn HW, Skyler JS, Penneys NS: Necrobiosis Lipoidica Diabeticorum: A
Clinicopathological Study and Review of the Literature. Journal of the American Academy of Dermatology 1988; 18:530-537
44) Boulton AJM, Kubrusly DB, Bowker JH, Gadia M, Quintero LC, Becker, DM, Skyler JS, Sosenko JM: Risk Factors for Diabetic
Foot Ulcers. Diabetic Medicine 1986; 3:335-337
45) Sosenko JM, Boulton AJM, Kubrusly DB, Weintraub JK, Pasin RA, Schneiderman N, Skyler, JS: Autonomic Function and Heart
Rate in Young Diabetic Patients. Journal of Pediatric Endocrinology 1985; 1:207-210
46) Sosenko JM, Boulton AJM, Kubrusly DB, Weintraub JK, Skyler, JS: The Vibratory Perception Threshold in Young Diabetic
Patients: Associations with Glycemia and Puberty. Diabetes Care 1985; 8:605-607
47) Sosenko JM, Kubrusly DB, Goldberg RB, Fournier AM, Hsia SL, Gadia MT, Skyler JS: High Density Lipoprotein Components
and Variation of Glycemia in Nondiabetic Individuals. Archives of Internal Medicine 1986; 146:1521-1524
48) Sosenko JM, Gadia MT, Fournier AM, O'Connell MT, Aguiar MC, Skyler JS: Body Stature: A Major Risk Factor for Diabetic
Peripheral Neuropathy. American Journal of Medicine 1986; 80:1031-1034
49) Fournier AM, Gadia MT, Kubrusly DB, Skyler JS, Sosenko JM: Blood Pressure, Insulin, and Glycemia in Non-Diabetic
Individuals. American Journal of Medicine 1986; 80:861-864
50) Harris R, Linn MW, Skyler JS, Sandifer R: Development of the Diabetes Health Beliefs Scale (DHBS). Diabetes Educator 1987;
13:292-297
51) Gadia MT, Natori N, Ramos LB, Ayyar DR, Skyler JS, Sosenko JM: The Influence of Height on Neurofunctional, Nerve
Conduction, and Clinical Indices of Diabetic Peripheral Neuropathy. Diabetes Care 1987; 10:613-616
52) Sosenko JM, Gadia MT, Natori N, Ramos LB, Ayyar DR, Ramos LB, Skyler JS: Neurofunctional Testing for the Detection of
Diabetic Peripheral Neuropathy. Archives of Internal Medicine 1987; 147:1741-1744
53) Sosenko JM, Boulton AJM, Gadia MT, Ward JD, Skyler JS: The Association Between Symptomatic Sensory Neuropathy and
Body Stature in Diabetic Patients. Diabetes Research & Clinical Practice 1988; 4:95-98
54) Gadia MT, Skyler JS, Sosenko JM: The Association Between Heart Rate and Glycemia in Adult Diabetic Subjects. Diabetes
Research & Clinical Practice 1988; 5:25-29
55) Satin W, LaGreca AM, Zigo MA, Skyler JS: Diabetes in Adolescence: Effects of Multi-Family Group Therapy and Parent
Simulation of Diabetes. Journal of Pediatric Psychology 1989; 14:259-276
56) LaGreca AM, Follansbee D, Skyler JS: Developmental and Behavioral Aspects of Diabetes Management Among Children and
Adolescents. Childrens Health Care 1990; 19:132-139
57) Boulton AJM, Levin S, Comstock J, and the North American Tolrestat in Neuropathy Research Group [Skyler JS – Study Group
Participant]. A Multicentre Trial of the Aldose Reductase Inhibitor, Tolrestat, in Patients with Symptomatic Diabetic Neuropathy.
Diabetologia 1990; 33:431-437
58) Martinez R, Rietberg B, Skyler J, Oster JR, Perez GO. Effect of Hyperkalemia on Insulin Secretion. Experentia 1991; 47:270272
59) Peckerman A, Saab PG, McCabe PM, Skyler JS, Winters RW, Llabre MM, Schneiderman N. Blood Pressure Reactivity and
Perception of Pain During the Forehead Cold Pressor Test. Psychophysiology 1991; 28:485-495
60) Seigler DE, Olsson GM, Agramonte RF, Lohman VL, Ashby MH, Reeves ML, Skyler JS: Pharmacokinetics of Long-Acting
(Ultralente) Insulin Preparations. Diabetes Nutrition & Metabolism 1991; 4:267-273.
61) Skyler JS, Rabinovitch A, and the Miami Cyclosporine Diabetes Study Group [Skyler JS, Rabinovitch A, Agramonte R, Lohman V, Reeves ML,
Goldberg RB, Shienvold FL, Esquenazi V, Fletcher MA, Palmberg PF, Mintz DH, Ashby M, Sumowski W, Rathjens M, Miceli G, Winter D, Winslow C, Ferstenberg LB,
Rodbard D]: Cyclosporine in Recent Onset Type I Diabetes Mellitus: Effects on Islet Beta Cell Function. Journal of Diabetes and Its
Complications 1992; 6:77-88.
62) Hirsch IB, Farkas-Hirsch R, Herbst JS, Skyler JS: The Effect of Ejaculation on Albumin Excretion Rate. Journal of Diabetes and
Its Complications 1992; 6:163-165.
Jay S. Skyler
Page 35
Curriculum Vitae
63) Seigler DE, Olsson GM, Skyler JS: Morning versus Bedtime NPH Insulin in Type II (Non-Insulin Dependent) Diabetes Mellitus.
Diabetic Medicine 1992; 9:826-833.
64) Skyler JS, Lorenz TJ, Schwartz S, Eisenbarth GS, Einhorn D, Palmer JP, Marks JB, Greenbaum C, Saria EA, Byers V, and the
CD5-Plus Diabetes Project Team: Effects of An Anti-CD5 Immunoconjugate (CD5-Plus) in Recent Onset Type I Diabetes Mellitus A Preliminary Investigation. Journal of Diabetes and Its Complications 1993; 7:224-232.
65) Burke GW, Cirocco R, Markou M, Agramonte RF, Rabinovitch A, Miller J, Skyler JS: Effect of Cyclosporine A on Serum Tumor
Necrosis Factor  in New Onset Type I (Insulin-Dependent) Diabetes Mellitus. Journal of Diabetes and Its Complications 1994;
8:40-44.
66) Hurwitz BE, Quillian RE, Marks JB, Schneiderman N, Freeman CR, LaGreca AM, Nagel JH, Agramonte RF, Skyler JS: Resting
Cardiac Parasympathetic Status and Cardiovascular Response to Challenge in Type I Insulin Dependent Diabetes Mellitus.
International Journal of Behavioral Medicine 1994; 1:137-162.
67) Radziuk J, Pye S, Seigler DE, Skyler JS, Offord R, Davies G: Splanchnic and Systemic Absorption of Intraperitoneal Insulin
Using a New Double Tracer Method. American Journal of Physiology 1994; 266: (Endocrinology & Metabolism 29):E750-E759.
68) LaGreca AM, Swales T, Klemp S, Madigan S, Skyler JS: Adolescents with Diabetes: Gender Differences in Psychosocial
Functioning and Glycemic Control. Childrens' Health Care 1995; 24:61-78.
69) Burke GW, Ricordi C, Karatzas T, Carreno M, Cirocco R, Ciancio G, Coker D, Quian T, Selvaggi G, Alejandro R, Skyler JS,
Tzakis A, Roth D, Nery J, Miller J: Donor Bone Marrow Infusion in Simultaneous Pancreas/Kidney Transplant Recipients: A
Preliminary Study. Transplantation Proceedings 1995; 27:3121-3122.
70) Burke GW, Alejandro R, Roth D, Colona J, Contreras N, Ciancio G, Skyler JS, Ricordi C, Nery J, Tzakis A, Miller J: Use of FK506 in Simultaneous Pancreas/Kidney Transplantation: Lack of Impairment of Glycemic or Lipid Metabolism. Transplantation
Proceedings 1995; 27:3119-3120.
71) Burke GW, Alejandro R, Ciancio G, Nery J, Roth D, Shapiro R, Scantlebury V, Skyler JS, Ricordi C, Tzakis A, Miller J: The
Use of FK-506 in Simultaneous Pancreas/Kidney Transplantation: Rescue, Induction, and Maintenance Immunosuppression.
Transplantation Proceedings 1995; 27:3123-3124.
72) Laffel LM, McGill JB, Gans DJ for the North American Microalbuminuria Study Group [Skyler JS – Study Group Participant].
The Beneficial Effect of Angiotensin-Converting Enzyme Inhibition with Captopril on Diabetic Nephropathy in Normotensive IDDM
Patients with Microalbuminuria. American Journal of Medicine 1995; 99:497-504.
73) Donahue RP, Prineas RJ, Donahue RC, Bean JA, Skyler JS: The Female “Insulin Advantage” in a Biracial Cohort: Results from
The Miami Community Health Study. International Journal of Obesity 1996; 20:76-82.
74) The Microalbuminuria Captopril Study Group [Skyler JS – Study Group Participant]. [Boner G, Van Dyk DJ, Tan MH, Tan J, Ekstrand A,
Koivisto VA, Groop LC, Groop PH, Lucas A, Romero R, Salinas I, Sanmarti A, Escobar F, Escobar-Jimenez F, Campos-Pastor MM, Mugoz M, Gomez M, Mangili R, Pozza
G, Spotti D, Hansen KW, Christiansen JS, Klein F, Mogensen CE, Van Doorn LG, Spooren PFMJ, Cruickshank JK, Jervell J, Paus PN, Barnes DJ, Collins A, Viberti GC,
Williams G, Nelstrop GA, Amorosa L, Anolik JR, Aronoff SL, Eubank B, Bailie M, Pelletier L, Blevins T, Charles MA, Perry M, Clarke D, Tomkey D, Einhorn D, Humphries
D, Garber AJ, Haag B, Williams E, Hoy W, Watkins M, Kahkonen D, Kruger D, Kilo C, Laffel L , Golden E, Lodewick P, Lovinskyad, Mason J, Johnson S, McGill J, Schmidt
L, Orlander P, Sorenson K, Raskin P , Hellenbrand D, Rosenblatt S, Schwartz S, Aufieri J, Sheehan JP, Ulchaker M, Skyler JS, Agramonte R, Starr J, Gagliastre D, Taylor T,
Dawn K, Ward WK, Rigdon M.]. Captopril Reduces The Risk of Nephropathy in IDDM Patients With Microalbuminuria. Diabetologia 1996;
39:587-593.
75) Donahue RP, Donahue RC, Prineas RJ, Bean JA, Gutt M, Skyler JS, Schneiderman N: Insulin Sensitivity and Blood Pressure in
a Biethnic Sample: The Miami Community Health Study. Journal of Clinical Epidemiology 1996; 49:859-864.
76) Anderson JH, Brunnelle RL, Koivisto VA, Pfutzner A, Trautmann ME, Vignati L, DiMarchi R, and the Multicenter Insulin
Lispro Study Group [Skyler JS – Study Group Participant]. Reduction of Postprandial Hyperglycemia and Frequency of
Hypoglycemia in IDDM Patients During Insulin Analog Treatment. Diabetes 1997; 46:265-270.
77) Weber SL, Gkonos PJ, Skyler JS: Combined Octreotide and Insulin Therapy in Acromegaly. Endocrine Practice 1997; 3:1921.
78) Burke GW, Ricordi C, Karatzas T, Carreno M, Markou M, Cirocco R, Ciancio G, Qian T, Selvaggi G, Alejandro R, Skyler JS,
Roth D, Tzakis A, Miller J: Donor Bone Marrow Infusion in Simultaneous Pancreas/Kidney Transplantion with OKT3 Induction:
Evidence for Augmentation of Chimerism. Transplantation Proceedings 1997; 29:1207-1208.
79) Donahue RP, Prineas RJ, Bean JA, Donahue RC, Goldberg RB, Skyler JS, Schneiderman N: The Relationship of Fasting Insulin
to Blood Pressure in a Multiethnic Population: The Miami Community Health Study. Annals of Epidemiology 1998; 8:236-244.
Jay S. Skyler
Page 36
Curriculum Vitae
80) Burke GW, Ciancio G, Alejandro R, Roth D, Ricordi C, Skyler JS, Tzakis A, Miller J: Cholesterol Control: Long-Term Benefit
of Pancreas-Kidney Transplantion with FK 506 Immunosuppression. Transplantation Proceedings 1998; 30:513-514.
81) Bril V, Ellison R, Ngo M, Bergstrom B, Raynard D, Gin H, and the Roche Neuropathy Study Group [Skyler JS – Study Group
Participant]. Electrophysiological Monitoring in Clinical Trials. Muscle & Nerve 1998; 21:1368-1373.
82) Donahue RP, Prineas RJ, Donahue RD, Zimmet P, Bean JA, De Courten M, Collier G, Goldberg RB, Skyler JS, Schneiderman N.
Is Fasting Leptin Associated with Insulin Resistance among Nondiabetic Persons? The Miami Community Health Study. Diabetes
Care 1999; 22: 1092-1096.
83) Gutt M, Davis CL, Spitzer S, Llabre MM, Kumar M, Czarnnecki E, Schneiderman N, Skyler JS, Marks JB. Validation of the
Insulin Sensitivity Index (ISI0,120): Comparison with Other Measures. Diabetes Research & Clinical Practice 2000; 47:177-184.
84) Donahue RP, Zimmet P, Bean JA, de Courtier M, Donahue RC, Collier G, Goldberg RB, Skyler JS, Schneiderman N, Prineas RJ:
Cigarette Smoking, Alcohol Use and Physical Activity in Relation to Serum Leptin Levels in a Multiethnic Population: The Miami
Community Health Study. Annals of Epidemiology 1999; 9:108-113.
85) Motivala SJ, Hurwitz BE, LaGreca AM, Llabre MM, Marks JB, Skyler JS, Schneiderman N. Aberrant Parasympathetic and
Hemodynamic Function Distinguishes A Sub-Group of Psychologically-Distressed Individuals with Asymptomatic Type 1 Diabetes
Mellitus. International Journal of Behavioral Medicine 1999; 6:78-94.
86) Davis CL, Gutt M, Llabre MM, Marks JB, O’Sullivan MJ, Potter JE, Landel JL, Schneiderman N, Kumar M, Gellman M, Skyler
JS. History of Gestational Diabetes, Insulin Metabolism, and Coronary Risk. Journal of Diabetes and Its Complications 1999;
13:216-223.
87) Heller A, McGarraugh G, Feldman B, Bohannon N, Skyler J, DeLeeuw E, Clarke D. FreeStyle™ : A Small (300 nL ) Volume
Electrochemical Glucose Sensor for Home Blood Glucose Testing. Diabetes Technology & Therapeutics 2000; 2:221-229.
88) Goldstein RZ, Hurwitz BE, Llabre MM, Schneiderman N, Gutt M, Skyler JS, Prineas RJ, Donahue RP. Modeling Preclinical
Cardiovascular Risk for Use in Epidemiologic Studies: Miami Community Health Study. American Journal of Epidemiology 2001;
154:765-776..
89) Bode B, Weinstein R, Bell D, McGill J, Nadeau D, Raskin P, Davidson J, Henry R, Huang WC, Reinhardt RR for The Insulin
Aspart CSII Pump Study Group [Skyler JS – Study Group Participant]. Comparison of insulin aspart with buffered regular insulin and
insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes.
Diabetes Care 2002; 25:439-444.
90) Raskin P, Bode BW, Marks JB, Hirsch IB, Weinstein RL, Janet B. McGill JB, Peterson GE, Mudaliar SR, Reinhardt RR, and The
Insulin Aspart CSII Study Group in Type 2 Diabetes [Skyler JS – Study Group Participant]. Continuous Subcutaneous Insulin
Infusion and Multiple Daily Injection Therapy Are Equally Effective in Type 2 Diabetes: A randomized, parallel-group, 24-week study
Diabetes Care 2003; 26:2598-2603
91) Hurwitz BE, Klimas NG, Llabre MM, Maher KJ, Skyler JS, Bilsker MS, McPherson-Baker S, Lawrence PJ, LaPerriere AR,
Greeson JM, Klaus J, Lawrence R, Schneiderman N. HIV, Metabolic Syndrome X, Inflammation, Oxidative Stress, and Coronary
Heart Disease Risk: Role of Protease Inhibitor Exposure. Cardiovascular Toxicology 2004; 4:303-316.
92) Bolton WK, Cattran DC, Williams ME, Adler SG, Appel GB, Cartwright K, Foiles PG, Freedman BI, Raskin P, Ratner RE,
Spinowitz BS, Whittier FC, Wuerth JP; ACTION I Investigator Group [Skyler JS – Study Group Participant]. Randomized trial of
an inhibitor of formation of advanced glycation end products in diabetic nephropathy. American Journal of Nephrology 2004;
24:32-40
93) Hurwitz BE, Klaus JR, Llabre MM, Gonzalez A, Lawrence PJ, Maher KJ, Greeson JM, Baum MK, Shor-Posner G, Skyler JS,
Schneiderman N. Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized
controlled trial. Archives of Internal Medicine 2007; 167:148-154.
94) Klaus JR, Hurwitz BE, Llabre MM, Skyler JS, Goldberg RB, Marks JB, Bilsker MS, Schneiderman N. Central Obesity and
Insulin Resistance in the Cardiometabolic Syndrome: Pathways to Preclinical Cardiovascular Structure and Function. Journal of
Cardiometabolic Syndrome 2009; 4:63–71.
95) Han D, Leyva CA, Della Matheson D, Mineo D, Messinger S, Blomberg BB, Hernandez A, Meneghini LF, Allende G, Skyler JS,
Alejandro R, Pugliese A, Kenyon NS. Immune Profiling by Multiple Gene Expression Analysis in Patients At-risk and with Type 1
Diabetes. Clinical Immunology 2011; 139:290-301.
96) Faleo G, Fotino F, Bocca N, Molano RD, Zahr-Akraw E, Molina J, Villate S, Umland O, Skyler JS, Bayer AL, Ricordi C, Pileggi
Jay S. Skyler
Page 37
Curriculum Vitae
A. Prevention of Autoimmune Diabetes and Induction of Beta-Cell Proliferation in NOD mice by Hyperbaric Oxygen Therapy.
Diabetes 2012; 61:1769-1778.
97) Han D, Cai X, Wen J, Matheson D, Skyler JS, Kenyon NS, Chen Z. Innate and adaptive immune gene expression profiles as
biomarkers in human type 1 diabetes. Clinical and Experimental Immunology 2012; 170:131-138.
98) Roep BO, Solvason N, Gottlieb PA, Abreu JR, Harrison LC, Eisenbarth GS, Yu L, Leviten M, Hagopian WA, Buse JB, von
Herrath M, Quan J, King RS, Robinson WH, Utz PJ, Garren H; BHT-3021 Investigators, Steinman L [Skyler JS – Study Group
Participant]. Plasmid-encoded proinsulin preserves C-peptide while specifically reducing proinsulin-specific CD8⁺ T cells in type 1
diabetes. Science Translational Medicine 2013 Jun 26;5(191):191ra82. doi: 10.1126/scitranslmed.3006103.
99) Garg SK, Buse JB, Skyler JS, Vaughn DE, Muchmore DB. Subcutaneous Injection of Hyaluronidase with Human Regular Insulin
Compared with Insulin Lispro in Type 1 Diabetes. Diabetes Obesity Metabolism 2014; 16:1065-1069.
100) Eckel RC, Henry RR, Yue P, Dhalla A, Wong P, Jochelson P, Belardinelli L, Skyler JS. The effect of ranolazine monotherapy
on glycemic control in subjects with type 2 diabetes mellitus. Diabetes Care 2015; 38:1189-1196.
101) Hurwitz BE, Schneiderman N, Marks JB, Mendez AJ, Gonzalez A, Llabre MM, Smith SR, Bizzotto R, Santini E, Manca ML,
Skyler JS, Mari A, Ferrannini E. Adaptation of β-cell and Endothelial Function to Carbohydrate Loading: Influence of Insulin
Resistance. Diabetes 2015; 64:2550-2559.
102) Skyler JS, Fonseca VA, Segal KR, Rosenstock J, on behalf of the MSB-DM003 Investigators. Allogeneic Mesenchymal
Precursor Cells in Type 2 Diabetes: A Randomized, Placebo-controlled, Dose Escalation Safety and Tolerability Pilot Study. Diabetes
Care 2015; 38:1742-1749.
103) Bode BW, Skyler JS, Hirsch IB, Garg SK, Buse JB, Zinman B, Rodbard D, Hompesch M, Morrow LA, Wu XW, Huang Y,
Bruce SR, Vaughn DE, Muchmore DB. Pretreatment of Subcutaneous Insulin Infusion Sites with Recombinant Human Hyaluronidase
Provides Consistent Acceleration of Rapid Acting Analog Insulin Absorption and Action with Improved Postprandial Glucose Control.
Submitted for Publication.
104) Saab PG, McCalla JR, Spitzer SB, Musto AA, Llabre MM, Goldberg RB, Zhao F, Fitzpatrick S, LaPerriere A, Skyler JS,
Hurwitz BE, Schneiderman N. Cardiovascular Risk in Adolescents: The Influence of Blood Pressure Status. Submitted for
Publication.
a. DPT-1 Study Group References
1) DPT-1 Study Group. The Diabetes Prevention Trial-Type 1 Diabetes (DPT-1) [Skyler JS – Study Group Chairman].
Implementation of Screening and Staging of Relatives. Transplantation Proceedings 1995; 27: 3377.
2) Greenbaum CJ, Schatz DA, Cuthbertson D, Zeidler A, Eisenbarth GS, Krischer JP, The Diabetes Prevention Trial–Type 1 Study
Group [Skyler JS – Study Group Chairman]. Islet Cell Antibody-Positive Relatives With Human Leukocyte Antigen DQA1*0102,
DQB1*0602: Identification by the Diabetes Prevention Trial-Type 1. Journal of Clinical Endocrinology & Metabolism 2000;
85:1255-1260
3) Greenbaum CJ, Cuthbertson D, Krischer JP, and the Diabetes Prevention Trial of Type 1 Diabetes Study Group [Skyler JS – Study
Group Chairman]. Type 1 Diabetes Manifested Solely by 2-h Oral Glucose Tolerance Test Criteria. Diabetes 2001; 50:470-476
4) Chase HP, Cuthbertson DD, Dolan LM, Kaufman F, Krischer JP, Schatz DA, White NH, Wilson DM, Wolfsdorf J, The Diabetes
Prevention Trial–Type 1 Study Group [Skyler JS – Study Group Chairman]. First-phase Insulin Release During The Intravenous
Glucose Tolerance Test As A Risk Factor For Type 1 Diabetes. Journal of Pediatrics 2001; 138:244-249
5) Yu L, Cuthbertson DD, Maclaren N, Jackson R, Palmer JP, Orban T, Eisenbarth GS, Krischer JP, DPT-1 Participating
Investigators [Skyler JS – Study Group Chairman]. Expression of GAD65 and Islet Cell Antibody (ICA512) Autoantibodies Among
Cytoplasmic ICA+ Relatives Is Associated With Eligibility for the Diabetes Prevention Trial-Type 1. Diabetes 2001; 50: 1735-1740.
6) Diabetes Prevention Trial - Type 1 Diabetes Study Group [Skyler JS – Study Group Chairman]. Effects of Insulin in Relatives of
Patients with Type 1 Diabetes Mellitus. New England Journal of Medicine 2002; 346:1685-1691.
7) Yu L, Cuthbertson DD, Eisenbarth GS, Krischer JP, DPT-1 Participating Investigators [Skyler JS – Study Group Chairman].
Diabetes Prevention Trial 1: Prevalence of GAD and ICA512 (IA-2) Autoantibodies by Relationship to Proband. Annals of the New
York Academy of Sciences 2002; 958:254-258.
8) Krischer JP, Cuthbertson DD, Yu L, Orban T, Maclaren N, Jackson R, Winter WE, Schatz DA, Palmer JP, Eisenbarth GS, and
The Diabetes Prevention Trial–Type 1 Study Group [Skyler JS – Study Group Chairman]. Screening Strategies for the Identification
Jay S. Skyler
Page 38
Curriculum Vitae
of Multiple Antibody Positive Relatives of Individuals with Type 1 Diabetes. Journal of Clinical Endocrinology & Metabolism
2003; 88:103-108.
9) Redondo MJ, Fain PR, Krischer JP, Yu L, Cuthbertson D, Winter WE, Eisenbarth GS; on behalf of the DPT-1 Study Group
[Skyler JS – Study Group Chairman]. Expression of beta-cell autoimmunity does not differ between potential dizygotic twins and
siblings of patients with type 1 diabetes. Journal of Autoimmunity 2004; 23:275-279.
10) Krischer JP, Cuthbertson DD, Greenbaum C; Diabetes Prevention Trial-Type 1 Study Group [Skyler JS – Study Group
Chairman]. Male sex increases the risk of autoimmunity but not type 1 diabetes. Diabetes Care 2004; 27:1985-1990.
11) Greenbaum CJ, Eisenbarth G, Atkinson M, Yu L, Babu S, Schatz D, Zeidler A, Orban T, Wasserfall C, Cuthbertson D, Krischer
J, DPT-1 Study Group [Skyler JS – Study Group Chairman]. High Frequency of Abnormal Glucose Tolerance in
DQA1*0102/DQB1*0602 Relatives Identified as Part of the Diabetes Prevention Trial – Type 1 Diabetes. Diabetologia 2005; 48:6874.
12) Diabetes Prevention Trial - Type 1 Diabetes Study Group [Skyler JS – Study Group Chairman]. Effects of Oral Insulin in
Relatives of Patients with Type 1 Diabetes Mellitus. Diabetes Care 2005; 28:1068-1076.
13) Rhodes ET, Wolfsdorf JI, Cuthbertson DD, Feldman HA, Ludwig DS; Diabetes Prevention Trial-Type 1 Study Group [Skyler JS
– Study Group Chairman]. Effect of low-dose insulin treatment on body weight and physical development in children and adolescents
at risk for type 1 diabetes. Diabetes Care 2005; 28:1948-1953.
14) Sosenko JM, Palmer JP, Greenbaum CJ, Mahon J, Cowie C, Krischer JP, Chase HP, White NH, Buckingham B, Herold KC,
Cuthbertson D, Skyler JS, and the Diabetes Prevention Trial-1 Study Group. Patterns of Metabolic Progression to Type 1 Diabetes in
the Diabetes Prevention Trial–Type 1. Diabetes Care 2006; 29: 643-649.
15) Tsai EB, Sherry NA, Palmer JP, Herold KC, and the DPT-1 Study Group [Skyler JS – Study Group Chairman]. The Rise and
Fall of Insulin Secretion in Type 1 Diabetes Mellitus. Diabetologia 2006; 49: 261-270.
16) Barker JM, McFann K, Harrison LC, Fourlanos S, Krischer JP, Cuthbertson D, Chase HP, Eisenbarth GS, and the DPT-1 Study
Group [Skyler JS – Study Group Chairman]. Pre-Type 1 Diabetes Dysmetabolism: Maximal sensitivity achieved with both Oral and
Intravenous Glucose Tolerance Testing. Journal of Pediatrics 2007; 150:31-36.
17) Redondo MJ, Babu S, Zeidler A, Orban T, Yu L, Greenbaum C, Palmer JP, Cuthbertson D, Eisenbarth GS, Krischer JP, Schatz
D, and the DPT-1 Study Group [Skyler JS – Study Group Chairman]. Specific HLA DQ Influence on Expression of Anti-Islet
Autoantibodies and Progression to Type 1 Diabetes. Journal of Clinical Endocrinology & Metabolism 2006; 91: 1705-1713.
18) Sosenko JM, Palmer JP, Greenbaum CJ, Mahon J, Cowie C, Krischer JP, Chase HP, White NH, Buckingham B, Herold KC,
Cuthbertson D, Skyler JS, and the Diabetes Prevention Trial-1 Study Group. Increasing the accuracy of oral glucose tolerance testing
and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes Prevention
Trial- Type 1. Diabetes Care 2007; 30:38-42.
19) Barker JM, McFann KK, Orban T, on behalf of the DPT-1 Study Group [Skyler JS – Study Group Chairman]. Effect of oral
insulin on insulin autoantibody levels in the Diabetes Prevention Trial Type 1 oral insulin study. Diabetologia 2007; 50:1603-1606.
20) Xu P, Cuthbertson D, Greenbaum C, Palmer JP, Krischer JP, and Diabetes Prevention Trial-Type 1 Study Group [Skyler JS –
Study Group Chairman]. The Role of Insulin Resistance in Predicting the Progression to Type 1 Diabetes. Diabetes Care 2007;
30:2314-2320.
21) Johnson SB, Baughcum AE, Hood K, Rafkin-Mervis LE, Schatz DA, for the DPT-1 Study Group [Skyler JS – Study Group
Chairman]. Participant and Parent Experiences in the Parenteral Insulin Arm of the Diabetes Prevention Trial for Type 1 Diabetes.
Diabetes Care 2007; 30: 2193-2197.
22) Sosenko JM, Krischer JP, Palmer JP, Mahon J, Cowie C, Greenbaum CJ, Cuthbertson D, Lachin JM, Skyler JS, and the Diabetes
Prevention Trial-1 Study Group. A Risk Score for Type 1 Diabetes Derived from Autoantibody Positive Participants in The Diabetes
Prevention Trial-Type 1. Diabetes Care 2008; 31: 528-533.
23) Sosenko JM, Palmer JP, Rafkin-Mervis L, Krischer J, Cuthbertson D, Matheson D, Skyler JS, and the DPT-1 Study Group.
Glucose and C-peptide Changes in the Perionset Period of Type 1 Diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care
2008; 31: 2188-2192.
24) Butty V, Campbell C, Mathis D, Benoist C, and the Diabetes Prevention Trial-Type 1 Study Group [Skyler JS – Study Group
Chairman]. Impact of diabetes susceptibility loci on progression from pre-diabetes to diabetes in at-risk individuals of the DPT1 trial.
Diabetes 2008; 57: 2348-2359.
Jay S. Skyler
Page 39
Curriculum Vitae
25) Sherr J, Sosenko J, Skyler JS, Herold K. Prevention of Type 1 diabetes. The time has come. Nature Clinical Practice
Endocrinology & Metabolism 2008; 4:334-343.
26) Johnson SB, Baughcum AE, Rafkin-Mervis LE, Schatz DA, for the DPT-1 Study Group [Skyler JS – Study Group Chairman].
Participant and parent experiences in the oral insulin study of the Diabetes Prevention Trial for Type 1 Diabetes. Pediatric Diabetes
2009; 10:177-183.
27) Sosenko JM, Palmer JP, Rafkin-Mervis L, Krischer J, Cuthbertson D, Skyler JS, and the DPT-1 Study Group. Incident
Dysglycemia and the Progression to Type 1 Diabetes among Participants in the Diabetes Prevention Trial-Type 1. Diabetes Care
2009; 32: 1603-1607.
28) Triolo TM, Chase HP, Barker JM, for the DPT-1 Study Group [Skyler JS – Study Group Chairman]. Diabetic subjects diagnosed
through the Diabetes Prevention Trial-Type 1 (DPT-1) are often asymptomatic with normal A1C at diabetes onset. Diabetes Care
2009; 32:769-773.
29) Orban T, Sosenko JM, Cuthbertson D, Krischer JP, Skyler JS Jackson R, Yu L, Palmer JP, Schatz DA, Eisenbarth GS, and the
DPT-1 Study Group. Pancreatic Autoantibodies as Predictors of Type 1 Diabetes in the Diabetes Prevention Trial-Type 1 (DPT-1).
Diabetes Care 2009; 32:2269-2274.
30) Ferrannini E, Mari A, Nofrate V, Sosenko JM, Skyler, JS, for the DPT-1 Study Group. Progression to diabetes in relatives of
patients with type 1 diabetes: mechanisms and mode of onset. Diabetes 2010; 59:679-685.
31) Sosenko JM, Palmer JP, Rafkin-Mervis L, Krischer J, Cuthbertson D, Greenbaum CJ, Eisenbarth GS, Skyler JS, and the DPT-1
Study Group. Trends of Earlier and Later Responses of C-peptide to Oral Glucose Challenges with Progression to Type 1 Diabetes in
Diabetes Prevention Trial-Type 1 Participants. Diabetes Care 2010; 33:620-625.
32) Sosenko JM, Skyler JS, Krischer JP, Greenbaum CJ, Rafkin LE, Cuthbertson D, Cowie C, Herold K, Eisenbarth GS, Palmer JP,
and The Diabetes Prevention Trial-1 Study Group. Glucose Excursions between States of Glycemia with Progression to Type 1
Diabetes in the Diabetes Prevention Trial-Type 1 (DPT-1). Diabetes 2010; 58: 2386-2389.
33) Xu P, Wu Y, Zhu Y, Dagne G, Johnson G, Cuthbertson D, Krischer JP, Sosenko JM, Skyler JS, on behalf of the DPT-1 Study
Group. Prognostic Performance of Metabolic Indexes in Predicting Onset of Type 1 Diabetes. Diabetes Care 2010; 33:2508-2513.
34) Vehik K, Haller MJ, Beam CA, Schatz DA, Wherrett DK, Sosenko JM, Krischer JP; DPT-1 Study Group [Skyler JS – Study
Group Chairman]. Islet Autoantibody Seroconversion in the DPT-1 Study: Justification for repeat screening throughout childhood.
Diabetes Care 2011; 34:358-62.
36) Greenbaum CJ, Buckingham, B, Chase HP, Krischer J, for the DPT-1 Study Group [Skyler JS – Study Group Chairman].
Metabolic tests to determine risk for type 1 diabetes in clinical trials. Diabetes Metabolism Research & Reviews 2011; 27:584-589.
37) Xu P, Beam C, Cuthbertson D, Sosenko JM, Skyler JS, Krischer JP, on behalf of the DPT-1 Study Group. Prognostic accuracy of
immunologic and metabolic markers for type 1 diabetes in a high risk population: Receiver operating characteristic analysis. Diabetes
Care 2012; 35:1975-1980.
38) Ismail H, Krischer J, Chase HP, Cuthbertson D, Palmer J and DPT-1 Study Group [Skyler JS – Study Group Chairman]. First Test
Effect in Intravenous Glucose Tolerance Testing. Pediatric Diabetes 2013, Aug 5 Epub ahead of print.
39) Xu P, Qian X, Schatz DA, Cuthbertson D, Krischer JP, and the DPT-1 Study Group [Skyler JS – Study Group Chairman].
Distribution of C-Peptide and its Determinants in North American Children at Risk for Type 1 Diabetes. Diabetes Care 2014;
37:1959-1965..
40) Lin Y, Qian X, Krischer JP, Vehik K, Lee HS, Huang S, for the DPT-1 Study Group [Skyler JS – Study Group Chairman]. A
Rule-Based Prognostic Model for Type 1 Diabetes by Identifying and Synthesizing Baseline Profile Patterns. PLos One 2014; 9(6):
e91095. doi:10.1371.
41) Hao W, Greenbaum CJ, Krischer JP, Cuthbertson D, Marks JB, Palmer JP, for the DPT-1 Study Group [Skyler JS – Study Group
Chairman]. The Effect of DPT-1 Intravenous Insulin Infusion and Daily Subcutaneous Insulin on Endogenous Insulin Secretion and
Postprandial Glucose Tolerance. Diabetes Care 2015; Feb 26. [Epub ahead of print]
b. Type 1 Diabetes TrialNet Study Group References
Jay S. Skyler
Page 40
Curriculum Vitae
1) Skyler JS, Greenbaum CJ, Lachin JM, Leschek E, Rafkin-Mervis L, Savage P, Spain L, and the Type 1 Diabetes TrialNet Study
Group. Type 1 Diabetes TrialNet – An International Collaborative Clinical Trials Network. Annals of the New York Academy of
Sciences 2008; 1150: 14-24.
2) Skyler JS and the Type 1 Diabetes TrialNet Study Group. Update on Worldwide Efforts to Prevent Type 1 Diabetes. Annals of the
New York Academy of Sciences 2008; 1150: 190-196.
3) Greenbaum CJ, Mandrup-Poulsen T, Friedenberg-McGee P, Battelino T, Haastert B, Ludvigsson J, Pozzilli P, Lachin JM, Kolb H,
and The Type 1 Diabetes TrialNet Research Group [Skyler JS – Study Group Chairman] and The European C-peptide Trial Study
Group. The Mixed Meal Tolerance Test versus the Glucagon Stimulation Test for the Assessment of Beta Cell Function in Therapeutic
Trials in Type 1 Diabetes. Diabetes Care 2008; 31:1966-1971.
4) Mahon J, Sosenko JM, Rafkin-Mervis LE, Krause-Steinrauf H, Lachin JM, Thompson C, Bingley PJ, Bonifacio E, Palmer JP,
Eisenbarth GS, Wolfsdorf J, Skyler JS, for the TrialNet Natural History Committee and Type 1 Diabetes TrialNet Study Group. The
TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results. Pediatric Diabetes
2009: 10:97-104.
5) Chase HP, Leschek E, Rafkin-Mervis L, Krause-Steinrauf J, Chritton S, Asare SM, Adams S, Skyler JS, Clare-Salzler M, and the
Type 1 Diabetes TrialNet NIP Study Group. Nutritional Intervention to Prevent (NIP) Type 1 Diabetes; A Pilot Trial. ICAN: Infant,
Child, & Adolescent Nutrition 2009; 1:98-107.
6) Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, McGee PF, Moran
AM, Raskin P, Rodriguez H, Schatz DA, Wherrett D, Wilson DM, Lachin JM, Skyler JS, and The Type 1 Diabetes TrialNet AntiCD20 Study Group. Rituximab, B-lymphocyte Depletion and Preservation of Beta-cell Function. New England Journal of Medicine
2009; 361:2143-2152.
7) Gottlieb PA, Quinlan S, Krause-Steinrauf H, Greenbaum CJ, Wilson DM, Rodriguez H, Schatz DA, Moran AM, Lachin JM, Skyler
JS, and the Type 1 Diabetes TrialNet MMF/DZB Study Group. Failure to Preserve beta-cell function with Mycophenolate Mofetil and
Daclizumab Combined Therapy in patients with new onset Type 1 Diabetes. Diabetes Care 2010; 33:826-832.
8) Herold KC, Brooks-Worrell B, Palmer JP, Dosch HM, Peakman M, Gottlieb PA, Reijonen H, Arif S, Spain LM, Thompson C,
Lachin JM, and The Type 1 Diabetes TrialNet Research Group [Skyler JS – Study Group Chairman]. Validity and Reproducibility of
Measurement of Islet Autoreactivity by T-cell Assays in Subjects with Early Type 1 Diabetes. Diabetes 2009; 58:2588-2595.
9) Sosenko JM, Mahon J, Rafkin-Mervis L, Lachin JM, Krause-Steinrauf H, Krischer J, Cuthbertson D, Palmer JP, Thompson C,
Greenbaum CJ, Skyler JS, and the Diabetes Prevention Trial-Type 1 Diabetes (DPT-1) and Type 1 Diabetes TrialNet Study Groups. A
Comparison of the Baseline Metabolic Profiles between Diabetes Prevention Trial-Type 1 and TrialNet Natural History Study
Participants. Pediatric Diabetes 2011; 12:85-90.
10) Sosenko JM, Skyler JS, Mahon J, Krischer JP, Beam CA, Boulware DC, Greenbaum CJ, Rafkin LE, Cowie C, Cuthbertson D,
Palmer JP, and The TrialNet and Diabetes Prevention Trial-Type 1 Study Groups. Validation of the Diabetes Prevention Trial-Type 1
Risk Score (DPTRS) in the TrialNet Natural History Study. Diabetes Care 2011; 34: 1785-1787.
11) Vehik K, Cuthbertson D, Ruhling H, Schatz DA, Peakman M, Krischer JP, on behalf of the DPT-1 & TrialNet Study Groups. Long
Term Outcome of Those Treated with Oral Insulin: DPT-1 Oral Insulin Trial. Diabetes Care 2011; 34: 1585-1590.
12) Orban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Marks JB, Monzavi R, Moran
A, Raskin P, Rodriguez H, Russell WE, Schatz D, Wherrett D, Wilson DM, Skyler JS, and and The Type 1 Diabetes TrialNet
Abatacept Study Group. Co-Stimulation Modulation with Abatacept in Patients with Recent-Onset Type 1 Diabetes: A Randomised
Double-Blind, Placebo-Controlled Trial. Lancet 2011; 378: 412-419.
13) Wherrett DK, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Herold KC, Marks JB,
Monzavi R, Moran A, Orban T, Raskin P, Rodriguez H, Russell WE, Schatz D, Wilson DM, Skyler JS, and and The Type 1 Diabetes
TrialNet GAD Study Group. Antigen-Based Therapy with Glutamic Acid Decarboxylase (GAD) Vaccine in Patients with RecentOnset Type 1 Diabetes: A Randomised Double-Blind Trial. Lancet 2011; 378: 319-327.
14) Herold KC, Pescovitz MD, McGee PF, Krause-Steinrauf HJ, Spain LM, Bourcier K, Asare A, Liu Z, Lachin JM, Dosch HM, for
the Type 1 Diabetes TrialNet Study Group [Skyler JS – Study Group Chairman]. Increased T-cell proliferative responses to islet
antigens identify clinical responders to anti-CD20 monoclonal antibody (rituximab) therapy in Type 1 diabetes. Journal of
Immunology 2011; 187:1998-2005.
15) Pescovitz MD, Torgerson TR, Ochs HD. Ocheltree E, Friedenberg-McGee P, Krause-Steinrauf HJ, Lachin JM, Canniff J,
Weinberg A, Greenbaum CJ, Herold KC, Skyler JS, for the Type 1 Diabetes TrialNet Study Group. Effect of rituximab on human in
vivo antibody immune responses. Journal of Allergy and Clinical Immunology 2011; 128:1295-1302.
Jay S. Skyler
Page 41
Curriculum Vitae
16) Vehik K, Beam CA, Mahon JL, Schatz DA, Haller MJ, Sosenko JM, Skyler JS, Krischer JP, for the TrialNet Natural History Study
Group. Development of Autoantibodies in the TrialNet Natural History Study. Diabetes Care 2011; 34:1897-1901.
17) Yu L, Herold K, Lachin J, Bundy B, Pugliese A, Krischer J, Eisenbarth G, Pescovitz M, T1D Type 1 Diabetes TrialNet Anti-CD20
Study Group [Skyler JS – Study Group Chairman]. Rituximab Selectively Suppresses Specific Islet Antibodies. Diabetes 2011;
60:2560-2565.
18) Mahon JL, Beam CA, Marcovina SM, Boulware D, Palmer JP, Winter WE, Skyler JS, Krischer JP, for the TrialNet-Type 1
Diabetes Study Group. Comparison of two insulin assays for first-phase insulin release in type 1 diabetes prediction and prevention
trials. Clinical Chemica Acta 2011; 412:2128-2131.
20) Sosenko JM, Skyler JS, Palmer JP, Krischer JP, Cuthbertson D, Yu L, Schatz D, Orban T, Eisenbarth GS, and The Diabetes
Prevention Trial-1 and Type 1 Diabetes TrialNet Study Groups. Brief Report - A Longitudinal Study of GAD65 and ICA512
Autoantibodies during the Progression to Type 1 Diabetes in Diabetes Prevention Trial-Type 1 (DPT-1) Participants. Diabetes Care
2011; 34:2435-2437.
21) Lachin JM, McGee PL, Greenbaum CJ, Palmer JP, Pescovitz MD, Gottlieb PA, Skyler JS, for the Type 1 Diabetes TrialNet Study
Group. Sample Size Requirements for Studies of Treatment Effects on Beta-Cell Function in Newly Diagnosed Type 1 Diabetes.
PLoS One 2011; 6(11):e26471. Epub 2011 Nov 10.
22) Yu L, Boulware DC, Beam CA, Hutton JC, Wenzlau JM, Greenbaum CJ, Bingley PJ, Krischer JP, Sosenko JM, Skyler JS,
Eisenbarth GS, Mahon JL, for the Type 1 Diabetes TrialNet Study Group. Zinc Transporter-8 Autoantibodies Improve Prediction of
Type 1 Diabetes in Relatives Positive for the Standard Biochemical Autoantibodies. Diabetes Care 2012; 35:1213-1218.
23) Greenbaum CJ, Beam C, Boulware D, Gitelman SE, Gottlieb PA, Herold KC, Lachin JM, McGee P, Palmer JP, Krause-Steinrauf
H, Skyler JS, Sosenko JM, on behalf of the Type 1 Diabetes TrialNet Study Group. Fall in C-peptide Over First Two Years from
Diagnosis: Evidence of At Least Two Distinct Phases from Composite TrialNet Data. Diabetes 2012; 61: 2066-2073.
25) Sosenko JM, Skyler JS, Herold KC, Palmer JP, the Type 1 Diabetes TrialNet Study and Diabetes Prevention Trial-Type 1 Study
Groups. The Metabolic Progression to Type 1 Diabetes as Indicated by Serial Oral Glucose Tolerance Testing in the Diabetes
Prevention Trial-Type 1. Diabetes 2012; 61:1331-1337.
24) Sosenko JM, Skyler JS, Mahon J, Krischer JP, Beam CA, Boulware DC, Greenbaum CJ, Rafkin LE, Cowie C, Cuthbertson D,
Palmer JP, the TrialNet and Diabetes Prevention Trial Type 1 Study Groups. The Application of the Diabetes Prevention Trial Risk
Score (DPTRS) for Identifying a Pre-Clinical State of Type 1 Diabetes. Diabetes Care 2012; 35:1552-1555.
25) Vehik K, Cuthbertson D, Boulware D, Beam CA, Rodriguez H, Legault L, Hyytinen M, Rewers MJ, Schatz DA, Krischer JP, The
TEDDY, TRIGR, Diabetes Prevention Trial-Type 1, and Type 1 Diabetes TrialNet Natural History Study Groups [Skyler JS – DPT-1
and TrialNet Study Groups Chairman]. Performance of HbA1c as an Early Diagnostic Indicator of Type 1 Diabetes in Children and
Youth. Diabetes Care 2012; 35:1821-1825.
26) Long SA, Rieck M, Sanda S, Bollyky JB, Samuels PL, Goland R, Ahmann A, Rabinovitch A, Aggarwal S, Phippard D, Turka LA,
Ehlers MR, Bianchine PJ, Boyle KD, Adah SA, Bluestone JA, Buckner JH, Greenbaum CJ; for Diabetes TrialNet and the Immune
Tolerance Network [Skyler JS –TrialNet Study Group Chairman].. Rapamycin/IL-2 Combination Therapy in Patients with Type 1
Diabetes Augments Tregs yet Transiently Impairs β-Cell Function. Diabetes 2012; 61: 2340-2348.
27) Moran A, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Greenbaum CJ, Herold KC, Marks JB, Raskin P, Sanda S,
Schatz D, Wherrett D, Wilson DM, Skyler JS, and the Type 1 Diabetes TrialNet Canakinumab Study Group; and Pickersgill L, de
Koning E, Ziegler A-G, Böehm B, Badenhoop K, Schloot N, Bak JF, Pozzilli P, Mauricio D, Donath MY, Castaño L, Wägner A,
Lervang HH, Perrild H, Mandrup-Poulsen T, on behalf of the AIDA Study Group. Interleukin-1 Antagonism in Type 1 Diabetes of
Recent Onset: Two Multicenter, Randomized Double-Masked, Placebo-Controlled Trials. Lancet 2013; 381:1905-1915.
28) Loechelt BJ, Boulware D, Green M, Baden LR, Gottlieb P, Krause-Steinrauf H, Weinberg A; for the Type 1 Diabetes TrialNet
Daclizumab/Mycophenolic Acid Study Group [Skyler JS – Study Group Chairman]. Epstein-Barr and Other Herpesvirus Infections in
Patients With Early Onset Type 1 Diabetes Treated With Daclizumab and Mycophenolate Mofetil. Clinical Infectious Diseases 2013;
56:248-254.
29) Kroll JL, Beam C, Li S, Viscidi R, Dighero B, Cho A, Boulware D, Pescovitz M, Weinberg A; the Type 1 Diabetes TrialNet Anti
CD-20 Study Group [Skyler JS – Study Group Chairman]. Reactivation of latent viruses in individuals receiving rituximab for new
onset type 1 diabetes. Journal of Clinical Virology 2013; 57:115-119.
30) Orban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Marks JB, Monzavi R, Moran
A, Peakman M, Raskin P, Rodriguez H, Russell WE, Schatz D, Wherrett D, Wilson DM, Skyler JS, and and The Type 1 Diabetes
Jay S. Skyler
Page 42
Curriculum Vitae
TrialNet Abatacept Study Group. Co-Stimulation Modulation with Abatacept in Patients with Recent-Onset Type 1 Diabetes: FollowUp One Year After Cessation of Treatment. Diabetes Care 2014; 37:1069-1075.
31) Pescovitz MD, Greenbaum CJ, Bundy BN, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, McGee PF, Moran AM,
Raskin P, Rodriguez H, Schatz DA, Wherrett D, Wilson DM, Skyler JS, and The Type 1 Diabetes TrialNet Anti-CD20 Study Group.
B-Lymphocyte Depletion with Rituximab and Beta-Cell Function: Two-Year Results. Diabetes Care 2014; 37:453-459.
32) Diabetes Research in Children Network (DirecNet) Study Group, Type 1 Diabetes Trial Network [Skyler JS – TrialNet Study
Group Chairman]. The Effects of Inpatient Hybrid Closed-Loop Therapy Initiated within 1 Week of Type 1 Diabetes Diagnosis.
Diabetes Technology & Therapeutics 2013; 15:401-408.
33) Buckingham B, Beck RW, Ruedy KJ, Cheng P, Kollman C, Weinzimer SA, Dimeglio LA, Bremer AA, Slover R, Tamborlane
WV; Diabetes Research in Children Network (DirecNet) and Type 1 Diabetes TrialNet Study Groups [Skyler JS – TrialNet Study
Group Chairman]. Effectiveness of Early Intensive Therapy on β-Cell Preservation in Type 1 Diabetes. Diabetes Care 2013;
36:4030-4035.
34) Sosenko JM, Skyler JS, Palmer JP, Krischer JP, Yu L, Mahon J, Beam CA, Boulware DC; Rafkin L; Schatz D, Eisenbarth G, The
Type 1 Diabetes TrialNet and the Diabetes Prevention Trial-Type 1 Study Groups. The Prediction of Type 1 Diabetes by Multiple
Autoantibody Levels and Their Incorporation into an Autoantibody Risk Score in Relatives of Type 1 Diabetes Patients. Diabetes
Care 2013; 36:2615-2620.
35) Sosenko JM, Skyler JS, Beam CA, Krischer JP, Greenbaum CG, Mahon J, Rafkin LE, Matheson D, Herold KC, Palmer JP, and
The Diabetes Type 1 TrialNet and Diabetes Prevention Trial-Type 1 Study Groups. Acceleration of the Loss of the First-Phase Insulin
Response during the Progression to Type 1 Diabetes in Diabetes Prevention Trial-Type 1 Participants. Diabetes 2013; 62:4179-4183.
36) Weinberg A, Boulware D, Dighero B, Orban T; Type 1 Diabetes TrialNet Abatacept Study Group [Skyler JS – Study Group
Chairman]. Effect of abatacept on immunogenicity of vaccines in individuals with type 1 diabetes. Vaccine 2013; 31:4791-4794.
37) Krischer JP, the Type 1 Diabetes TrialNet Study Group [Skyler JS – Study Group Chairman]. The use of intermediate endpoints
in the design of type 1 diabetes prevention trials. Diabetologia 2013; 56:1919-1924.
38) Sosenko JM, Skyler JS, Mahon J, Krischer JP, Greenbaum CG, Rafkin LE, Beam CA, Boulware DC, Matheson D, Cuthbertson D,
Herold KC, Eisenbarth GS, Palmer JP, and The Diabetes Type 1 TrialNet and Diabetes Prevention Trial-Type 1 Study Groups. Use of
the Diabetes Prevention Trial Risk Score (DPTRS) for Improving the Accuracy of the Risk Classification of Type 1 Diabetes.
Diabetes Care 2014;37:979-984.
39) Orban T, Beam CA, Xu P, Moore K, Jiang Q, Deng J, Muller S, Gottlieb P, Spain L, Peakman M, and The Type 1 Diabetes
TrialNet Abatacept Study Group [Skyler JS – TrialNet Study Group Chairman]. Reduction in CD4 Central Memory T-cell subset in
Co-Stimulation Modulator Abatacept-Treated Patients with Recent-Onset Type 1 Diabetes is Associated with Slower C-Peptide
Decline. Diabetes 2014; 63:3449-3457.
40) Loechelt B, Green M, Gottlieb P, Blumberg E, Weinberg A, Quinlan S, Baden L, Marks J, Type 1 Diabetes TrialNet [Skyler JS –
TrialNet Study Group Chairman]. Screening and Monitoring of Infectious Complications when Immunosuppression Agents are
Studied in the Treatment of Autoimmune Disorders. Journal of the Pediatric Infectious Disease Society 2014; on-line 6/26/14
41) Chase HP, Boulware D, Rodriguez H, Donaldson D, Chritton S, Rafkin LE, Krischer JP, Skyler JS, Clare-Salzler M, and the Type
1 Diabetes TrialNet Nutritional Intervention to Prevent (NIP) Type 1 Diabetes Study Group. Effect of Docosahexaenoic Acid (DHA)
Supplementation on Infant Inflammatory Cytokine Levels in Infants at High Genetic Risk for Type 1 Diabetes. Pediatric Diabetes
2014; On-Line July 12
42) Beam CA, Gitelman SE, Palmer J, Type 1 Diabetes TrialNet Study Group [Skyler JS – TrialNet Study Group Chairman].
Recommendations for the Definition of Clinical Responder in Insulin Preservation Studies. Diabetes 2014; 63:3120-3127.
43) Sosenko JM, Skyler JS, Mahon J, Krischer JP, Greenbaum CJ, Rafkin LE, Beam CA, Boulware DC, Matheson D, Cuthbertson D,
Herold KC, Eisenbarth GS, Palmer JP, and The Diabetes Type 1 TrialNet and Diabetes Prevention Trial-Type 1 Study Groups.
Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for Improving the Accuracy of the Risk Classification of Type 1
Diabetes. Diabetes Care 2014; 37:979-984.
44) Loechelt B, Green M, Gottlieb P, Blumberg E, Weinberg A, Quinlan S, Baden L, Marks J, Type 1 Diabetes TrialNet [Skyler JS –
TrialNet Study Group Chairman]. Screening and Monitoring of Infectious Complications when Immunosuppression Agents are
Studied in the Treatment of Autoimmune Disorders. Journal of the Pediatric Infectious Disease Society, accepted 5/14/14
45) Max Andersen ML, Nielsen LB, Svensson J, Pörksen S, Hougaard P, Beam C, Greenbaum C, Becker D, Petersen JS, Hansen L,
Mortensen HB, for the Type 1 Diabetes TrialNet [Skyler JS – TrialNet Study Group Chairman]. Disease progression among 446
Jay S. Skyler
Page 43
Curriculum Vitae
children with newly diagnosed type 1 diabetes located in Scandinavia, Europe, and North America during the last 27 yr. Pediatric
Diabetes 2014; 15:345-354.
46) Beam CA, Gitelman SE, Palmer J, Type 1 Diabetes TrialNet Study Group [Skyler JS – TrialNet Study Group Chairman].
Recommendations for the Definition of Clinical Responder in Insulin Preservation Studies. Diabetes 2014; 63:3120-3127.
47) Sosenko JM, Skyler JS, DiMeglio LA, Beam CA, Krischer JP, Greenbaum CJ, Boulware D, Rafkin LE, Matheson D, Herold KC,
Mahon J, Palmer JP; Type 1 Diabetes TrialNet Study Group; Diabetes Prevention Trial-Type 1 Study Group. A new approach for
diagnosing type 1 diabetes in autoantibody-positive individuals based on prediction and natural history. Diabetes Care 2015; 38:271276.
48) Sosenko JM, Skyler JS, Beam CA, Boulware D, Mahon JL, Krischer JP, Greenbaum CJ, Rafkin LE, Matheson D, Herold KC,
Palmer JP; and the Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups. The Development and Utility of a
Novel Scale That Quantifies the Glycemic Progression Toward Type 1 Diabetes Over 6 Months. Diabetes Care 2015; 38:940-942.
49) Miao D, Steck AK, Zhang L, Guyer KM, Jiang L, Armstrong T, Muller SM, Krischer J, Rewers M, Yu L; Type 1 Diabetes
TrialNet Study Group [Skyler JS – TrialNet Study Group Chairman]. Electrochemiluminescence assays for insulin and glutamic acid
decarboxylase autoantibodies improve prediction of type 1 diabetes risk. Diabetes Technology and Therapeutics 2015; 17:119-127.
50) Usmani-Brown S, Lebastchi J, Steck AK, Beam C, Herold KC, Ledizet M for the Type 1 Diabetes TrialNet [Skyler JS – TrialNet
Study Group Chairman]. Analysis of β-cell death in type 1 diabetes by droplet digital PCR. Endocrinology 2014; 155:3694-3698.
51) Herold KC, Usmani-Brown S, Ghazi T, Lebastchi J, Beam CA, Bellin MD, Ledizet M, Sosenko JM, Krischer JP, Palmer JP and
the Type 1 Diabetes TrialNet [Skyler JS – TrialNet Study Group Chairman]. β Cell death and dysfunction during type 1 diabetes
development in at-risk individuals. Journal of Clinical Investigation 2015; 125:1163-1173.
52) Bollyky JB, Xu P, Butte AJ, Wilson DM, Beam CA, Greenbaum CJ; Type 1 Diabetes TrialNet Study Group [Skyler JS – Study
Group Chairman]. Heterogeneity in recent onset type 1 diabetes - a clinical trial perspective. Diabetes Metabolism Research and
Reviews 2015; Feb 17. [Epub ahead of print].
53) Sosenko JM, Skyler JS, Palmer JP, for The Diabetes Type 1 TrialNet and Diabetes Prevention Trial-Type 1 Study Groups. The
Development, Validation, and Utility of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS). Current Diabetes Reports 2015;
15: Aug; 15(8):626 doi: 10.1007/s11892-015-0626-1.
c. Inhaled Insulin Study Group References
1)
Skyler JS, Cefalu WT, Kourides IA, Landschulz WH, Balagtas CC, Cheng S-L, Gelfand RA, for The Inhaled Insulin Phase II
Study Group. Efficacy of Inhaled Human Insulin in Type 1 Diabetes Mellitus: A Randomised Proof-of-Concept Study. Lancet 2001;
357:331-335.
2)
Cefalu WT, Skyler JS, Kourides IA, Landschulz WH, Balagtas CC, Cheng S-L, Gelfand RA, for The Inhaled Insulin Phase II
Study Group. Inhaled Human Insulin Treatment of Patients with Type 2 Diabetes Mellitus. Annals of Internal Medicine 2001;
134:203-207.
3)
Gerber RA, Cappelleri JC, Kourides IA, Gelfand RA for The Inhaled Insulin Phase II Study Group [Skyler JS – Study Group
Participant]. Treatment satisfaction with inhaled insulin in patients with type 1 diabetes: a randomized controlled trial. Diabetes
Care 2001; 24:1556-1559.
4) Cappelleri JC, Cefalu WT, Rosenstock J, Kourides IA, Gerber RA for The Inhaled Insulin Phase II Study Group [Skyler JS – Study
Group Participant]. Treatment satisfaction in type 2 diabetes: a comparison between an inhaled insulin regimen and a subcutaneous
insulin regimen. Clinical Therapeutics 2002; 24:552-564.
5) Weiss SR, Cheng SL, Kourides IA, Gelfand RA, Landschulz WH; Inhaled Insulin Phase II Study Group [Skyler JS – Study Group
Participant]. Inhaled insulin provides improved glycemic control in patients with type 2 diabetes mellitus inadequately controlled
with oral agents: a randomized controlled trial. Archives of Internal Medicine 2003;163:2277-2282.
6) Rosenstock J, Cappelleri JC, Bolinder B, Gerber RA, for the Inhaled Insulin Phase II Study Group [Skyler JS – Study Group
Participant]. Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2
diabetes. Diabetes Care 2004; 27:1318-1323
7) Hollander PA, Blonde L, Rowe R, Mehta AE, Milburn JL, Hershon KS, Chiasson JL, Levin SR for the Exubera Phase III Study
Group [Skyler JS – Study Group Participant]. Efficacy and Safety of Inhaled Insulin (Exubera) Compared With Subcutaneous Insulin
Therapy in Patients With Type 2 Diabetes: Results of a 6-month, randomized, comparative trial. Diabetes Care 2004; 27: 2356-2362
Jay S. Skyler
Page 44
Curriculum Vitae
8) Skyler JS, Weinstock R, Raskin P, Yale JF, Barrett E, Gerich JE, Gerstein H for The Inhaled Insulin Phase III Type 1 Diabetes
Study Group. Use of inhaled insulin in a basal/bolus insulin regimen in patients with type 1 diabetes: a 6-month, randomized,
comparative trial. Diabetes Care 2005; 28: 1630-1635
9) Rosenstock J, Zinman B, Murphy LJ, Clement SC, Moore P, Bowering CK, Hendler R, Lan SP, Cefalu WT for The Inhaled Insulin
Phase III Type 2 Diabetes Study Group [Skyler JS – Study Group Participant]. Inhaled Insulin Improves Glycemic Control When
Substituted for or Added to Oral Combination Therapy in Type 2 Diabetes. Annals of Internal Medicine 2005; 143:549-558.
10) Skyler JS, Jovanovic L, Klioze S, Reis J, Duggan W, for The Inhaled Insulin Type 1 Study Group. Two-year safety and efficacy
of inhaled human insulin (Exubera) in adult patients with type 1 diabetes mellitus. Diabetes Care 2007; 30:579-585.
11) Skyler JS, Hollander PA, Jovanovic L, Klioze S, Krasner A, Riese RJ, Reis J, Schwartz P, Duggan W, for The Inhaled Human
Insulin Type 1 Diabetes Study Group. Safety and efficacy of inhaled human insulin (Exubera) during discontinuation and
readministration of therapy in adults with type 1 diabetes: a 3-year randomized controlled trial. Diabetes Research and Clinical
Practice 2008; 82:238-246.
12) Cefalu WT, Bohannon NJ, Edwin Fineberg S, Teeter JG, Schwartz PF, Reis JM, Krasner AS [Skyler JS – Study Group
Participant]. Assessment of long-term immunological and pulmonary safety of inhaled human insulin with up to 24 months of
continuous therapy. Current Medical Research and Opinion 2008; 24:3073-3083.
2. BOOKS AND BOOK CHAPTERS
a. BOOKS AND MONOGRAPHS
1) Skyler JS: Notes on Diabetes Mellitus. Health Care Systems, Inc., Durham, North Carolina, 1973.
2) Skyler JS (Editor): Recommended Standards for Camps for Children with Diabetes. American Diabetes Association, New
York, 1976.
3) Skyler JS, Cahill GF (Editors): Diabetes Mellitus. Yorke Medical Books, New York, 1981
4) Skyler JS (Editor): Insulin Update 1982. Excerpta Medica, Princeton, N.J., 1982.
5) Schade DS, Santiago JV, Skyler JS, Rizza R: Intensive Insulin Therapy. Excerpta Medica, Princeton, N.J., 1983.
6) Schade DS, Santiago JV, Skyler JS, Rizza R: Insulinoterapia Intensiva. Jarpyo Editores, Madrid, 1984.
7) Rifkin H, Cahill GF, Colwell JA, DeFronzo RA, Holvey SM, Horton, ES, Lebovitz HE, Olefsky JM, Skyler JS (Editors): The
Physician's Guide to Type II Diabetes (NIDDM) - Diagnosis and Treatment. American Diabetes Association, New York, 1984.
8) Lebovitz HE, Clark CM, DeFronzo RA, Gerich J, Kreisberg R, Lockwood D, Rosenbloom A, Skyler JS, Vinicor F, Zimmerman B
(Editors): Physician's Guide to Non-Insulin-Dependent (Type II) Diabetes - Diagnosis and Treatment. Second Edition.
American Diabetes Association, Alexandria, Virginia, 1988.
9) McCabe PM, Schneiderman N, Field T, Skyler JS (Editors): Stress, Coping, and Disease. Lawrence Erlbaum Associates, Inc.,
Publishers, Hillside, N.J., 1991.
10) Skyler JS: Current Concepts: Insulin Treatment of Type I Diabetes Mellitus. The Upjohn Company, Kalamazoo, Michigan,
1991.
11) Bode BW, Davidson PC, Steed RD. Skyler JS (Editor). DiabetesDek - Professional Edition. Infodek, Inc., Atlanta, Georgia,
1993.
WHO Study Group on Prevention of Diabetes Mellitus [Akerblom H, Alberti KGMM, Baba S, Bennett PH, Dedov I, Keen H, Klein R, Nerup J, XiaoPrevention of Diabetes Mellitus - WHO Technical Report Series #844.
World Health Organization, Geneva, 1994.
12)
Ren P, Puchulu FE, Skyler J, Steiner G, Swai A, Zimmet P, Assal J-P].
13) Farkas-Hirsch, RM, Brackenridge BP, Lorenz R, Lorenzi GM, Schreiner B, Skyler JS, Strowig SM, White NH, Whitehouse FW,
Young-Hyman D (Editors). Intensive Diabetes Management. American Diabetes Association, Alexandria, Virginia, 1995.
14) Skyler JS (Editor): Medical Management of Type 1 Diabetes Mellitus. Third Edition. Alexandria, Va., American Diabetes
Association, 1998.
Jay S. Skyler
Page 45
Curriculum Vitae
15)
Skyler JS (Editor): Atlas of Diabetes. Second Edition. Philadelphia, Lippincott Williams & Wilkins, 2002.
16)
Raz I, Skyler JS, Shafrir E (Editors): Diabetes: From Research to Diagnosis and Treatment. London, Martin Dunitz, 2003.
17) Bode BW, Davidson PC, Steed RD, Robertson DG. Skyler JS (Editor). DiabetesDek - Professional Edition. How to Control
& Manage Diabetes Mellitus. American Diabetes Association, Alexandria, Virginia, 2004.
18)
Skyler JS (Editor): Atlas of Diabetes. Third Edition. Philadelphia, Lippincott Williams & Wilkins, 2006.
19) Skyler JS (Editor): Atlas of Diabetes. Third Edition, Second (Revised and Expanded) Printing. Philadelphia, Lippincott
Williams & Wilkins, 2008.
20)
Skyler JS (Editor): Atlas of Type 2 Diabetes. Philadelphia, Current Medical Group, 2009.
21)
Skyler JS (Editor): Atlas of Diabetes. Fourth Edition. New York, Springer, 2012.
b. BOOK CHAPTERS
1) Field RA, Skyler JS: Nonglucose Melliturias. In: Ellenberg M, Rifkin H (Editors): Diabetes Mellitus: Theory and Practice.
McGraw-Hill, New York, 1970, pages 546-563
2) Skyler JS, Ellis GJ, Delcher HK: The Value of Summer Camps. In: Laron Z (Editor): Diabetes in Juveniles: Modern Problems
in Pediatrics (S. Karger, Basle) 1975; 12:382-384
3) Skyler JS: Nutritional Management of Diabetes Mellitus. In: Katzen HM, Mahler RJ (Editors): Advances in Modern Nutrition,
Volume 2. Hemisphere Publishing, Washington, 1978, pages 645-698
4) Skyler JS: Diabetes in Adolescence - The Forgotten Years. In: Podolsky S (Editor), Clinical Diabetes Mellitus - Modern
Management, Appleton-Century-Crofts, New York, 1980, pages 463-479
5) Skyler JS, Mintz DH, O'Sullivan MJ: Management of Diabetes and Pregnancy. In: Rifkin H, Raskin P (Editors): Diabetes
Mellitus - Diagnosis and Treatment (5th Edition). American Diabetes Association, New York, 1980, pages 161-177
6) Skyler JS: Living with Complications of Diabetes. In: Hamburg BA, Lipsett LF, Inoff GE, Drash AL (Editors): Behavioral and
Psychosocial Issues in Diabetes: Proceedings of the National Conference. Government Printing Office, Washington, NIH
Publication No. 80-1993, 1980, pages 167-181
7) Skyler JS: Disorders of Galactose, Fructose, and Pentose Metabolism. In: Ellenberg M, Rifkin H (Editors): Diabetes Mellitus:
Theory and Practice, Third Edition. Medical Examination Publishing Co., New Hyde Park, N.Y., 1983, pages 1021-1036
8) Barkin JS, Skyler JS: Diabetes and the Gastrointestinal System. In: Ellenberg M, Rifkin H (Editors): Diabetes Mellitus: Theory
and Practice, Third Edition. Medical Examination Publishing Co., New Hyde Park, N.Y., 1983, pages 863-877
9) Skyler JS: Nondiabetic Melliturias. In: Brodoff BN, Bleicher SJ (Editors): Diabetes Mellitus and Obesity. Williams & Wilkins,
Baltimore, 1982, pages 407-413
10) Alejandro R, Skyler JS: The Diagnosis of Diabetes Mellitus. In: Brodoff BN, Bleicher SJ (Editors): Diabetes Mellitus and
Obesity. Williams & Wilkins, Baltimore, 1982, pages 400-406
11) Barkin JS, Skyler JS: The Gastrointestinal System in Diabetes. In: Brodoff BN, Bleicher SJ (Editors): Diabetes Mellitus and
Obesity. Williams & Wilkins, Baltimore, 1982, pages 697-701
12) Skyler JS: Dietary Management of Diabetes Mellitus. In: Peterson CM (Editor): Diabetes Management in the 80's: The Role of
Home Blood Glucose Monitoring and New Insulin Delivery Systems. Prager Scientific, New York, 1982, pages 126-151
13) Citrin WS, Kleiman GA, Skyler JS: Emotions: A Critical Factor in Diabetic Control. In: Davidson MB (Editor): Diabetes
Mellitus: Diagnosis and Treatment. John Wiley and Sons, New York, 1981, pages 400-419
Jay S. Skyler
Page 46
Curriculum Vitae
14) Skyler JS, Galloway JA, Chance RE: Human Insulin Produced by Recombinant DNA Technology. In: Skyler JS, Cahill GF
(Editors): Diabetes Mellitus. Yorke Medical Books, New York, 1981, pages 146-151
15) Skyler JS, Reeves ML, Seigler DE, Ryan EA: Self-Monitoring of Blood Glucose and Intensive Coventional Therapy: Comparison
with Continuous Subcutaneous Insulin Infusion in Insulin-Dependent Diabetes Mellitus. In: Brunetti P, Alberti KGMM, Albisser AM,
Hepp KD, Massi-Benedetti M (Editors): Artificial Systems for Insulin Delivery. Raven Press, New York, 1983, pages 329-338
16) Skyler JS, Miller NE, O'Sullivan MJ, Reeves ML, Ryan EA, Seigler DE, Skyler DL, Zigo MA: The Use of Insulin in InsulinDependent Diabetes Mellitus. In: Skyler JS (Editor): Insulin Update 1982. Excerpta Medica, Princeton, 1982, pages 125-156
17) Skyler JS: On the Pathogenesis and Treatment of Non-Insulin-Dependent Diabetes Mellitus. In: Skyler JS (Editor): Insulin
Update 1982. Excerpta Medica, Princeton, 1982, pages 247-259
18) Ryan EA, O'Sullivan MJ, Skyler JS, Mintz DH: Glucose Control During Labor and Delivery. In: Skyler JS (Editor): Insulin
Update 1982. Excerpta Medica, Princeton, 1982, pages 290-294
19) Skyler JS: Problems with Oral Agents. In: Krall LP (Editor): World Book of Diabetes in Practice. Excerpta Medica,
Amsterdam, 1982, pages 52-54
20) Skyler JS, Chance RE, Horwitz D, Weis-Fogh O, Hansen B, Levin M, Chiu Y: Report of the Consensus-Forming Session on
Insulins. In: Gueriguian J, Bransome ED, Outschoorn AS (Editors): Hormone Drugs. United States Pharmacopeial Convention,
Rockville, Maryland, 1983, pages 254-281
21) Skyler JS: Diabetes and Pregnancy - The 1980's and Beyond. In: Sutherland H, Stowers J (Editors): Carbohydrate Metabolism
in Pregnancy and the Newborn 1983. Churchill Livingstone, Edinburgh, 1984, pages 226-234
22) Skyler JS, Reeves ML, Seigler DE: Intensive Insulin Therapy. In: Sakamoto N, Min HK, Baba S (Editors): Current Topics in
Clinical and Experimental Aspects of Diabetes Mellitus. Excerpta Medica, Amsterdam, 1984, pages 438-450
23) Skyler JS, Reeves ML: Intensive Treatment of Type I Diabetes Mellitus. In: Olefsky JM, Sherwin RS (Editors): Diabetes
Mellitus: Management and Complications. Churchill Livingstone, New York, 1985, pages 31-79
24) Citrin WS, LaGreca AM, Skyler JS: Group Intervention in Type I Diabetes Mellitus. In: Ahmed PI, Ahmed N (Editors): Coping
with Juvenile Diabetes. Charles C Thomas, Springfield, 1985, pages 181-204
25) Skyler JS: The Etiology, Pathogenesis and Therapy of Type I Diabetes Mellitus. In: Lavin N (Editor): Manual of Endocrinology
and Metabolism. Little Brown and Company, Boston, 1986, pages 565-572
26) Skyler JS: Diabetes in 2021 - One Hundred Years After Insulin. In: Baba S, Gould M, Zimmet P (Editors): Diabetes - Recent
Knowledge on Aetiology, Complications and Treatment. Academic Press, Sydney, 1984, pages 237-252
27) Skyler JS: Self-monitoring of Blood Glucose - 1987. In: Consensus Development Conference on Self-Blood Glucose
Monitoring. American Diabetes Association, Alexandria, Virginia, 1986, pages 12-16
28) Skyler JS: Insulin-Dependent Diabetes Mellitus. In: Kohler PO (Editor): Clinical Endocrinology. John Wiley and Sons, New
York, 1986, pages 491-573
29) Skyler JS, O'Sullivan, MJ: Diabetes and Pregnancy. In: Kohler PO (Editor): Clinical Endocrinology. John Wiley and Sons,
New York, 1986, pages 603-622
30) Citrin WS, Kleiman GA, Skyler JS: Emotions: A Critical Factor in Diabetic Control. In: Davidson MB (Editor): Diabetes
Mellitus: Diagnosis and Treatment, Second Edition, John Wiley and Sons, New York, 1986, pages 487-510
31) Skyler JS: Forward. In: Jackson RL, Guthrie RA (Editors): The Physiological Management of Diabetes in Children. Medical
Examination Publishing Co., New York, 1986, pages xiii-xvi
32) Skyler JS: Self-monitoring of Blood Glucose. In: Reeves-Ellington B (Editor): Blood Glucose Monitoring: For the Phases of
Your Life, Health Education Technologies, New York, 1986, pages 18-24
33) Skyler JS: Non-insulin-dependent Diabetes Mellitus: A Clinical Strategy. In: Clinical Diabetes Reviews Volume 1. American
Diabetes Association, Alexandria, Virginia, 1987, pages 65-77
34) Ryan EA, Enns L, O'Sullivan MJ, Skyler JS: Insulin Action in Pregnancy. In: Goren HJ, Hollenberg MD, Roncari DAK (Editors):
Insulin Action in Diabetes, Raven Press, New York, 1988, pages 191-201
Jay S. Skyler
Page 47
Curriculum Vitae
35) Skyler JS: Monitoring of Diabetes. In: Galloway JA, Potvin JH, Shuman CR (Editors): Diabetes Mellitus. Eli Lilly and
Company, Indianapolis, 1988, pages 159-173
36) Skyler JS: Methods for the Study of Carbohydrate Metabolism. In: Schneiderman N, Kaufmann PG, Weiss SM (Editors):
Handbook of Research Methods in Cardiovascular Behavioral Medicine, Plenum Press, New York, 1989, pages 145-166
37) Seigler DE, Olsson GM, Skyler JS: Patient Self-Design of a Meal Plan: An Experiential Approach to Diabetes Nutritional
Management. In: Challenges in Diabetes Management/Milestone in Monitoring: Colloquium Proceedings, Health Education
Technologies, New York, 1988, pages 18-22
38) Drexler AJ, Hunt JA, Skyler JS, Yale JF, Alojado NC, Olsson GM, Robertson C, Seigler DE: Multicenter Study to Determine the
Accuracy and Precision of the One Touch System When Used by Patients and Technicians. In: Challenges in Diabetes
Management/Milestone in Monitoring: Colloquium Proceedings, Health Education Technologies, New York, 1988, pages 50-54
39) Skyler JS: Diabetes and Pregnancy: Consensus and Controversy. In: Sutherland HW, Stowers JM, Pearson DWM (Editors):
Carbohydrate Metabolism in Pregnancy and the Newborn IV. Springer-Verlag, London, 1989, pages 363-372
40) Skyler JS: Relationship of Metabolic Control of Diabetes Mellitus to Chronic Complications. In: Rifkin H, Porte D (Editors):
Ellenberg & Rifkin's Diabetes Mellitus: Theory and Practice, Fourth Edition. Elsevier Science Publishing, New York, 1990, pages
856-868
41) Hartford JD, Barkin JS, Skyler JS: Diabetes and the Gastrointestinal System. In: Rifkin H, Porte D (Editors): Ellenberg &
Rifkin's Diabetes Mellitus: Theory and Practice, Fourth Edition. Elsevier Science Publishing, New York, 1990, pages 824-837
42) Skyler JS: Issues, Controversies, and Directions in Diabetes Care. In: Larkins RG, Zimmet PZ, Chisholm DJ (Editors): Diabetes
1988. Excerpta Medica, Amsterdam, 1989, pages 793-801
43) Skyler JS: Continuous Subcutaneous Insulin Infusion [CSII] With External Devices: Current Status. In: Ensminger WD, Selam JL
(Editors): Update in Drug Delivery Systems. Futura Publishing, Mount Kisco, N.Y., 1989, pages 163-183
44) Skyler JS, Fili MD: Intensive Therapy of Type I Diabetes: 1989. In: Sakamoto N, Alberti KGMM, Hotta N (Editors): Current
Status of Prevention and Treatment of Diabetic Complications. Excerpta Medica, Amsterdam, 1990, pages 235-242
45) LaGreca AM, Skyler JS: Psychosocial Issues in IDDM: A Multivariate Framework. In: McCabe PM, Schneiderman N, Field T,
Skyler JS (Editors): Stress, Coping, and Disease. Lawrence Erlbaum Associates, Hillside, N.J., 1991, pages 169-190
46) LaGreca AM, Rappoport WS, Skyler JS: Emotions: A Critical Factor in Diabetes Control. In: Davidson Mayer B (Editor):
Diabetes Mellitus: Diagnosis and Treatment, Third Edition, Churchill Livingstone, New York, 1991, pages 403-417.
47) O'Sullivan MJ, Skyler JS, Reimer K, Abu Hamad A: Diabetes and Pregnancy. In: Gleicher N (Editor): Principles of Medical
Therapy In Pregnancy, Second Edition. Appleton & Lange, Norwalk, Connecticut, 1992, pages 357-378
48) Skyler JS: Insulin Treatment. In: Lebovitz HE (Editor): Therapy for Diabetes Mellitus & Related Disorders. American
Diabetes Association, Alexandria, Virginia, 1991, pages 127-137
49) Marks JB, Skyler JS: Acute Complications of Diabetes: Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic Nonketotic
Coma. In: Hurst JW (Editor): Medicine for the Practicing Physician, Third Edition. Butterworth-Heineman, Boston, 1992, pages
592-596.
50) Skyler JS, Marks JB: Type I (Insulin-Dependent) Diabetes Mellitus. In: Hurst JW (Editor): Medicine for the Practicing
Physician, Third Edition. Butterworth-Heineman, Boston, 1992, pages 582-588.
51) Skyler JS, Marks JB, Thompson NE, Fili MD, Schneiderman N: Insulin Sensitivity and Blood Pressure. In: Schneiderman N,
McCabe PM, Baum A (Editors): Stress and Disease Processes: Perspectives in Behavioral Medicine. Lawrence Erlbaum
Associates, Inc., Publishers, Hillside, N.J., 1992, pages 197-223.
52) Skyler JS, Donahue RP, Marks JB, Thompson NE, Schneiderman N: Insulin: A Determinant of Blood Pressure? In: Johnson E,
Gentry WD, Julius S (Editors): Personality, Elevated Blood Pressure, and Essential Hypertension. Hemisphere Taylor & Francis,
Washington, 1992, pages 257-281.
53) Skyler JS: Complicaciones de la Diabetes en los Noventas. In: Rull JA, Zorrilla E, Jadzinsky M, Santiago JV (Editors):
Complicaciones de la Diabetes Mellitus. Interamericana McGraw Hill, Mexico City, 1992, pages 31-44.
Jay S. Skyler
Page 48
Curriculum Vitae
54) Skyler JS: Insulin Dependent (Type I) Diabetes Mellitus. In: Kreisberg R (Editor): Diabetes Mellitus: Diagnosis &
Management. National Health Laboratories, La Jolla, 1992, pages 4-15.
55) Antoni MH, Schneiderman N, LaPerriere A, O'Sullivan MJ, Marks J, Efantis J, Skyler J, Fletcher MA: Mothers with AIDS. In:
Ahmed PI (Editor): Living and Dying with AIDS. Plenum Press, New York, 1992, pages 47-85.
56) Skyler JS: Forward. In: Current Trends in Diabetes Management: A Guide for the Diabetes Professional, Third Edition.
Diabetes Treatment Centers of America, Inc., Nashville, 1992, pages iii-v.
57) Skyler JS: Etiology, Pathogenesis and Therapy of Type I Diabetes Mellitus. In: Lavin N (Editor): Manual of Endocrinology
and Metabolism, Second Edition. Little Brown and Company, Boston, 1993, pages 519-527.
58) Skyler JS: Insulin Treatment. In: Lebovitz HE (Editor): Therapy for Diabetes Mellitus & Related Disorders, Second Edition.
American Diabetes Association, Alexandria, Virginia, 1994, pages 131-141.
59) LaGreca AM, Skyler JS: Psychological Management of Diabetes. In: Kelnar CJH (Editor): Childhood Diabetes. Chapman and
Hall, London, 1995, pages 295-309.
60) Schneiderman N, Skyler JS: Insulin Metabolism, Sympathetic Nervous System Regulation, and Coronary Heart Disease
Prevention. In: Orth-Gomer K, Schneiderman N (Editors): Behavioral Medicine Approaches to Cardiovascular Disease
Prevention. Lawrence Erlbaum Associates, Inc., Publishers, Hillside NJ, 1996, pages 105-133.
61) Skyler JS: Relationship of Glycemic Control to Diabetic Complications. In: Porte D, Sherwin R (Editors): Ellenberg & Rifkin's
Diabetes Mellitus: Theory and Practice, Fifth Edition. Appleton and Lange, Norwalk, CT, 1997, pages 1235-1254.
62) Skyler JS, Marks JB, O’Sullivan MJ: Prevention and Immunotherapy. In: Reece EA, Coustan DR (Editors): Diabetes Mellitus
in Pregnancy, Second Edition. Churchill Livingstone, New York, 1995, pages 27-34.
63) Skyler JS: Multiple-Component Insulin Regimens. In: Farkas-Hirsch, RM (Editor). Intensive Diabetes Management. American
Diabetes Association, Alexandria, Virginia, 1995, pages 51-64.
64) Skyler JS, Marks JB: Future Approaches to Prevention. In: Palmer JP (Editors): Prediction, Prevention, and Genetic
Counseling in IDDM. John Wiley and Sons, Sussex, England, 1996, pages 369-389.
65) Marks JB, Skyler JS: Acute Complications of Diabetes: Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic Nonketotic
Coma. In: Hurst JW (Editor): Medicine for the Practicing Physician, Fourth Edition. Butterworth-Heineman, Boston, 1996, pages
639-643.
66) Skyler JS, Marks JB: Type I (Insulin-Dependent) Diabetes Mellitus. In: Hurst JW (Editor): Medicine for the Practicing
Physician, Fourth Edition. Butterworth-Heineman, Boston, 1996, pages 628-635.
67) Skyler JS, Marks JB: Immune Intervention. In: LeRoith D, Taylor SI, Olefsky JM (Editors): Diabetes Mellitus: A
Fundamental and Clinical Text. Lippincott-Raven, Philadelphia, 1996, pages 402-408.
68) Skyler JS: Diabetes Mellitus, Types I and II. In: Kelley WN (Editor). Textbook of Internal Medicine, Third Edition.
Lippincott-Raven, Philadelphia, 1997, pages 2238-2252.
69) Skyler JS: Approach to Hyperglycemia in the Patient with Diabetes Mellitus. In: Kelley WN (Editor). Textbook of Internal
Medicine, Third Edition. Lippincott-Raven, Philadelphia, 1997, pages 2155-2165.
70) Schneiderman N, Gellman M, Peckerman A, Hurwitz B, Saab P, Llabre M, Ironson G, Durel L, Skyler J, McCabre P:
Cardiovascular Reactivity as an Indicator of Risk for Future Hypertension. In: In P. M. McCabe, N. Schneiderman, T. Field, & A. R.
Wellens (Editors), Stress, Coping, and Cardiovascular Disease. Lawrence Erlbaum Associates, Inc., Publishers, Mahwah, NJ, 2000,
pages 181-202.
71) Skyler JS: Insulin Therapy in Type 1 Diabetes Mellitus. In: DeFronzo RA (Editor): Current Therapy of Diabetes Mellitus.
Mosby, St. Louis, 1998, pages 36-49.
72) Skyler JS: Monitoring of Type 1 Diabetes Mellitus. In: DeFronzo RA (Editor): Current Therapy of Diabetes Mellitus. Mosby,
St. Louis, 1998, pages 50-54.
73) Skyler JS: Insulin Therapy in Type 2 Diabetes Mellitus. In: DeFronzo RA (Editor): Current Therapy of Diabetes Mellitus.
Mosby, St. Louis, 1998, pages 108-116.
Jay S. Skyler
Page 49
Curriculum Vitae
74) Skyler JS, Cohen M: Self-Monitoring of Blood Glucose. In: Alberti KGMM, DeFronzo RA, Keen H, Zimmet PZ (Editors):
International Textbook of Diabetes Mellitus, Second Edition. John Wiley and Sons, Sussex, England, 1997, pages 1031-1046.
75) Skyler JS: Insulin Treatment. In: Lebovitz HE (Editor): Therapy for Diabetes Mellitus & Related Disorders, Third Edition.
American Diabetes Association, Alexandria, Virginia, 1998, pages 186-203.
76) Skyler JS: Multiple-Component Insulin Regimens. In: Farkas-Hirsch, RM (Editor). Intensive Diabetes Management, Second
Edition. American Diabetes Association, Alexandria, Virginia, 1998, pages 73-98.
77) Marks JB, Skyler JS: The Liver and The Endocrine System. In: Schiff ER, Sorrell MF, Maddrey WC (Editors). Schiff's Diseases
of the Liver, Eighth Edition. Lippincott-Raven, Philadelphia, 1999, pages 477-488.
78) Pugliese A, Skyler JS. Type 1 Diabetes Pathogenesis: Overview and Genetics. In: Turtle JR, Kaneko T, Osato S (Editors).
Diabetes in the New Millennium. The Endocrinology & Diabetes Research Foundation of the University of Sydney, Sydney,
Australia, 1999, pages 119-130.
79) Skyler JS. Medical Management of Diabetic Retinopathy. In: Flynn HW, Smiddy WE (Editors). Diabetes and Ocular Disease –
Past, Present, & Future Therapies. Ophthalmology Monographs 14, Foundation of the American Academy of Ophthalmology, San
Francisco, 2000, pages 181-201.
80) Skyler JS: Diabetes Mellitus: Old Assumptions and New Realities. In: Bowker J, Pfeifer M (Editors). The Diabetic Foot, Sixth
Edition. Mosby, St. Louis, 2000, pages 3-12..
81) Skyler JS, Marks JB: Immune Intervention. In: LeRoith D, Taylor SI, Olefsky JM (Editors): Diabetes Mellitus: A
Fundamental and Clinical Text. Second Edition. Lippincott-Williams & Wilkins, Philadelphia, 2000, pages 500-506.
82) Skyler JS, Hirsch IB: Diabetes Mellitus. In: Noble J (Editor): Textbook of Primary Care Medicine, Third Edition. Mosby, St.
Louis, 2001, pages 821-842.
83) Skyler JS: Diabetes Mellitus, Types I and II. In: Humes HD (Editor). Kelley’s Textbook of Internal Medicine, Fourth Edition.
Lippincott-Williams & Wilkins, Philadelphia, 2000, pages 2751-2769.
84) Skyler JS: Approach to Hyperglycemia in the Patient with Diabetes Mellitus. In: Humes HD (Editor). Kelley’s Textbook of
Internal Medicine, Fourth Edition. Lippincott-Williams & Wilkins, Philadelphia, 2000, pages 2635-2648.
85) Skyler JS, Pugliese A, Bernal C, Marks JB. Prevention of Type 1 Diabetes Mellitus. In: Ekoe JM, Zimmet P, Williams R
(editors). The Epidemiology of Diabetes Mellitus: An International Perspective. John Wiley and Sons, Chichester, England, 2001,
pages 31-40.
86) Skyler JS: Etiology, Pathogenesis and Therapy of Type I Diabetes Mellitus. In: Lavin N (Editor): Manual of Endocrinology
and Metabolism, Third Edition. Lippincott-Williams & Wilkins, Philadelphia, 2002, pages 575-583.
87) Skyler JS: Relationship of Glycemic Control to Diabetic Complications. In: Porte D, Sherwin R, Baron A (Editors): Ellenberg
& Rifkin's Diabetes Mellitus: Theory and Practice, Sixth Edition. McGraw-Hill, New York, 2003, pages 905-926.
88) Skyler JS: Prevention of Type 1 Diabetes. In: Williams R, Herman W, Kinmouth AL, Wareham NJ (Editors). The Evidence
Base for Diabetes Care. John Wiley and Sons, West Sussex, England, 2002, pages 45-68.
89) Marks JB, Skyler JS: The Liver and The Endocrine System. In: Schiff ER, Sorrell MF, Maddrey WC (Editors). Schiff's Diseases
of the Liver, Ninth Edition. Lippincott-Williams & Wilkins, Philadelphia, 2003, pages 529-542.
90) Skyler JS: Immunotherapy for Interdicting the Type 1 Diabetes Disease Process. In: Pickup J, Williams G (Editors), Textbook
of Diabetes, Third edition, Blackwell Publishing Ltd., Oxford, UK, 2003, pages 74-1 to 74-12.
91) Skyler JS: Diabetes Mellitus: Pathogenesis and Natural History. In: Gruessner RWG , Sutherland DER (Editors),
Transplantation of the Pancreas, Springer, 2004, pages 11-27.
92) Skyler JS: A View of the Future. In: Raz I, Skyler JS, Shafrir E (Editors): Diabetes: From Research to Diagnosis and
Treatment. London, Martin Dunitz, 2003, pages 547-558.
93) Skyler JS, Marks JB: Immune Intervention. In: LeRoith D, Taylor SI, Olefsky JM (Editors): Diabetes Mellitus: A
Fundamental and Clinical Text. Third Edition. Lippincott-Williams & Wilkins, Philadelphia, 2004, pages 701-709.
Jay S. Skyler
Page 50
Curriculum Vitae
94) Skyler JS: Insulin Treatment. In: Lebovitz HE (Editor): Therapy for Diabetes Mellitus & Related Disorders, Fourth Edition.
American Diabetes Association, Alexandria, Virginia, 2004, pages 207-223.
95) Skyler JS: Self-Monitoring of Blood Glucose. In: DeFronzo RA, Ferrannini E, Keen H, Zimmet P (Editors): International
Textbook of Diabetes Mellitus, Third Edition. John Wiley and Sons, Sussex, England, 2004, pages 1672-1683.
96) Skyler JS: Relationship of Glycemic Control to Diabetic Complications. In: Inzucchi SE (Editor): The Diabetes Mellitus
Manual (A Primary Care Companion to Ellenberg & Rifkin's Sixth Edition). McGraw-Hill, New York, 2005, pages 290-302.
97) Lopez-Sandrin M, Skyler JS. Prevention of Diabetes Mellitus. In: Dulmus CN, Rapp-Paglicci LA (Editors): Handbook of
Preventive Interventions for Adults. John Wiley and Sons, Hoboken NJ, 2005, pages 187-213.
98) Atkinson MA, Skyler JS. Type 1 Diabetes. In: Skyler JS (Editor): Atlas of Diabetes. Third Edition. Lippincott Williams &
Wilkins, Philadelphia, 2006, pages 57-76.
99) Hirsch IB, Skyler JS. Management of Type 1 Diabetes. In: Skyler JS (Editor): Atlas of Diabetes. Third Edition. Lippincott
Williams & Wilkins, Philadelphia, 2006, pages 77-88.
100) Hirsch IB, Skyler JS. The Management of Type 1 Diabetes. In: Goldfine I, Rushakoff RJ (Section Editors). Endotext.com.
2006. (http://www.endotext.com/diabetes/diabetes20/diabetesframe20.htm)
101) Skyler JS. Diabetes Mellitus: Old Assumptions and New Realities. In: Bowker J, Pfeifer M (Editors). The Diabetic Foot,
Seventh Edition. Mosby, St. Louis, 2008, pages 23-32.
102) Skyler JS. Newer Diabetes Medications. In: Skyler JS (Editor): Atlas of Diabetes. Third Edition, Second Printing. Lippincott
Williams & Wilkins, Philadelphia, 2008, pages 275-302.
103) Skyler JS: Etiology, Pathogenesis and Therapy of Type I Diabetes Mellitus. In: Lavin N (Editor): Manual of Endocrinology
and Metabolism, Fourth Edition. Lippincott-Williams & Wilkins, Philadelphia, 2009, pages 589-597.
104) Skyler JS. Medical Management of the Diabetic Patient. In: Scott IU, Flynn HW, Smiddy WE. Diabetes and Ocular Disease Past, Present, & Future Therapies, Second Edition (Ophthalmology Monographs 14). Oxford University Press, New York, 2009,
pages 353-371.
105) Skyler JS. Insulin Treatment. In: Lebovitz HE (Editor): Therapy for Diabetes Mellitus & Related Disorders, Fifth Edition.
American Diabetes Association, Alexandria, Virginia, 2009, pages 273-289.
106) Skyler JS. Prevention of Type 1 Diabetes. In: Herman WH, Kinmonth AL, Wareham NJ, Williams R (Editors): The Evidence
Base for Diabetes Care, Second Edition. Wiley-Blackwell, Chichester UK, 2010, pages 31-48.
107) Skyler JS. Immunomodulation (Immunotherapy) for Type 1 Diabetes Mellitus. In: Phillip M, Battelino T (Editors). ATTD
2009 Year Book - Advanced Technologies and Treatment for Diabetes. Wiley-Blackwell, Chichester UK, 2010, pages 168-182.
108) Skyler JS. Diabetes Management and CVD Risk Reduction. In: Eckel RH (Editor). Metabolic Risk for Cardiovascular
Disease. American Heart Association Clinical Series. Wiley-Blackwell, Chichester UK, 2011, pages 198-219.
109) Skyler JS. Immune Intervention for Type 1 Diabetes Mellitus. In: Phillip M, Battelino T (Editors). ATTD 2010 Year Book Advanced Technologies and Treatment for Diabetes. Wiley-Blackwell, Chichester UK, 2011, pages 176-204.
110) Atkinson MA, Skyler JS. Type 1 Diabetes. In: Skyler JS (Editor): Atlas of Diabetes. Fourth Edition. Springer, New York,
2012, pages 65-94.
111) Hirsch IB, Skyler JS. Management of Type 1 Diabetes. In: Skyler JS (Editor): Atlas of Diabetes. Fourth Edition. Springer,
New York, 2012, pages 95-113.
112) Skyler JS. Newer Diabetes Medications. In: Skyler JS (Editor): Atlas of Diabetes. Fourth Edition. Springer, New York, 2012,
pages 375-419.
113) Skyler JS. Type 1 Diabetes Mellitus: Immune Intervention. In: Phillip M, Battelino T (Editors). ATTD 2011 Year Book Advanced Technologies and Treatment for Diabetes. Wiley-Blackwell, Chichester UK, 2012, pages 157-173.
114) Garg SK, Skyler JS. New Medications for the Treatment of Diabetes. In: Phillip M, Battelino T (Editors). ATTD 2011 Year
Book - Advanced Technologies and Treatment for Diabetes. Wiley-Blackwell, Chichester UK, 2012, pages 243-270.
Jay S. Skyler
Page 51
Curriculum Vitae
115) Skyler JS. Immune Intervention in Type 1 Diabetes. In: Vora J, Buse J (Editors). Evidence-Based Management of Diabetes.
Tfm Publishing, Shrewsbury UK, 2012, pages 187-210.
116) Hirsch IB, Skyler JS: The management of type 1 diabetes. Endotext.org. (http://www.endotext.com/diabetes/diabetes20/diabetesframe20.htm)
117) Skyler JS. The Year in Immune Intervention for Type 1 Diabetes. In: Phillip M, Battelino T (Editors). ATTD 2012 Year Book
- Advanced Technologies and Treatment for Diabetes. Wiley-Blackwell, Chichester UK, 2013, pages 189-205.
118) Skyler JS. Immune Intervention for Type 1 Diabetes 2012-2013. In: Phillip M, Battelino T (Editors). ATTD 2013 Year Book Advanced Technologies and Treatment for Diabetes. Wiley-Blackwell, Chichester UK, 2014, pages 181-195.
119) Skyler JS. Preservation and Prevention Strategies for Type 1 Diabetes. In: Umpierrez GE (Editor): Therapy for Diabetes
Mellitus & Related Disorders, Sixth Edition. American Diabetes Association, Alexandria, Virginia, 2014, pages 116-127.
120) Skyler JS. Prevention of type 1 diabetes. In: DeFronzo RA, Ferrannini E, Zimmet P, Alberti KGMM (Editors): International
Textbook of Diabetes Mellitus, Fourth Edition. John Wiley and Sons, Sussex, England, 2015, pages 541-549.
121) Skyler JS. Immune Intervention for Type 1 Diabetes, 2013-2014. In: Phillip M, Battelino T (Editors). ATTD 2014 Year Book Advanced Technologies and Treatment for Diabetes. Mary Ann Liebert Inc, New Rochelle, NY, 2015, pages 170-186.
122) Skyler JS, Krischer JP, Becker D, Rewers M. Prevention of Type 1 Diabetes. In: Diabetes in America, Third Edition. In
Press.
c. SYMPOSIA EDITED
1) Skyler JS (Editor): Symposium on Social Issues and Medicine. Archives of Internal Medicine 1971; 127:49-110
2) Skyler JS (Editor): The Walter Kempner Symposium. Archives of Internal Medicine 1974; 133:751-807
3) Skyler JS, Cahill GF (Editors): Symposium on Diabetes Mellitus. American Journal of Medicine 1981; 70: 101-214, 325-378,
579-626.
4) Skyler JS, Raptis S (Editors): Symposium on Biosynthetic Human Insulin. Diabetes Care 1981; 4:139-264
5) Skyler JS (Editor): Symposium on Human Insulin of Recombinant DNA Origin. Diabetes Care 1982; 5(Suppl. 2):1-186
6) Skyler JS (Editor): Symposium on Immunology and Diabetes. Diabetes/Metabolism Reviews 1987; 3: 723-1090.
7) Skyler JS (Editor): Symposium on Diabetes in Childhood and Adolescence. Pediatric Annals 1987; 16: 679-740.
8) Skyler JS (Guest Editor): Diabetic Control: Reducing the Risk of Complications? Diabetes Spectrum 1988; 1: 89-120.
9) Skyler JS, Erkelens W, Becker D (Editors): Human Insulin: A Decade of Experience and Future Developments. Diabetes Care
1993; 16 (Supplement 3): 1-165.
10) Skyler JS (Editor): Prevention & Treatment Of Diabetes & Its Complications. Medical Clinics of North America 1998; 82: 4:
665-979 (July 1998).
11) Skyler JS (Editor): Advances in Continuous Glucose Monitoring in Diabetes Mellitus. Diabetes Technology and Therapeutics
2000; 2:(Supplement 1): S1-S97.
12) Skyler JS. Islet Replacement Therapy. International Diabetes Monitor 2004; 16:(6):1-29
13) Skyler JS (Editor): Inhaled Insulin. Diabetes Technology and Therapeutics 2007; 9:(Supplement 1): S1-S114.
14) Skyler JS. Type 1 Diabetes. International Diabetes Monitor 2010; 22: 99-137.
3. REVIEW ARTICLES
Jay S. Skyler
Page 52
Curriculum Vitae
1) Dranov J, Skyler JS, Gunnells JC: Malignant Hypertension - Current Modes of Therapy. Archives of Internal Medicine 1974;
133:791-801
2) Mintz DH, Skyler JS, Chez RA: Diabetes Mellitus and Pregnancy. Diabetes Care 1978; 1:49-63
3) Blankenship GW, Skyler JS: Diabetic Retinopathy - A General Survey. Diabetes Care 1978; 1:127-137
4) Skyler JS: Clinical Implications: Exercise in Diabetes. Diabetes Care 1979; 2:307-311
5) Skyler JS: Complications of Diabetes Mellitus: Relationship to Metabolic Dysfunction. Diabetes Care 1979; 2:499-509
6) Skyler JS, Miller NE: The Use of Sweeteners by Diabetic Patients. Practical Cardiology 1980; 6(10):119-129
7) Skyler JS, Pfeiffer EF, Raptis S, Viberti GC: Biosynthetic Human Insulin: Progress and Prospects - An Overview. Diabetes Care
1981; 4:140-143
8) Citrin WS, Zigo MA, LaGreca A, Skyler JS: Group Strategies for Diabetes in Adolescence. Pediatric and Adolescent
Endocrinology 1982; 10:219-223
9) Skyler JS: Psychosocial Aspects of Diabetes in Children and Adolescents: A Perspective of the Symposium. Pediatric and
Adolescent Endocrinology 1983; 11:205-209
10) Skyler JS, Seigler DE, Reeves ML: A Comparison of Insulin Regimens in Insulin-Dependent Diabetes Mellitus. Diabetes Care
1982; 5(Suppl 1):11-18
11) Miller NE, O'Sullivan MJ, Skyler JS: Diabetes in Pregnancy: Nutritional Management. Perinatology/Neonatology 1983;
7(1):37-44
12) Skyler JS: Patient Self-Monitoring of Blood Glucose. Medical Clinics of North America 1982; 66:1227-1250
13) Skyler JS: Human Insulin of Recombinant DNA Origin: Clinical Potential. Diabetes Care 1982; 5(Suppl 2): 181-186
14) Skyler JS: Diabetes Update on Dx, Drugs and Diet. Modern Medicine 1982; 50(11);74-105
15) Skyler JS: Patient Self-Monitoring of Blood Glucose. Clinical Diabetes 1983; 1(4):12-17
16) Skyler JS: Dietary Planning in Insulin Dependent Diabetes Mellitus. Pediatric Annals 1983; 12:652-657
17) Skyler JS: Non-Insulin Dependent Diabetes Mellitus - A Clinical Strategy. Diabetes Care 1984; 7(Suppl 1):118-129
18) Skyler JS, Beatty CM, Goldberg RB: Managing Diabetes: An Updated Look at Diet. Geriatrics 1984; 39:7:57-68
19) Linn MW, Linn BS, Skyler JS, Edelstein J, Sandifer R: A Possible Role for Self-Management Techniques in Control of Diabetes.
Diabetes Educator 1985; 11(2):13-16
20) Skyler JS: What's New in Today's & Tomorrow's Diabetes Therapy? Pharmacy Times 1985; 51:10:37-49
21) Rosenbloom AL, Malone JI, Morrison AD, Skyler JS: Screening for Diabetes Mellitus. Journal of the Florida Medical
Association 1985; 72:1033-1037
22) Skyler JS, Bonheim R: Diabetes Self-Liberation. Rx Being Well 1986; 4(6):12-16, 42-44
23) Skyler JS: Insulin-Dependent Diabetes Mellitus: Flexibility in Contemporary Management. Postgraduate Medicine 1987;
81(6):163-174
24) Skyler JS: Immune Intervention Studies in Insulin-Dependent Diabetes Mellitus. Diabetes/Metabolism Reviews 1987; 3:10171035
25) Skyler JS, Rabinovitch A: Etiology and Pathogenesis of Insulin-Dependent Diabetes Mellitus. Pediatric Annals 1987; 16:682692
26) Skyler JS: Why Control Blood Glucose? Pediatric Annals 1987; 16:713-724
27) Skyler JS: How to Improve Diabetes Control. Diabetes in the News 1988; 5:1:32-34
Jay S. Skyler
Page 53
Curriculum Vitae
28) Skyler JS: Insulin Pharmacology. Medical Clinics of North America 1988; 72:1337-1354
29) Skyler JS: Intensive Insulin Therapy - A Personal and Historical Perspective. Diabetes Educator 1989; 15:33-39
30) Skyler JS: Controversies and Directions in Diabetes Care. Jefferson Alumni Bulletin 1989; 38:4:25-28
31) Rabinovitch A, Skyler JS: Immunotherapy of Type I Diabetes. Medicographia 1990; 12:24-26,29
32) Donahue RP, Skyler JS, Schneiderman N, Prineas RJ: Hyperinsulinemia and Elevated Blood Pressure: Cause, Confounder, or
Coincidence? American Journal of Epidemiology 1990; 132:827-836
33) Hirsch IB, Farkas-Hirsch R, Skyler JS: Intensive Insulin Therapy for the Treatment of Type I Diabetes Mellitus. Diabetes Care
1990; 13:1265-1283
34) Marks JB, Skyler JS: Clinical Review: Immunotherapy of Type I Diabetes Mellitus. Journal of Clinical Endocrinology &
Metabolism 1991; 72:3-9
35) Marks JB, Skyler JS: Insulin Update. Pharmacy Times 1990; 56(10):102-110
36) Skyler JS: Strategies in Diabetes Mellitus: Start of a New Era. Postgraduate Medicine 1991; 89(6):45-63
37) Skyler JS: Is Tight Blood Sugar Control Effective and Justified? Affirmative. Hospital Practice 1992; 27:(Suppl 1):17-20,24-25
38) Skyler JS: Can Type I Diabetes Be Prevented? International Diabetes Monitor 1992; 4(6):1-6.
39) Skyler JS, Marks JB: Immune Intervention in Type I Diabetes Mellitus. Diabetes Reviews 1993; 1:15-42.
40) Skyler JS: Awaiting the DCCT. International Diabetes Monitor 1993; 5(2):1-3.
41) Skyler JS: The Impact of the DCCT. International Diabetes Monitor 1993; 5(3):1-3.
42) Burke GW, Alejandro R, Nery J, Roth D, Skyler JS, Ricordi C, Ciancio G, Miller J: Combined Kidney/Pancreas Transplantation
in Diabetes Mellitus. Journal of the Florida Medical Association 1994: 81:339-343.
43) Skyler JS: Recent Advances in Insulin Therapy. The Diabetes Annual 1995; 10:193-207.
44) Skyler JS, Marks JB, Schneiderman N: Hypertension In Patients With Diabetes. American Journal of Hypertension 1995;
8:100S-105S.
45) Skyler JS: Diabetic Complications: Glucose Control Is Important. Endocrinology and Metabolism Clinics of North America
1996; 25:243-254.
46) Skyler JS: Insulin Therapy in Type II Diabetes: Who Needs It, How Much of It, and For How Long? Postgraduate Medicine
1997; 101(2):85-90,92-94,96.
47) Skyler JS: Tactics in Type 1 Diabetes. Endocrinology and Metabolism Clinics of North America 1997; 26: 647-657.
48) Rabinovitch A, Skyler JS: Prevention of Type 1 Diabetes. Medical Clinics of North America 1998; 82:739-755.
49) Skyler JS: Targeted Glycemic Control in Type 2 Diabetes. Journal of the Florida Medical Association 1998: 85:2:7-15.
50) Skyler JS: Prediction and Prevention of Type 1 Diabetes. Topical Endocrinology 1998: 10:6-9.
51)
Skyler JS: Treating Diabetes: Rationale for Control. Managed Care Interface 1999; 12: Supplement 3: 10-14.
52)
Skyler JS: New Diabetes Criteria and Clinical Implications. Drugs 1999; 58: Supplement 1: 1-2.
53) Beck-Nielsen H, Skyler J, Hanefeld M, Eschwege E, Finn J-R, DeFronzo R, Del Prato S, Bjorntorp P, Groop L, Haring H,
Vague P, Charles A. Discussion . Drugs 1999; 58: Supplement 1: 75-82.
54) Skyler JS: The Economic Burden of Diabetes and the Benefits of Improved Glycemic Control: The Potential Role of a
Continuous Glucose Monitoring System. Diabetes Technology and Therapeutics 2000; 2:(Supplement 1): S7-S12.
Jay S. Skyler
Page 54
Curriculum Vitae
55) Skyler JS: Microvascular Complications: Retinopathy and Nephropathy. Endocrinology and Metabolism Clinics of North
America 2001; 30: 833-856.
56) Skyler JS, Oddo C. Diabetes Trends in the United States of America. Diabetes Metabolism Research Reviews 2002;
18(Supplement 3):S21-S26.
57) Home P, Chacra A, Chan J, Emslie-Smith A, Sorensen L, Van Crombrugge P, Boulton A, Davidson J, Dornan T, Heine R,
Jimenez J, Kangas T, Kawamori R, Landgraf R, Massi-Benedetti M, Mogensen CE, Christiansen JS, Skyler J, Sorensen L, Uccioli L,
Van Crombrugge P, Worldwide Initiative for Diabetes Education (WorldWIDE). Considerations on blood glucose management in
type 2 diabetes mellitus. Diabetes Metabolism Research Reviews 2002; 18:273-285
58) Skyler JS. Evidence for Glycated Hemoglobin Targets from The Diabetes Control and Complications Trial. Endocrine
Practice 2002; 8(Supplement 1):27-30.
59)
Skyler JS. Diabetes Mellitus: Pathogenesis and Treatment Strategies. Journal of Medicinal Chemistry 2004; 47:4113-4117.
60) Skyler JS. DCCT: the study that forever changed the nature of treatment of type 1 diabetes. The British Journal of Diabetes
and Vascular Disease 2004; 4:29-32.
61) Skyler JS. Effects of Glycemic Control on Diabetic Complications and on Prevention of Diabetes. Clinical Diabetes 2004;
22:162-166.
62)
Skyler JS. Pulmonary Insulin Update. Diabetes Technology and Therapeutics 2005; 7:834-839.
63)
Skyler JS. Pulmonary Insulin – Current Status. Diabetes Voice 2006; 51:1:23-25.
64) Skyler JS, Rafkin-Mervis LE. Inhaled Insulin – A New Tool in Diabetes Management. On the Cutting Edge 2006; 27:2:911,14.
65) Skyler JS. Prediction and Prevention of Type 1 Diabetes: Progress, Problems, and Prospects. Clinical Pharmacology and
Therapeutics 2007; 81:768-771.
66) Skyler JS, Ponder S, Kruger D, Matheson D, Parkin CG. Is There a Place for Insulin Pump Therapy in Your Practice? Clinical
Diabetes 2007; 25:50-56.
67) Ponder SW, Skyler JS, Kruger DF, Matheson D, Brown BW. Unexplained hyperglycemia in continuous subcutaneous insulin
infusion: evaluation and treatment. Diabetes Educator 2008; 34:327-333
68) Skyler JS. Latent autoimmune diabetes in adults: the search for interventions continues. Nature Clinical Practice
Endocrinology & Metabolism 2008; 4: 600-601.
69)
Skyler JS. Glycemic control and cardiovascular disease. International Diabetes Monitor 2008; 20:183-187.
70) Lane W, Cochran E, Jackson JA, Scism-Bacon J, Corey I, Hirsch IB, Skyler JS. High-Dose Insulin Therapy: Is It Time for U-500
Insulin? Endocrine Practice 2009; 15:71-79.
71) Skyler, JS. Continuous Glucose Monitoring: An Overview of Its Development. Diabetes Technology and Therapeutics 2009;
11: (Supplement 1): S5-S10.
72) Cernea S, Raz I, Herold KC, Hirshberg B, Roep BO, Schatz DA, Fleming GA, Pozzilli P, Little R, Schloot NC, Leslie RDG,
Skyler JS, Palmer JP. Challenges in Developing Endpoints for Type 1 Diabetes Intervention Studies. Diabetes Metabolism Research
Reviews 2009; 25:694-704.
73) Aschner P, Horton E, Leiter LA, Munro N, Skyler JS on behalf of the Global Partnership for Effective Diabetes Management.
Practical steps to improving the management of type 1 diabetes. Recommendations from the Global Partnership for Effective Diabetes
Management. International Journal of Clinical Practice 2010; 64:305-315.
74) Skyler JS. Immunomodulation for type 1 diabetes mellitus. International Journal of Clinical Practice 2010; 64 (Suppl 166):
59-63
75)
Skyler JS. Approaches to Interdicting Type 1 Diabetes. International Diabetes Monitor 2010; 22: 132-137.
76) Skyler, JS. Continuous Subcutaneous Insulin Infusion – A Historical Perspective. Diabetes Technology and Therapeutics
2010; 12: (Supplement 1): S5-S9.
Jay S. Skyler
Page 55
Curriculum Vitae
77)
Skyler JS, Ricordi C. Stopping Type 1 Diabetes: Attempts to Prevent or Cure Type 1 Diabetes in Man. Diabetes 2011; 60:1-8.
78)
70.
Skyler JS. Immune intervention for type 1 diabetes mellitus. International Journal of Clinical Practice 2011; (Suppl 170): 61-
79)
61.
Skyler JS. Type 1 diabetes mellitus: immune intervention. International Journal of Clinical Practice 2012; (Suppl 175): 56-
80) Garg S, Skyler JS. New medications for the treatment of diabetes. International Journal of Clinical Practice 2012; (Suppl
175): 85-93.
81) Shuster JJ, Guo JD, Skyler JS. Meta-analysis of safety for low event-rate binomial trials. Research Synthesis Methods 2012;
3:30-50.
82) Skyler JS. The year in immune intervention for type 1 diabetes. Diabetes Technology and Therapeutics 2013; 15: Supplement
1:S88-S95.
83)
Skyler JS. Primary and Secondary Prevention of Type 1 Diabetes. Diabetic Medicine 2013; 30:161-169.
84) Rustad JK, Musselman DL, Skyler JS, Matheson D, Delamater A, Kenyon NS, Caceda R, Nemeroff CB. Decision Making in
Diabetes Mellitus Type 1. Journal of Neuropsychiatry and Clinical Neurosciences 2013;24:40-50.
85) Pugliese A, Skyler JS. Profiles in Progress – George S. Eisenbarth: Insulin and Type 1 Diabetes. Diabetes Care 2013; 36:
1437-1442.
86) Skyler JS, Pugliese A. Immunotherapy Trials for Type 1 Diabetes – the Contribution of George Eisenbarth. Diabetes
Technology and Therapeutics 2013; 15: Supplement 2: S213-S220.
87) Hirsch IB, Buse JB, Leahy J, McGill JB, Peters A, Rodbard HW, Rubin RR, Skyler JS, Verderese CA, Riddle MC. Options for
Prandial Glucose Management in Type 2 Diabetes Patients Using Basal Insulin: Addition of a Short-acting GLP-1 Analogue versus
Progression to Basal-Bolus Therapy. Diabetes Obesity Metabolism 2014; 16:206-214.
88) Bailey CJ, Aschner P, Del Prato S, LaSalle J, Ji L, Matthaei S, and on behalf of the Global Partnership for Effective Diabetes
Management [Skyler JS – Partnership Group Member]. Individualized glycaemic targets and pharmacotherapy in type 2
diabetes. Diabetes and Vascular Disease Research 2013; 10:397-409.
89) Harja E, Lord J, Skyler JS. Critique: An analysis of characteristics of subjects examined for incretin effects on pancreatic
pathology. Diabetes Technology and Therapeutics 2013; 15: 609-618.
90) Skyler JS. Immune intervention for type 1 diabetes, 2012-2013. Diabetes Technology and Therapeutics 2014; 16
Supplement 1:S85-S91.
91) Peyser T, Dassau E, Breton M, Skyler JS. The artificial pancreas: current status and future prospects in the management of
diabetes. Annals of the New York Academy of Sciences 2014; 1311:102-123.
92)
Skyler JS. T1DM in 2014: Progress Towards a Bionic Pancreas. Nature Reviews Endocrinology 2015; 11:75-76
93) Skyler JS. Immune intervention for type 1 diabetes, 2013-2014. Diabetes Technology and Therapeutics 2015; 17 Supplment
1:S80-S87.
94) Skyler JS. The Prevention & Reversal of Type 1 Diabetes – Past Challenges & Future Opportunities. Diabetes Care 2015;
38:997-1007.
4. EDITORIALS, COMMENTARIES, and CRITIQUES
1) Skyler JS (Editor): Symposium on Social Issues and Medicine. Archives of Internal Medicine 1971; 127:49-11
(a) Introductory Remarks. Archives of Internal Medicine 1971; 127:50
(b) Concluding Remarks. Archives of Internal Medicine 1971; 127:110
2)
Skyler JS: Differential Certification of Physician's Assistants. Archives of Internal Medicine 1973; 132:29
Jay S. Skyler
Page 56
Curriculum Vitae
3)
Skyler JS: Walter Kempner - A Biographical Note. Archives of Internal Medicine 1974; 133:752-755
4)
Skyler JS: Diabetes Care - Striking a Balance. Diabetes Care 1978; 1:70
5)
Skyler JS: Lipids, Diet, Diabetes, and Atherogenesis. Diabetes Care 1978; 1:138-139
6)
Skyler JS: “Control” and Complications. Diabetes Care 1978; 1:204-205
7)
Skyler JS: Sulfonylurea Drugs - 1978. Diabetes Care 1978; 1:205-206
8)
Skyler JS: The UGDP and Insulin Therapy. Diabetes Care 1978; 1:328-329
9)
Skyler JS: Thoughts Along the Way. Diabetes Care 1979; 2:58-59
10)
Skyler JS: The Spectrum of Insulin Resistance. Diabetes Care 1979; 2:319-322
11)
Skyler JS: Counter-Regulatory Hormones, Rebound Hyperglycemia, and Diabetic Control. Diabetes Care 1979; 2:526-529
12)
Skyler JS: The Editor's Notebook. Diabetes Care 1980; 3:198-199
13)
Skyler JS: Diabetes Mellitus: At Least Two Distinct Entities. Diabetes Care 1980; 3:395-396
14)
Citrin W, Ellis GJ, Skyler JS: Glycosylated Hemoglobin: A Tool in Identifying Psychological Problems? Diabetes Care 1980;
3:563-564
15)
Skyler JS: A Plethora of Insulins. Diabetes Care 1980; 3:638-639
16)
Skyler JS, Cahill GF: Forward. Diabetes Mellitus: Progress and Directions. American Journal of Medicine 1981; 70:101-104
17)
Skyler JS: The Editor Reflects... Diabetes Care 1981; 4:134-135
18)
Skyler JS, Neelon FA: An Algebra For Adiposity. Diabetes Care 1981; 4:328-329
19)
Skyler JS: The Shoulder Bag. Diabetes Care 1981; 4:331
20)
Skyler JS: Evidence, Implications, and Corollaries. Diabetes Care 1981; 4:573-575
21)
Skyler JS: Psychological Issues in Diabetes. Diabetes Care 1981; 4:656-657
22)
Skyler JS: From The Editor's Desk... Diabetes Care 1982; 5:75-76
23)
Skyler JS: Diabetic Retinopathy. JAMA 1982; 247:3246-3247
24)
Skyler JS: Type II Diabetes: Towards Improved Understanding and Rational Therapy. Diabetes Care 1982; 5:447-448
25)
Skyler JS: Type I Diabetes: Regimens, Targets & Caveats. Diabetes Care 1982; 5:547-552
26)
Skyler JS: A Parting Word... Diabetes Care 1982; 5:642-643
27)
Skyler JS: Control of Diabetes During Pregnancy - 1985. JAMA 1986; 247:647-648
28)
Skyler JS: Lessons From Insulin Pharmacokinetics. Diabetes Care 1986; 9:666-668
29)
Skyler JS: Introduction: Symposium on Immunology and Diabetes. Diabetes/Metabolism Reviews 1987; 3:723-724, 857-858
30)
Skyler JS: Diabetic Control: Reducing the Risk of Complications? Introduction and Conclusions. Diabetes Spectrum 1988;
1:90, 118-120
31)
Skyler JS: Keeping Up. International Diabetes Monitor 1989; 1:(1):1
32)
Skyler JS: Overview: Progress in Diabetes Care. On The Cutting Edge Newsletter 1992; 13(4):2-3.
33)
Skyler JS: Presidential Address. The Winds of Change. Diabetes 1993; 42:637-642.
Jay S. Skyler
34)
Page 57
Curriculum Vitae
Skyler JS: Presidential Address. The Challenges of the Future. American Journal of Medical Sciences 1993; 305:5-9; and
The Endocrinologist 1993; 3:233-238.
35)
Skyler JS: Human Insulin After Ten Years. Diabetes Care 1993; 16(Suppl 3): 1-3.
36)
Skyler JS: The Monitor After Five Years. International Diabetes Monitor 1994; 6:(1):1-2.
37)
Skyler JS: Who Is The “Diabetes Team?” International Diabetes Monitor 1994; 6:(3):1-2.
38)
Skyler JS: After the DCCT......... International Diabetes Monitor 1994; 6:(4):1-2.
39)
Deeb LC, Skyler JS: Upgrading Diabetes Therapy. Now That We Know It Matters. Journal of the Florida Medical
Association 1994: 81:599-602.
40)
Skyler JS, Lefebvre P: Merging of Interests…..Broadening of Scope. International Diabetes Monitor 1995; 7:(1):1.
41)
Skyler JS: Glucose Control is Important in Type 2, Too! International Diabetes Monitor 1996; 8:(6):1-2.
42)
Skyler JS: Glucose Control in Type 2 Diabetes Mellitus. Annals of Internal Medicine 1997; 127:837-839.
43)
Skyler JS, Lefebvre PJ: Beginning Year 10. International Diabetes Monitor 1998; 10:(1):1.
44)
Skyler JS: Diabetes Mellitus - Facts & Paradoxes. Medical Clinics of North America 1998; 82:4:xi-xii.
45)
Skyler JS: Simplifying the Diagnosis of Diabetes Mellitus. American Family Physician 1998; 58:1290-1292.
46)
Skyler JS: UKPDS – What Does It Mean to Diabetes Management? International Diabetes Monitor 1999; 11:(2): 1-5.
47)
Schatz DA, Krischer JP, Skyler JS: Now Is the Time to Prevent Type 1 Diabetes. Journal of Clinical Endocrinology and
Metabolism 2000; 85: 495-498.
48)
Skyler JS: Type 2 Diabetes: Insulin Secretion versus Insulin Action. International Diabetes Monitor 2000; 12:(3):1-3
49)
Skyler JS, Lefebvre PJ: IDM – Changing with The Times. International Diabetes Monitor 2004; 16:(1):1
50)
Skyler JS. Islet Replacement Therapy. International Diabetes Monitor 2004; 16:(6):1-2.
51)
Skyler JS. PROactive Results Overstated and Misleading. DOCNews 2005; 2:(12):4.
52)
Skyler JS. PROactive – A Sad Tale of Inappropriate Analysis and Unjustified Interpretation. Clinical Diabetes 2006; 24: 63-65.
52)
Skyler JS. Cellular Therapy for Type 1 Diabetes Mellitus – Has The Time Come? JAMA 2007; 297:1599-1600.
53)
Skyler JS. Pulmonary Insulin Delivery—State of the Art 2007. Diabetes Technology & Therapeutics 2007; 9: (Supplement 1):
S1-S3.
54)
Skyler JS, Lefebvre P, Feldt-Rasmussen B. The ‘Monitor’ evolves. Gutenberg requiescat in pace! International Diabetes
Monitor 2007; 19:(6):1.
55)
Skyler JS. Thirty Years of Diabetes Care – Reflections on the Beginning. Diabetes Care 2008; 31: 183-184.
56)
Skyler JS. CGM – A Technology in Evolution. Diabetes Technology and Therapeutics 2009; 11: 63-64.
57)
Garg, SK, Hirsch IB, Skyler JS. Insulin Glargine and Cancer—An Unsubstantiated Allegation. Diabetes Technology and
Therapeutics 2009; 11: 473-476.
58)
Skyler JS. Probing Type 1 Diabetes. International Diabetes Monitor 2010; 22: 99-100.
59)
Skyler JS. Glycemia and Cardiovascular Diseases in Type 2 Diabetes. Journal of Internal Medicine 2010; 268: 468-470.
60)
Skyler JS, Sosenko JM. The Evolution of Type 1 Diabetes. JAMA 2013; 309:2491-2492.
61)
Skyler JS. The Compelling Case for Anti-CD3 in Type 1 Diabetes. Diabetes 2013; 62:3656-3657.
Jay S. Skyler
Page 58
Curriculum Vitae
62)
Skyler JS. Antithymocyte Globulin in Type 1 Diabetes – An Unanswered Question. Lancet Diabetes & Endocrinology 2013;
1: 265-266.
63)
Skyler JS. Struggles with Clinical Translation of Immune Intervention Trials. Diabetes Care 2014; 37: 1173-1175.
64)
Skyler JS. Characterizing Subgroups of Type 1 Diabetes. Diabetes 2014; 63:3578-3580.
65)
Skyler JS. Immune Therapy for Treating Type 1 Diabetes: Challenging Existing Paradigms. Journal of Clinical Investigation
2015; 125:94-96.
66)
Skyler JS. Towards Primary Prevention of Type 1 Diabetes. JAMA 2015; 313:1520-1521.
67)
Cefalu WT, Tamborlane WV, Skyler JS. Type 1 Diabetes at a Crossroad! Diabetes Care 2015; 38: 968-970.
.
5. POSITION STATEMENTS
1) Assan R, Bach JF, Czernichow P, Dupre J, Stiller CR, Eisenbarth GS, Gries FA, Kolb H, Harrison LC, Lafferty K, Maclaren NK,
Nerup J, Rabinovitch A, Skyler J: Immunosuppressive Drugs in Diabetes. Lancet 1986; 2:1097
2) Kolb H, Bach JF, Eisenbarth GS, Harrison LC, Maclaren NK, Pozzilli P, Skyler J, Stiller CR: Criteria for Immune Trials in Type I
Diabetes. Lancet 1989; 2:686
3) American Diabetes Association Ad Hoc Expert Committee [Jay S. Skyler, Chairman]. Prevention of Type I Diabetes Mellitus.
Diabetes 1990; 39:1151-1152 and Diabetes Care 1990; 13:1026-1027.
4) Robbins DC, Andersen L, Bowsher R, Chance R, Dinesen B, Frank B, Gingerich R, Goldstein D, Widemeyer H-M, Haffner S,
Hales CN, Jarett L, Polonsky K, Porte D, Skyler J, Webb G, Gallagher K: Report of the American Diabetes Association Task Force on
Standardization of the Insulin Assay. Diabetes 1996; 45:242-256.
5) American College of Physicians [Ginsburg JA, Addington WW, Bertram PD, Eisenberg JM, Fogarty WM, Gary NE, Gullen DJ,
Herbert-Carter J, Honsinger R Jr, Kamholz SL, Latos DL, Lavizzo-Mourey RJ, Riley WJ, Tompkins RK, Webster J, Thomson GE,
Cassel CK, Reynolds WA, Murray J, Khan FA, Sidorov J, Skyler JS, Smith LG, Vanselow N, Whitcomb M]. The Physician
Workforce and Financing of Graduate Medical Education. Annals of Internal Medicine 1998;128:142-148.
6) Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, Lachin JM, Polonsky KS, Pozzilli P, Skyler JS, Steffes
MW. C-peptide is the Appropriate Outcome Measure for Type 1 Diabetes Clinical Trials to Preserve Beta Cell Function: Report of an
ADA Workshop, 21-22 October 2001. Diabetes 2004; 53:250-264.
7) Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EAM, Howard BV, Kirkman MS, Kosiborod M, Reaven P,
Sherwin RS. Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE,
and VADT Diabetes Trials. A Position Statement of the American Diabetes Association and A Scientific Statement of the American
College of Cardiology Foundation and the American Heart Association. Diabetes Care 2009; 32: 187-192, Circulation 2009;
119:351-357, and Journal of the American College of Cardiology 2009: 53:298-304.
8) Insel RA, Dunne JL, Atkinson MA, Chiang JL, Dabelea D, Gottlieb PA, Greenbaum CJ, Herold KC, Krischer JP, Lernmark A,
Ratner RE, Rewers MJ, Schatz DA, Skyler JS, Sosenko JM, Ziegler AG. Staging Presymptomatic Type 1 Diabetes: A Scientific
Statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care 2015; 38:1964-1974.
6. LETTERS TO THE EDITOR
1) Skyler JS: Medical Student Dissent Deplored. New England Journal of Medicine 1968; 278:624-625
2) Skyler JS: Detecting Hypothyroidism. Lancet 1969; 1:259
3) Skyler JS, Skyler DL, Seigler DE, O'Sullivan MJ: Algorithms: Reply. Diabetes Care 1981; 4:506
4) Skyler JS: Management of Diabetic Retinopathy. JAMA 1982; 248:2970-2971
5) Skyler JS: Diabetic Control and Fetal Malformations. New England Journal of Medicine 1988; 319:648
Jay S. Skyler
Page 59
Curriculum Vitae
6) Skyler JS. Competing Perspectives on PROactive – Response from Dr. Skyler. Clinical Diabetes 2007; 25:3-4
7) Skyler JS. Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE,
and VA Diabetes Trials: A Position Statement of the American Diabetes Association and a Scientific Statement of the American
College of Cardiology Foundation and the American Heart Association. Diabetes Care 2009; 32:e92-93.
7. OTHER PROFESSIONAL ITEMS
a. AUDIOTAPES
1) Skyler JS: Management Strategy for Type II Diabetes. Audio-Digest 1988; 35:7
b. VIDEOTAPES
1) Skyler JS, Sherwin RS, Jovanovic L: Diabetes Mellitus: Advances in Control, Exercise, and Pregnancy. NCME Program
#409, Network for Continuing Medical Eudcation, New York, 1983
2) Skyler JS, Feldman JM: Modern Management of Diabetes. Eli Lilly & Co. Pharmaceutical Division Video Communications,
Indianapolis, 1983
3) Skyler JS: Pathogenesis of Type I Diabetes. In: Davidson MB, Video-Clinic - Diabetes Mellitus - Tape 1. American Medical
Association AMA-CME Video Clinics, 1984
4) Skyler JS, Campbell K: Principles of Diabetic Management - Modern Management. Pharmacy Update. American Medical
Video, 1990
5) Skyler JS, Campbell K: Principles of Diabetic Management - Monitoring the Diabetic Patient. Pharmacy Update. American
Medical Video, 1990
6) Skyler JS, Weir G: Prediction and Prevention of Diabetic Renal Disease. In: Bone R, Internal Medicine Update #9105.
American College of Physicians & Lifetime Television Network, 1991
7) Skyler JS, Weir G: Emerging Treatments for Diabetes. In: Bone R, Internal Medicine Update #9106. American College of
Physicians & Lifetime Television Network, 1991
8. PUBLICATIONS ABOUT JAY S. SKYLER
1) About the Editors and Editorial Board. Diabetes Care 1978; 1(1):XX
2) Service FJ: Jay Skyler and Diabetes Care. Diabetes Care 1983; 6:100
3) Biographical Note: Jay S. Skyler, M.D. Diabetes Spectrum 1988; 1:120.
Jay S. Skyler
9. PUBLISHED ABSTRACTS
Page 60
Curriculum Vitae
1) Bivins CH, Lebovitz HE, Skyler JS, Feldman JM: Enhancement of Insulin Secretion in Acromegaly by Serotonin Antagonists. Diabetes 1972;
21:352
2) Skyler JS, Newborg BC, Peschel RL, Kempner W: Weight Reduction of the Massively Obese. Clinical Research 1974; 22:569A
3) Skyler JS, Rogol AD, Knazek RA, Lovenberg W: Characterization of Growth Hormone and Prolactin Produced by Human Tumor Culture.
Clinical Research 1974; 22:713A
4) Skyler JS, Knazek RA, Rogol AD, Lovenberg W: Characterization of Growth Hormone and Prolactin Produced by Human Tumor Culture.
Clinical Research 1975; 23:423A
5) Knazek R, Skyler JS: Production of Human Prolactin by Pituitary Adenomata Grown on Artificial Capillaries. Program of the 57th Annual
Meeting of the Endocrine Society 1975; #426, p 264
6) Baumann G, Skyler JS, Chrambach A: Preparation of Isohormones of Human Growth Hormone in Milligram Amounts by Isoelectric Focusing.
Program of the 57th Annual Meeting of the Endocrine Society 1975; #122, p 111
7) Zweerink HJ, Morgan EM, White CK, Skyler JS: Structure and Function of Subviral Particles in Reovirus Infected Cells. Proceedings of the
Third International Congress for Virology 1975
8) Skyler JS, Chrambach A: Catalogue of Isohormones of Human Growth Hormone. Program of the International Symposium on Growth
Hormone and Related Peptides, Milan, Italy, 1975; p 14
9) Knazek RA, Skyler JS: Production of Growth Hormone and Prolactin in Tissue Culture. Program of the International Symposium on Growth
Hormone and Related Peptides, Milan, Italy, 1975; p 131
10) Skyler JS, Robertson EG, Skyler DL, Lasky IA, Burkett G, McLeod AGW, O'Sullivan MJ: Blood Glucose Control During Pregnancy. Program of
the Southern Sugar Club 1979
11) Citrin W, Ellis GJ, Skyler JS: A Therapeutic Paradigm for Discrepant Urine Records. Diabetes 1980: 29(Suppl 2):42A
12) Scott CS, Skyler JS: Cultural Beliefs Influence Compliance to Therapy for Diabetes Mellitus. Diabetes 1980; 29(Suppl 2):6A
13) Harris R, Linn MW, Pollack L, Tewksbury D, Skyler JS: Relationship Between the Health Belief Model and Compliance as a Basis for
Intervention. Diabetes 1981; 30(Suppl 1):98A
14) Citrin WS, Zigo MA, Skyler JS: Multi-Family Group Meetings Alter Feelings, Behavior and Management of Diabetes in Adolescents. Diabetes
1981; 30(Suppl 1):140A
15) Seigler DE, Reeves ML, Ryan EA, Goldberg RB, Skyler JS: Glycemic Control with Intensified Conventional Therapy. Diabetologia 1981;
21:326-327
16) Skyler JS, Seigler DE, Reeves ML, Ryan EA, Goldberg RB: Glycemic Control Using Intensified Conventional Therapy and Patient SelfMonitoring of Blood Glucose. Bulletin of the International Study Group of Diabetes in Children and Adolescents 1981
17) Reeves ML, Seigler DE, Ryan EA, Goldberg RB, Skyler JS: Comparison of Intensified Conventional Therapy and Continuous Subcutaneous
Insulin Infusion in Outpatient Management of Type I Diabetes Mellitus. Diabetologia 1981; 21:512-513
18) Skyler JS, Reeves ML, Seigler DE, Ryan EA: Self-Monitoring of Blood Glucose and Intensive Conventional Therapy: Comparison with
Continuous Subcutaneous Insulin Infusion in Insulin-Dependent Diabetes Mellitus. Abstracts of the International Symposium on Artifician
Systems for Insulin Delivery, Assisi, 1981; p 112
19) Citrin WS, Zigo MA, LaGreca A, Skyler JS: Diabetes in Adolescence: Effects of Multi-Family Group Therapy and Parent Simulation of Diabetes.
Diabetes 1982; 31(Suppl 2):13A
20) Ryan EA, Brower E, O'Sullivan MJ, Skyler JS: Insulin Resistance in Pregnancy. Diabetes 1982; 31(Suppl 2):31A
21) Ryan EA, Brower E, O'Sullivan MJ, Skyler JS: Changes in Insulin Action Associated with Pregnancy. Proceedings of the British Diabetic
Association. Diabetologia 1982; 23:474
22) Linn MW, Linn BS, Skyler JS, Jensen J: Stress and Immune Function in Diabetes. Psychosomatic Medicine 1982; 44:128
23) Kubrusly DB, Goldberg RB, Fournier AM, Skyler JS, Hsia SL, Sosenko JM: Association Between Plasma Lipoprotein, Components and Glycmeia
in Normal Women. Clinical Research 1984; 33:225A
24) Sosenko JM, Pasin RA, Kubrusly DB, Weintraub J, Skyler JS, Boulton AJM: Heart Rate, Autonomic Function, and Glycemia in Young Type I
Diabetes Patients. Diabetes 1984; 33(Suppl 1):91A
25) Boulton AJM, Kubrusly DB, Bowker JH, Skyler JS, Becker DM, Sosenko JM: The Importance of Diabetic Peripheral Neuropathy in the Etiology
of Foot Ulceration. Proceedings of the Diabetic Peripheral Neuropathy Meeting 1984
Jay S. Skyler
Page 61
Curriculum Vitae
26) Sosenko JM, Gadia MT, Fournier AM, O'Connell MT, Aguiar MC, Skyler JS: Body Stature: A Major Risk Factor for Diabetic Sensory
Neuropathy. Clinical Research 1985; 33:445A
27) Seigler DE, Reeves ML, Goldberg RB, Lohman VL, Agramonte RF, Ashby MH, Skyler JS: Pharmacokinetics of Ultralente Insulin Preparations.
Diabetes 1985; 34(Suppl 1):61A
28) Boulton AJM, Abouganem D, Penneys NL, Angus E, Skyler JS: A Clinicopathologic Study of Necrobiosis Lipoidica Diabeticorum. Diabetes
1985; 34(Suppl 1):102A
29) Boulton AJM, Kubrusly DB, Gadia M, Quintero LC, Bowker JH, Skyler JS, Sosenko JM: The Etiology and Prognosis of Diabetic Foot Ulceration.
Diabetes Research & Clinical Practice 1985; 1(Suppl 1):S65
30) Schiffrin A, Belmonte M, Sheinvold FL, Rabinovitch A, Skyler J: A Prospective Study of the Natural Course of Beta-Cell Function in InsulinDependent Diabetic Children. Diabetes Research & Clinical Practice 1985; 1(Suppl 1):S499
31) Seigler DE, Reeves ML, Goldberg RB, Lohman VL, Agramonte, RF, Ashby MH, Skyler JS: Pharmacokinetics of Long-Acting (Ultralente) Insulin
Preparations. Diabetes Research & Clinical Practice 1985; 1(Suppl 1):S508
32) Gadia MT, Ayyar DR, Ramos LB, Natori N, Skyler JS, Sosenko JM: The Association Between Diabetic Neurological Dysfunction and Body
Stature. Diabetes 1986; 35(Suppl 1):103A
33) Sosenko JM, Gadia MT, Goldberg RB, Hsia SL, Fournier AM, Skyler JS: The Association Between HDL-2-Cholesterol and Insulin in Nondiabetic
Women. Clinical Research 1986; 34:555A
34) Fournier AM, Gadia MT, Kubrusly DB, Skyler JS, Sosenko JM: Blood Pressure, Insulin and Glycemia in Non-Diabetic Individuals. Clinical
Research 1986; 34:817A
35) Boulton AJM and The Tolrestat Neuropathy Study Group: Effects of Tolrestat, A New Aldose Reductase Inhibitor, on Nerve Conduction and
Paresthetic Symptoms in Diabetic Neuropathy. Diabetologia 1986; 29:521A
36) Seigler DE, Olsson M, Skyler JS: Use of Human Ultralente Insulin in IDDM. Diabetes 1987; 36(Suppl 1):76A
37) Olsson M, Seigler DE, Lohman VL, Agramonte RF, Ashby MH, Skyler JS: Protamine Content Does Not Influence the Pharmacokinetics of Human
NPH Insulin. Diabetes 1987; 36(Suppl 1):132A
38) Seigler DE, Olsson GM, Skyler JS: Morning versus Bedtime NPH Insulin in Type II (Non-Insulin Dependent) Diabetes Mellitus. Diabetologia
1987; 30:581A
39) Skyler JS for the Miami Cyclosporine Diabetes Study Group: Cyclosporine in Insulin Dependent Diabetes Mellitus: Effects on Islet Beta Cell
Function. The Second International Congress on Cyclosporine Abstracts 1987; pg 88
40) Herbst JS, Hirsch IB, Skyler JS: The Effect of Ejaculation on Microalbuminuria. Diabetes 1988; 37(Suppl 1):130A
41) Skyler JS, Rabinovitch A, Fletcher MA, and the Miami Cyclosporine Diabetes Study Group: Increased Activated Macrophage/Monocytes and
Natural Killer Cells At Diagnosis Of Insulin-Dependent Diabetes Mellitus (IDDM). International Congress on Immunointervention in
Autoimmune Diseases Abstracts 1988; Workshop 14
42) Skyler JS, Rabinovitch A, and the Miami Cyclosporine Diabetes Study Group: Islet Beta Cell Function in Insulin-Dependent Diabetes Mellitus
(IDDM) Treated with Cyclosporine (CY). International Congress on Immunointervention in Autoimmune Diseases Abstracts 1988; Workshop 23
43) Skyler JS: Intensive Insulin Therapy - 1988. Third International Symposium on Treatment of Diabetes Mellitus, Nagoya Japan, Program
and Abstracts 1988; pg 36
44) Skyler JS for the Miami Cyclosporine Diabetes Study Group: Cyclosporine in Insulin Dependent Diabetes Mellitus: Effects on Islet Beta Cell
Function. 8th International Congress of Endocrinology Abstracts 1988; pg 506
45) Ireland S, Freeman C, Greco P, Gutt M, Wick P, Skyler JS, LaGreca AM: Diabetes-Specific Coping for Adults with IDDM. Diabetes 1989;
38(Suppl 2):108A
46) Ireland S, LaGreca AM, Agramonte R, Greco P, Freeman C, Gutt M, Skyler JS: Autonomic Neuropathy Among Adults With IDDM: Relationships
With Metabolic Control and Measures of Stress, Anger, and Hostility. Proceedings Society of Behavioral Medicine 1990
47) Peckerman A, Saab PG, McCabe PM, Skyler JS, Winters RW, Schneiderman N: Cold Pressor Pain and Cardiovascular Reactivity During the
Forehead Cold Stimulation Procedure. Proceedings Society of Behavioral Medicine 1990
48) Greco P, LaGreca AM, Ireland S, Freeman C, Gutt M, Agramonte, R, Skyler JS: Components of Diabetes Knowledge as Predictors of Metabolic
Control Among Adults With IDDM. Proceedings Society of Behavioral Medicine 1990
49) Freeman CR, Hurwitz BE, Agramonte RA, Quillian RE, Schneiderman N, Skyler JS: Cardiovascular Response in Type I Diabetics at Rest and in
Response to Autonomic Stimulation. Diabetes 1990; 39(Suppl):184A
Jay S. Skyler
Page 62
Curriculum Vitae
50) Greco P, LaGreca AM, Ireland S, Wick P, Freeman C, Agramonte R, Skyler JS: Assessing Adherence in IDDM: A Comparison of Two Methods.
Diabetes 1990; 39(Suppl):165A
51) Freeman CR, Hurwitz BE, LaGreca AM, Nagel JH, Schneiderman N, Skyler JS: Defects in Autonomic Mediation of Cardiovascular Functioning
in Type I Diabetics. Psychophysiology 1990; 27:S33
52) Quillian RE, Marks JB, Hurwitz BE, Thompson NE, Ansley J, Schneiderman N, Skyler JS: Acute Effects of Induced Hyperinsulinemia on Blood
Pressure & Sympathetic Tone in Healthy Men. Clinical Research 1990; 38:993A
53) Ansley J, Marks JB, Hurwitz BE, Thompson NE, Quillian RE, Olsson-Istel GM, Ashby M, Spitzer S, Fili M, Donahue RDP, Schneiderman N,
Skyler JS: Insulin Resistance and Blood Pressure. Proceedings of Society of Behavioral Medicine 1991; pg 88
54) LaGreca AM, Auslander W, Spetter D, Greco P, Skyler JS, Fisher EB, Santiago JV: Adolescents with IDDM: Family and Peer Support of Diabetes
Care. Proceedings of Society of Behavioral Medicine 1991; pg 110
55) Wick P, LaGreca A, Greco P, Ireland S, Agramonte R, Skyler J: Stress, Social Support, and Adherence: Relationships with Metabolic Control in
Adults with IDDM. Proceedings of Society of Behavioral Medicine 1991; pg 187
72) Marks JB, Hurwitz BE, Ansley J, Quillian RE, Thompson NE, Olsson-Istel GM, Spitzer S, Schneiderman N, Skyler JS: Effects of Induced
Hyperinsulinemia on Blood Pressure & Sympathetic Tone in Healthy Volunteers. Diabetes 1991; 40(Suppl 1):367A
73) Hurwitz BE, Marks JB, Freeman CR, LaGreca AM, Nagel JH, Agramonte RF, Schneiderman N, Skyler JS: Sympathetic Dysfunction Occurs
Early in the Course of Cardiovascular Autonomic Neuropathy. Diabetes 1991; 40(Suppl 1):330A
74) Thompson NE, Marks JB, Hurwitz BE, Quillian RE, Ansley J, Spitzer S, Schneiderman N, Skyler JS: Insulin Resistance Dampens the Acute
Effects of Insulin on Blood Pressure Regulation. Diabetes 1991; 40(Suppl 1):366A
75) LaGreca AM, Hurwitz BE, Freeman CR, Wick P, Ireland S, Agramonte RF, Marks JB, Schneiderman N, Skyler JS: Autonomic Dysfunction in
Adults with IDDM: Implications for Psychosocial Functioning. Diabetes 1991; 40(Suppl 1):431A
76) Wick P, LaGreca AM, Greco P, Ireland S, Agramonte RF, Skyler JS: Stress, Social Support, Adherence, and Metabolic Control in Adults with
IDDM. Diabetes 1991; 40(Suppl 1):538A
77) Greco P, LaGreca AM, Auslander W, Spetter D, Skyler JS, Fisher EB, Santiago JV: Family and Peer Support of Diabetes Care Among
Adolescents. Diabetes 1991; 40(Suppl 1):537A
78) Fisher E, Greco P, Spetter D, Quillian R, Skyler J, LaGreca A: Specific and General Characteristics of Social Support in Diabetes Care:
Relationship with Adherence and Metabolic Control. Diabetes 1991; 40(Suppl 1):538A
79) Schwartz S, Skyler J, Palmer J, Einhorn D, Eisenbarth G, Ma J, Byers V: Treatment of New Onset Type I Diabetes with a Pan T Lymphocyte
Immunoconjugate, H65-RTA. Diabetes 1991; 40(Suppl 1):58A
80) Skyler JS, Byers V, Einhorn D, Eisenbarth G, Lorenz T, Palmer J, Saria E. Schwartz S: Effects of An Anti-CD5 Immunoconjugate (H65-RTA) on
Pancreatic Islet Beta Cell Function in Type I Diabetes Mellitus. Diabetes Research & Clinical Practice 1991; 14(Suppl 1):S54
81) Pass M, Gellman MD, Landel J, LaGreca A, Skyler JS, Schneiderman N: Duration of Type I Diabetes, Metabolic Control, and Depression and
Hostility. Proceedings of Society of Behavioral Medicine 1992
82) Landel J, Gellman MD, Skyler JS, LaGreca A, Schneiderman N: Comparing Casual and Ambulatory Blood Pressure and Heart Rate in Subjects
with Type I Diabetes. Proceedings of Society of Behavioral Medicine 1992
83) Landel J, LaGreca A, Schneiderman N, Skyler JS: Adults with IDDM: The Role of Family Functioning in Diabetes Care. Proceedings of
Society of Behavioral Medicine 1994
84) Donahue RP, Donahue RD, Prineas RJ, Gutt M, Skyler JS, Schneiderman N: Blood Pressure and Insulin Sensitivity in a Biethnic Sample. The
Miami Community Health Study. Circulation Research.
85) Marks JB, Thompson NE, Ironson GH, Durel LA, Yount SE, Gellman M, Garza R, Benight C, Skyler JS, Schneiderman N: Sodium Intake
Affects Blood Pressure in Insulin Resistant Subjects. Diabetes 1994; 43(Suppl 1):100A
86)
DPT-1 Study Group. The Diabetes Prevention Trial of Type I Diabetes (DPT-1). Diabetes 1994; 43(Suppl 1):159A
87) DPT-1 Study Group. The Diabetes Prevention Trial-Type 1 Diabetes (DPT-1): Implementation of Screening and Staging of Relatives. Diabetes
1995; 44(Suppl 1):129A.
88) Schatz D for the DPT-1 Study Group. The Diabetes Prevention Trial-Type 1 Diabetes (DPT-1): Design and Implementation of the Oral Antigen
(Insulin) Protocol. Diabetes 1995; 44(Suppl 1):230A.
89) Skyler JS: Hypertension In Diabetes. American Journal of Hypertension 1995; 8:5A.
90) Skyler JS: Insulin Resistance And Hyperinsulinemia: Which Is The Culprit? Psychosomatic Medicine 1995; 57:64.
Jay S. Skyler
Page 63
Curriculum Vitae
91) DPT-1 Study Group. The Diabetes Prevention Trial-Type 1 Diabetes (DPT-1): Progress Report. Autoimmunity 1995; 21:66.
92) Landel J, Delameter AM, Schneiderman N, Skyler JS: The Medical Team’s Role in Health Outcomes in Gestational Diabetes. Proceedings of
Society of Behavioral Medicine 1996.
93). Landel J, Delameter AM, Schneiderman N, Skyler JS: Adherence Predicts Glycemia in Women with Gestational Diabetes. Proceedings of
Society of Behavioral Medicine 1996.
94). Davis CL, Gutt M, Doherty K, Skyler JS, Marks J, Weber S, Thompson N, Schneiderman N: Postpartum Metabolic Markers of Gestational
Diabetes. Annals of Behavioral Medicine 1996; (International Congress Supplement): S234.
95). Gellman MD, Ironson GH, Marks JB, Spencer S, Czarnecki E, Durel LA, Skyler JS, Schneiderman N: The Relationship Between Insulin
Resistance and Sodium Sensitivity Using Multiple Blood Pressure Measurements. Proceedings of Society of Behavioral Medicine 1996.
96). Marks JB, Weber SL, Miceli GR, Gutt M, Doheny K, Skyler JS: Metformin Does Not Improve Insulin Sensitivity in Insulin Resistant
Normoglycemic Women with Hirsutism. Proceedings of 10th International Congress of Endocrinology 1996; I:564.
97). Gutt M, Marks JB, Weber SL, Doheny K, Davis K, Gallagher CK, Schneiderman N, Skyler JS: Generalized Metabolic Syndrome Found in
Postpartum Women with a History of Diabetes and/or Hypertension. Proceedings of 10th International Congress of Endocrinology 1996; II:881.
98). Motivala SJ, Hurwitz BE, LaGreca AM, Skyler JS, Schneiderman N. Diminished Parasympathetic Cardiac Input Predicts Differences in
Psychosocial Functioning. Proceedings of 4th International Congress of Behavioral Medicine 1996; AD3.
99). Eisenbarth GS, Krischer J, Greenbaum C, Schatz D, Skyler J, for the DPT-1 Study Group. Differential Expression of Autoantibodies by
DQA1*0102,DQB1*0602+ Relatives of The Diabetes Prevention Trial-1 (DPT-1). Autoimmunity 1996; 24(Suppl 1):52.
100). DPT-1 Study Group. The Diabetes Prevention Trial-Type 1 Diabetes (DPT-1): Enrollment Report. Diabetes 1997; 46(Suppl 1):163A.
101). DPT-1 Study Group. Demographics of Relatives Screened and ICA Positive in The Diabetes Prevention Trial-Type 1 Diabetes (DPT-1).
Diabetes 1997; 46(Suppl 1):142A.
102). DPT-1 Study Group. The Diabetes Prevention Trial-Type 1 Diabetes (DPT-1): Progress Report. Diabetologia 1997; 40(Suppl 1):A66.
103). DPT-1 Study Group. The Diabetes Prevention Trial-Type 1 Diabetes (DPT-1): Demographics of Relatives Screened and ICA Positive.
Diabetologia 1997; 40(Suppl 1):A78.
104). Eisenbarth GS, Krischer J, Greenbaum C, Schatz D, Skyler J, for the DPT-1 Study Group. Role of DQA1*0102/DQB1*0602 In Risk
Characterization: The Diabetes Prevention Trial-Type 1 Diabetes (DPT-1). Diabetologia 1997; 40(Suppl 1):A48.
105). Eastman RC, Cowie CC, Harmon J, and the DPT-1 Study Group. Potential Cost-Effectiveness of Primary Prevention of Insulin-Dependent
Diabetes Mellitus. Diabetologia 1997; 40(Suppl 1):A39.
106). Gutt M, Marks JB, Weber SL, Spitzer S, Schneiderman N, Skyler JS: Insulin Sensitivity Measurements: Comparison of Euglycemic Clamp and
Insulin Sensitivity Index Derived from Oral Glucose Tolerance Test. Proceedings of 79th Annual Meeting of The Endocrine Society 1997; 476.
107). Davis, C., Gutt, M., Marks, J., Llabre, M., Schneiderman, N., & Skyler, J. Differences in glucose/insulin metabolism among postpartum
gestational diabetics and normals. Annals of Behavioral Medicine 1997; 19 (Suppl.): S119.
108). Gutt, M., Marks, J., Weber, S., Spitzer, S., Davis, C., Gallaher, C., Schneiderman, N., & Skyler, J. Do gestational women with compromised
cardiovascular risk profiles recover in the postpartum state? Annals of Behavioral Medicine 1997; 19 (Suppl.): S124.
109). Marks JB, Weber SL, Miceli GR, Van Splunteren F, Davis CL, Spitzer S, Schneiderman N, Skyler JS. Metformin Affects Sex Hormone Levels
In Women With Hyperandrogenism Independent Of Effects On Insulin Or Insulin Sensitivity. Diabetes 1998; 47(Suppl 1):A196.
110). Skyler JS, Gelfand RA, Kourides IA, for the Inhaled Insulin Phase II Study Group. Treatment of Type 1 Diabetes Mellitus with Inhaled Insulin:
A 3-Month Multicenter Study. Diabetes 1998; 47(Suppl 1):A61.
111). Cefalu WT, Gelfand RA, Kourides IA, for the Inhaled Insulin Phase II Study Group. Treatment of Type 2 Diabetes Mellitus with Inhaled
Insulin: A 3-Month Multicenter Study. Diabetes 1998; 47(Suppl 1):A61.
112). Cowie C, Cuthbertson D, Krischer J, Wilson D, Maclaren N, and the DPT-1 Study Group. Demographic Characteristics of Islet Cell Antibody
Positivity (ICA+) in The Diabetes Prevention Trial for Type 1 Diabetes (DPT-1). Diabetes 1998; 47(Suppl 1):A146.
113). Greenbaum CJ, Zeidler A, Schatz D, Eisenbarth G, Cuthbertson D, Krischer J, and the DPT-1 Study Group Characteristics of HLA DQA1*0102
DQB1*0602 Relatives Identified in The Diabetes Prevention Trial - Type 1 Diabetes (DPT-1). Diabetes 1998; 47(Suppl 1):A236.
114). Greenbaum CJ, Cuthbertson D, Krischer J, and the DPT-1 Study Group. Undiagnosed Hyperglycemia in Relatives of Type 1 Diabetes Patients.
Diabetes 1998; 47(Suppl 1):A236.
115). Gutt M, Marks JB, Davis CL, Spitzer S, Llabre M, Schneiderman N, Skyler JS: Identifiaction of a Simple Technique to Estimate A Insulin
Sensitivity Index. Proceedings of 80th Annual Meeting of The Endocrine Society 1998.
Jay S. Skyler
Page 64
Curriculum Vitae
116). Hernandez-Cassis C, Marks JB, Hernandez CK, Skyler JS. Insulin secretion Precedes Glucose Rise During a Frequent Sampling Oral Glucose
Tolerance Test. Proceedings of 80th Annual Meeting of The Endocrine Society 1998.
117). Davis, C., Gutt, M., Llabre, M., Marks, J., Gallaher, C., Leo, T., Landel, J., Skyler, J., & Schneiderman, N. Gestational diabetes and CAD risk
factors: It's all about "M". Annals of Behavioral Medicine 1998; 20 (Suppl.), S078.
118). Gallaher, C., Hurwitz, B., Gutt, M., Marks, J., Llabre, M., Skyler, J., Davis, C., Landel, J., Leo, T., Gellman, M., & Schneiderman, N.
Cardiovascular response to stress and insulin metabolic syndrome in gestational diabetes mellitus. Annals of Behavioral Medicine 1998; 20 (Suppl.),
S058.
119). Skyler JS, Gelfand RA, Kourides IA, for the Inhaled Insulin Phase II Study Group. A Three-Month Multicenter Clinical Trial of Therapy with
Inhaled Human Insulin in Type 1 Diabetes Mellitus. Diabetologia 1998; 41(Suppl 1):A45.
120). Cefalu WT, Gelfand RA, Kourides IA, for the Inhaled Insulin Phase II Study Group. A Three-Month Multicenter Clinical Trial of Therapy with
Inhaled Human Insulin in Type 2 Diabetes Mellitus. Diabetologia 1998; 41(Suppl 1):A226.
121). Berger S, Davidson MH, Kourides IA, Landschultz, Gelfand RA, for the Inhaled Insulin Phase II Study Group. Add-On Therapy with Inhaled
Human Insulin in Type 2 Diabetic Patients Failing Oral Agents: Preliminary Results of A Multicenter Trial. Diabetologia 1998; 41(Suppl 1):A226.
122).
Greenbaum CJ, Cuthbertson D, Krischer J, and the DPT-1 Study Group. Silent Type 1 Diabetes. Diabetes 1999; 48:(Suppl 1):A81.
123). Palmer J, Wei, Greenbaum C, Krischer J, Cuthbertson D, and the DPT-1 Study Group. The DPT-1 Intravenous Insulin Suppresses Endogenous
Insulin Secretion But Causes Post-Prandial Glucose Intolerance. Diabetes 1999; 48:(Suppl 1):A295.
124). Yu L, Cuthbertson DD, Maclaren N, Jackson R, Eisenbarth GS, Krischer JP, and the DPT-1 Study Group. Expression of GAD65 or ICA 512
(IA-2) Autoantibodies Amongst Cytoplasmic ICA Positive Relatives is Associated with Eligibility for DPT-1. Diabetes 1999; 48:(Suppl 1):A214.
125). Chase P, Cuthbertson D, Dolan L, Kaufman F, Krischer J, Schatz D, White N, Wilson D, Wolfsdorf J, and the DPT-1 Study Group. First Phase
Insulin Release (FPIR) During the Initial Intravenous Glucose Tolerance Test (IV-GTT) in the Diabetes Prevention Trial (DPT-1). Diabetes 1999;
48:(Suppl 1):A238-239.
126) Kaufman F, Cuthbertson D, Krischer J and the DPT-1 Study Group. HbA1c Corrlatated with Fasting and Postprandial Glucose Levels in
Subjects in the Diabetes Prevention Trial-type 1 (DPT-1). Diabetes 2001; 50(Suppl 1) A96
127) Kaufman F, Rafkin-Mervis L, Ricker A, Wherrett D and the DPT-1 Study Group. Recruitment of Subjects into the Diabetes Prevention TrialType 1 (DPT-1):Strategies and Progress Report from 1994-2000. Diabetes 2001; 50(Suppl 1) A96
128) Skyler JS, for the Exubera Phase III Study Group. Efficacy and Safety of Inhaled Insulin (Exubera) Compared to Subcutaneous Insulin Therapy
in an Intensive Insulin Regimen in Patients with Type 1 Diabetes: Results of a 6-month, Randomized, Comparative Trial. Diabetes 2002; 51(Suppl
2):A134.
129) Hernandez-Cassis CS, Hernandez CK, Solano MP, Marks JB, Skyler JS. The Oro-Enteric Phase of Insulin Secretion and the Effect of an Insulin
Secretagogue in Subjects with Type 2 Diabetes Mellitus. Diabetes 2002; 51(Suppl 2):A568.
130) Skyler JS, for the Exubera Phase III Study Group. Efficacy and Safety of Inhaled Insulin (Exubera) Compared to Subcutaneous Insulin Therapy
in an Intensive Insulin Regimen in Patients with Type 1 Diabetes: Results of a 6-month, Randomised, Comparative Trial. Diabetologia 2002;
45(Suppl 1):A17.
131) Prieto LM, Solano MP, Mintz DH, Skyler JS, Meneghini LF. Predicting Cardiac Autonomic Dysfunction in a Specialized Academic Diabetes
Center. Diabetes 2003; 52(Suppl 1):A487.
132) Redondo MJ, Babu S, Zeidler A, Orban T, Yu L, Cuthbertson D, Eisenbarth GS, Krischer J, Schatz D. Diabetes Prevention Trial (DPT)-1:
Influence of Protective HLA-DQ Alleles and Genotypes on Expression of Autoantibodies (Aab) and Progression to Type 1 Diabetes (T1DM). Diabetes
2004; 53(Suppl 1):A29(125-OR)
133) Sosenko JM, Greenbaum CJ, Palmer JP, Cowie CC, White NH, Cuthbertson DD, Krischer JP, Skyler JS, The DPT-1 Study Group. Fasting
Insulin Secretion Is Maintained More Than Stimulated Insulin Secretion with Progression to Type 1 Diabetes (T1D) in the Diabetes Prevention TrialType 1 (DPT-1). Diabetes 2004; 53(Suppl 1):A425 (1783-P)
134) Skyler J, For The Exubera Phase II Study Group. Sustained Long-Term Efficacy and Safety of Inhaled Insulin during 4 Years of Continuous
Therapy. Diabetes 2004; 53(Suppl 1):A115 (486-P)
135) Rhodes E, Wolfsdorf J, Feldman H, Ludwig D, DPT-1 Study Group. Effect of Low-Dose Insulin Treatment on Body Weight and Adiposity in
Children at Risk of Type 1 Diabetes Mellitus. Diabetes 2004; 53(Suppl 1):A415 (1743-P)
136) Skyler J, For The Exubera Phase II Study Group. Long-term, sustained efficacy and safety of inhaled insulin after 4 years of continuous
therapy. Diabetologia 2004; 47:(Suppl 1):P 863
137) Garcia C, Allende G, Matheson D, Marks J, Sanchez J, Skyler J, Mendez A, Pugliese A. Increased Proportions of Circulating Proins+
Peripheral Antigen Expressing (PAE) Cells in Type 1 Diabetes. Diabetes 2005; 54(Supplement 1): A79 (320-O).
Jay S. Skyler
Page 65
Curriculum Vitae
138) Sosenko JM, Palmer JP, Greenbaum CJ, Cowie CC, Mahon J, Chase HP, White NH, Cuthbertson DD, Krischer JP, Skyler JS, The DPT-1
Study Group. The 2-hr-Glucose and the AUC Glucose-AUC C-Peptide Ratio as Predictors of T1D in Diabetes Prevention Trial-Type 1 (DPT-1)
Participants. Diabetes 2005; 54(Supplement 1): A456 (1897-P).
139) Barker JM, Babu S, Fernando M, Greenbaum C, Mahon J, Skyler JS, Eisenbarth GS, and the TrialNet study group. Low prevalence of
DQA*0102 DQB*0602 subjects with Trialnet Initial Biochemical Autoantibody Screening. Diabetes 2006; 55:(Supplement): A251 (1061-P).
140) Lachin JM, Friedenberg P, Greenbaum C, and Type 1 Diabetes TrialNet. The Mixed Meal Tolerance Test versus the IV Glucagon Stimulation
Test for the Assessment of Beta Cell Function in Type 1 Diabetes. Diabetes 2006; 55:(Supplement): A537 (2325-PO).
141) Skyler JS, Jovanovic L, Klioze S, Reis J, Duggan W. Sustained efficacy and tolerability of inhaled human insulin (Exubera®). Therapy over 2
years: patients with type 1 diabetes. Diabetologia 2006; 49:(Suppl 1): 118.
142) Skyler JS, Krasner A, Klioze S, Schwartz P, Duggan W. Body Weight Changes Associated With Insulin Therapy: A Retrospective Pooled
Analysis of Inhaled Human Insulin (Exubera) Versus Subcutaneous Insulin in 5 Controlled Phase 3 Trials. Diabetic Medicine 2006; 23(suppl 4):958.
143) Hollander P, Skyler J, Jovanovic L, Klioze S, Krasner A, Riese R, Reis J, Schwartz P. Pulmonary Safety Following Discontinuation and
Readministration of Inhaled Human Insulin (Exubera) in Adults with Type 1 Diabetes. Diabetes 2007; 56:(Supplement 1): A125-126 (Abstract 472P).
144) Sosenko JM, Krischer JP, Palmer JP, Mahon J, Cowie C, Greenbaum CJ, Cuthbertson DD, Lachin J, Skyler JS, and the DPT-1 Study Group. A
Risk Score for Type 1 Diabetes Derived from Participants in the Diabetes Prevention Trial-Type 1 (DPT-1). Diabetes 2007; 56:(Supplement 1): A-55
(Abstract 210-0)
145) Herold KC, for the Type 1 Diabetes TrialNet Study Group, the TrialNet Study Group Mechanistic Assay Committee, and the TrialNet T-Cell
Assay Group. Report of the TrialNet T-Cell Validation Study in Type 1 Diabetes. Diabetes 2007; 56:(Supplement 1): A-319 (Abstract 1299-P)
146) Mari A, Ferrannini E, Skyler JS, and the DPT-1 Study Group. Mechanisms of Progression to Diabetes in Relatives of Type 1 Diabetic Patients.
Diabetes 2007; 56:(Supplement 1): A-384 (Abstract 1499-P)
147) Sosenko JM, Wherrett D, Rafkin-Mervis L, Palmer JP, Skyler JS, and the DPT-1 Study Group. Metabolic Characteristics of Converters to ICA
Positivity in the Diabetes Prevention Trial-Type 1 (DPT-1). Diabetes 2007; 56:(Supplement 1): A-482 (Abstract 1907-P)
148) Mahon J, Sosenko J, Lachin J, Krause-Steinrauf H, Rafkin-Mervis L, Eisenbarth G, Palmer J, Thompson C, Skyler J,for the Type 1 Diabetes
TrialNet Study Group. The Prevalence of Glucose Tolerance Abnormalities According to Autoantibody Number in the Type 1 Diabetes TrialNet
Natural History Study. Diabetes 2007; 56:(Supplement 1): A-486 (Abstract 1922-P)
149) Chase HP, Asare S, Greenbaum C, Lachin J, Lescheck E, Krause-Steinrauf H, Rafkin-Mervis L, Clare-Salzler M, for the Type 1 Diabetes
TrialNet NIP Study Group. Nutritional Intervention to Prevent (NIP) Type 1 Diabetes. Diabetes 2007; 56:(Supplement 1): A-689 (Abstract 2723-PO)
150) Krischer JP for the Type 1 Diabetes TrialNet Oral Insulin Study Group. Oral Insulin For the Prevention Of Diabetes In Relatives At Risk For
Type 1 Diabetes Mellitus (T1DM). Diabetes 2007; 56:(Supplement 1): A-699 (Abstract 2764-PO)
151) Skyler J, Hollander P, Jovanovic L, Klioze S, Krasner A, Riese R, Reis J, Schwartz P. Discontinuation and readministration of inhaled human
insulin (Exubera®) in adults with type 1 diabetes: 3-year pulmonary safety data. Diabetologia 2007; 50:(Supplement 1): S-400-401.
152) Mahon J, Sosenko JM, Lachin J, Krause-Steinrauf H, Rafkin-Mervis L, Eisenbarth GS, Palmer JP, Thompson C, and The Type 1 Diabetes
TrialNet Study Group. The Prevalence of Glucose Tolerance Abnormalities According to Autoantibody Number in the Type 1 Diabetes TrialNet
Natural History Study. Acta Diabetologia 2007; 44:(Supplement 1): S 30.
153) Herold K for the Mechanistic Outcomes Committee and the Type 1 Diabetes TrialNet Study Group. Report from TrialNet: Diagnostic Accuracy
and Reproducibility of T-Cell Responses to Islet Antigens in Subjects with Recently Diagnosed Type 1 Diabetes. Acta Diabetologia 2007;
44:(Supplement 1): S 21.
154) Sosenko JM, Rafkin-Mervis L, Mahon J, Lachin J, Krause-Steinrauf H, Krischer J, Cuthbertson D, Palmer JP, Skyler JS, and the DPT-1 and Type
1 Diabetes TrialNet Study Groups. Comparison Between Participants of the TrialNet Natural History Study and Participants of the Diabetes prevention
Trial-Type 1. Acta Diabetologia 2007; 44:(Supplement 1): S 50.
155) Sosenko JM, Palmer JP, Rafkin-Mervis L, Krischer J, Cuthbertson D, Matheson D, Skyler JS, and the DPT-1 Study Group. Glucose and CPeptide Changes in the Peri-onset Period of Type 1 Diabetes in the Diabetes Prevention Trial – Type 1 (DPT-1). Acta Diabetologia 2007;
44:(Supplement 1): S 49-50.
156) Ferrannini E, Nofrate V, Skyler JS, Mari A, for the DPT-1 Study Group. Progression to diabetes in relatives of people with type 1 diabetes:
predictors and mode of onset. Diabetes 2008; 57:(Supplement 1): A-45 (Abstract 150-OR).
157) Sosenko JM, Rafkin-Mervis L, Mahon J, Lachin J, Krause-Steinrauf H, Krischer J, Cuthbertson D, Palmer JP, Thompson C, Skyler JS, and the
Diabetes Prevention Trial-Type 1 Diabetes (DPT-1) and Type 1 Diabetes TrialNet Study Groups. Comparisons of OGTT Indices between Participants
of the TrialNet Natural History Study and Participants of the Diabetes Prevention Trial-Type 1. Diabetes 2008; 57:(Supplement 1): A-264 (Abstract
914-P).
Jay S. Skyler
Page 66
Curriculum Vitae
158) Sosenko JM, Palmer JP, Rafkin-Mervis L, Krischer J, Cuthbertson D, Skyler JS, and the DPT-1 Study Group. Incident Post-Challenge
Dysglycemia as a Predictor of Type 1 Diabetes in the Diabetes Prevention Trial-Type 1 (DPT-1). Diabetes 2008; 57:(Supplement 1): A-66 (Abstract
228-OR).
159) Sosenko JM, Palmer JP, Rafkin-Mervis L, Krischer J, Cuthbertson D, Matheson D, Skyler JS, and the DPT-1 Study Group. The Loss of PostChallenge C-Peptide Levels in the Peri-Onset Period of Type 1 Diabetes in the Diabetes Prevention Trial-Type 1 (DPT-1). Diabetes 2008;
57:(Supplement 1): A-502 (Abstract 1810).
160) Triolo TM, Chase HP, Barker JM, and the DPT-1 Study Group. Subjects Diagnosed with Diabetes through the Diabetes Prevention Trial Type 1
(DPT-1) are Often Asymptomatic and Have Rare Ketosis at Onset. Diabetes 2008; 57:(Supplement 1): A-501-502 (Abstract 1807).
161) Hernandez-Cassis C, Casanova-Romero P, Florez H, Gomez O, Skyler JS. The four time-point oral glucose tolerance test, the predictive value of
30 and 60 minutes for diagnosis of impaired glucose tolerance and type 2 diabetes mellitus. Endocrine Society Proceedings 2008.
162) Sosenko J, Palmer J, Rafkin-Mervis L, Krischer J, Cuthbertson D, Greenbaum C, Skyler JS, The DPT-1 Study Group. The Timing of the Peak CPeptide and Its Prediction of Type 1 Diabetes in the Diabetes Prevention Trial-Type 1 (DPT-1). Diabetes 2009; 58: (Supplement 1): Abstract 22-OR.
163) Pescovitz MD, Torgerson TR, Ochs HD, Ocheltree E, Mcgee P, Krause-Steinrauf H, for the Type 1 Diabetes Trial Network (TrialNet). In Vivo
Immune Responses in Type 1 Diabetes Following Treatment with Rituximab. Diabetes 2009; 58: (Supplement 1): Abstract 195-OR.
164) Jeffrey J, Eisenbarth GS, Fain PR, Yu L, Miao D. Persistent but Not Transient Biochemical Islet Autoantibody Expression Is Increased in
Prospectively Followed Monozygotic Versus Dizygotic Twins. Diabetes 2009; 58: (Supplement 1): Abstract 1141-P.
165) Sosenko J, Palmer J, Rafkin-Mervis L, Krischer J, Cuthbertson D, Greenbaum C, Skyler JS, The DPT-1 Study Group. Trends of Earlier and Later
C-Peptide Responses to Oral Glucose with Progression to Type 1 Diabetes in the Diabetes Prevention Trial-Type 1 (DPT-1). Diabetes 2009; 58:
(Supplement 1): Abstract 1801-P.
166) Gottlieb P, Colman PG, Kipnes M, Ratner R, Aroda V, Rendell M, Gerstman M, Zemel L, Dunn P, Hays R, Heazlewood V, Baker J, Scott R,
Davis T, Greenbaum C, Krebs J, Norwood P, Ovalle F, Raskin P, Skyler JS, Quan J, Solvason N, Roep B, Harrison LC, Eisenbarth G, Steinman L,
Garren H. Interim Results of a Phase I/II Clinical Trial of a DNA Plasmid Vaccine (BHT-3021) for Type 1 Diabetes. Diabetes 2009; 58: (Supplement
1): Abstract 114-OR.
167) Vehik K, Haller MJ, Xu P, Schatz DA, Krischer J, DPT-1 Study Group. Seroconversion in the DPT-1 Study: evidence of triggering of
autoimmune process at different ages. Diabetologia 2009; 52:(Supplement 1)S 119 (Abstract 277).
168) Pescovitz MD, McGee P, Krause-Steinrauf H, Canniff J, Weinberg A, Skyler JS, and Type 1 Diabetes TrialNet Study Group. Human in vivo De
Novo and Recall Antibody Responses after Rituximab Treatment for Type 1 Diabetes. FOCiS 2010.
169) Vehik K, Beam CA, Haller MJ, Sosenko JM, Schatz DA, Mahon JL, Krischer JP, Skyler JS, for the Type 1 Diabetes TrialNet Study Group.
Development of Autoantibodies in the TrialNet Natural History Study. Diabetes 2010; 53:(Supplement 1): Abstract 213-OR.
170) Ferrannini E, Mari A, Nofrate V, Krischer JP, Sosenko JM, Skyler JS, for the DPT-1 Study Group. Prediction of Diabetes in Relatives of People
with Type 1 Diabetes: Role of Clinical Testing. Diabetes 2010; 53:(Supplement 1): Abstract 236-OR.
171) Sosenko JM, Skyler JS, Krischer JP, Greenbaum CJ, Rafkin-Mervis L, Mahon J, Cuthbertson D, Palmer JP, and The DPT-1 Study Group.
Transient Diabetic Range Oral Glucose Tolerance Tests and Their Possible Relation to Insulin Sensitivity Prior to the Diagnosis of Type 1 Diabetes in
the Diabetes Prevention Trial Type-1 (DPT-1). Diabetes 2010; 53:(Supplement 1): Abstract
172) Sosenko JM, Skyler JS, Palmer JP, Krischer JP, Cuthbertson D, Yu L, Schatz DA, Orban T, Eisenbarth GS, and The DPT-1 Study Group.
Quantitative Changes in ICA512 and GAD65 Autoantibodies with Progression to Type 1 Diabetes in the Diabetes Prevention Trial-Type 1 (DPT-1).
Diabetes 2010; 53:(Supplement 1): Abstract 68-OR.
173) Chase HP, Boulware D, Krischer JP, Daniels M, Nathan B, Chritton S, Muller S, Clare-Salzler M, and the TrialNet Nutritional Intervention to
Prevent (NIP) Diabetes Study Group. Vitamin D and Inflammatory Cytokine Levels in Infants at High Genetic Risk for Type 1 Diabetes. Diabetes
2010; 53:(Supplement 1): Abstract
174) Chase HP, Boulware D, Krischer JP, Rodriguez H, Donaldson D, Chritton S, Muller S, Clare-Salzler M, and the TrialNet Nutritional
Intervention to Prevent (NIP) Diabetes Study Group. Inflammatory Cytokines in the Pre-Autoimmune Phase of Type 1 Diabetes. Diabetes 2010;
53:(Supplement 1): Abstract
175) Pescovitz MD, Krischer JP, Bundy B, Rodriguez H, Greenbaum CJ, Skyler JS, and The Type 1 Diabetes TrialNet Anti-CD20 Study Group.
Preservation of beta-cell function by B-lymphocyte depletion with rituximab- 2-year results. Diabetes 2010; 53:(Supplement 1): Abstract
176) Gottlieb P, Colman PG, Solvason N, Otto K, Roep B, Harrison LC, Eisenbarth G, Robinson W, Utz PJ, Steinman L, Garren H, Quan J, for the
BHT-3021 Study Group. One-Year Results from a Phase 1/2 Clinical Trial of BHT-3021, a DNA Plasmid Vaccine for Type 1 Diabetes. Diabetes
2010; 53:(Supplement 1): Abstract
177) Sosenko J, Skyler J, Mahon J, Krischer J, Greenbaum C, Rafkin L, Beam C, Boulware D, Matheson D, Cuthbertson D, Eisenbarth G, Palmer J,
Diabetes Prevention Trial-Type 1/TrialNet Study Groups. The Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for Identifying
Normoglycemic Subjects at High Risk for Type 1 Diabetes. Diabetes 2011; 60: (Suppl 1): Abstract 0158-OR.
Jay S. Skyler
Page 67
Curriculum Vitae
178) Yu L, Mahon J, Boulware D, Hutton J, Wenzlau J, Greenbaum C, Bingley P, Beam C, Krischer J, Sosenko J, Eisenbarth G, for the Type 1
Diabetes TrialNet Study Group. Zinc Transporter 8 Autoantibodies and Diabetes Risk in the TrialNet Natural History Study. Diabetes 2011; 60:
(Suppl 1): Abstract 0260-OR.
179) Long SA, Sanda S, Buckner JH, Bollyky JB, Goland R, Bianchine P, Phippard D, Ehlers M, Greenbaum C, ITN and TrialNet Study Groups.
Rapamycin Plus IL-2 Combination Therapy in Subjects with T1D Results in a Sustained Increase in IL-2 Responsiveness and a Transient Decrease in
C-Peptide Levels. Diabetes 2011; 60: (Suppl 1): Abstract 0332-OR.
180) McGee P, Krause-Steinrauf H, Greenbaum C, Pescovitz M, Herold K, Spain LM, Palmer JP, Skyler JS, and Lachin JM, for the Type 1 Diabetes
TrialNet Study Group. Selection of a Biological Response Criterion for Evaluation of Treatment Efficacy in Trials of New-Onset Type 1 Diabetes.
Diabetes 2011; 60: (Suppl 1): Abstract 437-P.
181) Johnson SB, Rafkin LE, Boulware D, Pescovitz M, and the Type 1 Diabetes TrialNet Study Group. Participant and Parent Experiences in a
Rituximab Trial to Preserve Beta Cell Function. Diabetes 2011; 60: (Suppl 1): Abstract 848-P.
182) Buckingham B, Buckingham J, Uttarwar A, Slover R, Messer L, Xing, D, Ruedy K, for the DirecNet and TrialNet Study Groups. The Accuracy
of the GlucoScout ® Blood Glucose Monitor in Inpatient Monitoring of Patients with Type 1 Diabetes. Diabetes 2011; 60: (Suppl 1): Abstract 0869-P
183) Buckingham B, Wilson D, Weinzimer S, Sherr J, Block J, Slover R, Chase P, Cantwell M, DiMeglio L, Bremer A, Ruedy K, Xing, D, and
DirecNet and Type 1 Diabetes TrialNet Study Groups. Use of A Hybrid Closed-Loop to Restore Metabolic Control at the Onset Of Diabetes. Diabetes
2011; 60: (Suppl 1): Abstract 0873-P
184) Sosenko J, Skyler J, Mahon J, Krischer J, Greenbaum C, Rafkin L, Matheson D, Cowie C, Beam C, Boulware D, Cuthbertson D, Palmer J,
Diabetes Prevention Trial-Type 1/TrialNet Study Groups. The OGTT Index as an Indicator of the pre-Diabetic State of Type 1 Diabetes in Children.
Diabetes 2011; 60: (Suppl 1): Abstract 1214-P.
185) Vehik K, Beam CA, Boulware D, Schatz DA, Krischer JP, and Type 1 Diabetes TrialNet Study Group. Autoantibody Reversion in the TrialNet
Natural History Study. Diabetes 2011; 60: (Suppl 1): Abstract 1286-P.
186) Jeffrey J, Yu L, Steck AK, Hays B, Eisenbarth GS, Fain PK, and Type 1 Diabetes TrialNet Study Group. Transient Autoantibody Positivity in
TrialNet Twins. Diabetes 2011; 60: (Suppl 1): Abstract 1394-P.
187) Wherrett DK, for Type 1 Diabetes TrialNet Study Group. Rapid Enrollment to GAD65-Alum Trial in Recent-Onset Type 1 Diabetes Including
Subjects as Young as Age 3. Diabetes 2011; 60: (Suppl 1): Abstract 2542-PO.
188) Faleo G, Fotino C, Bocca N, Molano RD, Zahr-Akrawi E, Molina J, Villate S, Umland O, Bayer AL, Skyler JS, Ricordi C, Pileggi A. Prevention
of Autoimmune Diabetes and Induction of β-Cell Proliferation in NOD Mice by Hyperbaric Oxygen Therapy. Diabetes 2011; 60: (Suppl 1): Abstract
1470-P.
189) Buse JB, Garg SK, Skyler JS, Vaughn DE, Muchmore DB. Comparison of Human Hyaluronidase + Recombinant Human Insulin (RHI) vs.
Insulin Lispro in a Basal-Bolus Regimen in Patients with Type 1 Diabetes (T1DM). Diabetes 2011; 60: (Suppl 1): Abstract 0069-OR
190) Garg SK, McGill JB, Rosenstock J, Hirsch IB, Petrucci RE, Chang P-C, Boss AH, Richardson PC, Skyler JS. Technosphere® Insulin vs Insulin
Lispro in Patients with Type 1 Diabetes Using Multiple Daily Injections. Diabetes 2011; 60: (Suppl 1): Abstract 0917-P.
191) Buckingham BA, Slover RH, Weinzimer SA, Dimeglio LA, Bremer A, Cantwell M, Xing D, Ruedy K, Diabetes Research In Children Network
(DIRECNET), TrialNet Study Group. Effect of a Hybrid Closed-Loop (HCL) on Restoring Metabolic Control at the Onset of Diabetes. Diabetes
2012; 61: (Suppl 1): Abstract 891-P.
192) Pugliese A, Boulware D, Babu S, Steck AK, Beam CA, Becker DJ, Eisenbarth GS, Greenbaum C, and The Type 1 Diabetes TrialNet Study
Group. The HLA-DR2, DQB1*0602 Haplotype is Associated with Lack of Disease Progression and Lower Autoantibody Prevalence in the TrialNet
Natural History Study. Diabetes 2012; 61: (Suppl 1): Abstract 360-OR.
193) Orban T, Type 1 Diabetes TrialNet Abatacept Study Group. Co-Stimulation Modulation with Abatacept in Patients with Recent-Onset Type 1
Diabetes; A Follow up Study at 3 Years. Diabetes 2012; 61: (Suppl 1): Abstract 150-LB.
194) Sosenko J, Skyler J, Eisenbarth GS, Krischer J, Yu L, Mahon J, Beam CA, Boulware D, Rafkin L, Schatz DA, Palmer J, Type 1 Diabetes TrialNet
Study Group. The Prediction of Type 1 Diabetes by Multiple Autoantibody Levels and Their Incorporation into an Autoantibody Risk Score in the
TrialNet Natural History Study. Diabetes 2012; 61: (Suppl 1): Abstract 202-OR.
195) Sosenko J, Skyler J, Krischer J, Herold KC, Greenbaum C, Rafkin L, Cuthbertson D, Palmer J, Diabetes Prevention Trial-Type 1 Study Group,
Type 1 Diabetes TrialNet Study Group. Characteristic Insulin Secretion Patterns Persist at the Diagnosis of Type 1 Diabetes in the Diabetes Prevention
Trial-Type 1 (DPT-1). Diabetes 2012; 61: (Suppl 1): Abstract 1256-P.
196) Beam CA, Gitelman SE, Herold KC, Krischer J, Type 1 Diabetes TrialNet Study Group. Diabetes 2012; 61: (Suppl 1): Abstract 2368-PO.
197) Hirsch IB, Skyler J, Garg S, Blevins T, Vaughn DE, Muchmore DB. Human Hyaluronidase + Rapid Analog Insulin (RAI) Improves Postprandial
Glycemic Control in Type 1 Diabetes Compared to Insulin Lispro Alone. Diabetes 2012; 61: (Suppl 1): Abstract 353-OR.
198) Skyler J, Garg S, Hirsch IB, Blevins T, Vaughn DE, Muchmore DB. Human Hyaluronidase + Rapid Analog Insulin (RAI) Improves Postprandial
Glycemic Control in Type 1 Diabetes Compared to Insulin Lispro Alone. Diabetologia 2012; 55: (Suppl 1): Abstarct 41, pages S22-S23.
Jay S. Skyler
Page 68
Curriculum Vitae
199) Sosenko JM, Skyler JS, Dimeglio LA, Krischer JP, Beam CA, Rafkin L, Matheson D, Palmer JP, Diabetes Prevention Trial-Type 1 and TrialNet.
A Potential New Diagnostic Index for Type 1 Diabetes. Diabetes 2013; 62: (Suppl 1): Abstract 1316-P
200) Sosenko JM, Skyler JS, Krischer JP, Beam CA, Rafkin L, Palmer JP, Diabetes Prevention Trial-Type 1 and TrialNet. The Loss of the First-Phase
Insulin Response (FPIR) Accelerates During the Progression to Type 1 Diabetes. Diabetes 2013; 62: (Suppl 1): Abstract 352-OR
201) Boyle P, Boniol M, Koechlin A, Bota M, Robertson C, Pizot C, Skyler J, Bolli GB, Rosenstock J, Autier P. Safety of Glucose-Lowering
Medications: The Diabetes Adverse Event Monitor (DIABAMON) Project: II Cardiovascular Disease. Diabetes 2013; 62: (Suppl 1): Abstract 1405-P
202) Fotino C, Faleo G, Molano RD, Bocca N, Zahr-Akrawi E, Skyler J, Ricordi C, Bayer AL, Pileggi A. Anti-CD3 and Hyperbaric Oxygen Therapy
(HOT) to Halt Autoimmune Diabetes Onset in NOD Mice. Diabetes 2013; 62: (Suppl 1): Abstract 1705-P
203) Pugliese A, Boulware D, Babu S, Marks JB, Schatz DA, Dimeglio LA, Harrison LC, Greenbaum C, Becker DJ, Steck AK, Rodriguez H, and The
Type 1 Diabetes TrialNet Study Group. The High Risk HLA DR4-DQB1*03:02 Haplotype is Associated with Increased Progression to T1D in
Relatives with a Single Autoantibody Specificity. Diabetes 2013; 62: (Suppl 1): Abstract 128-OR
204) Pugliese A, Skyler J, Palmer J, Beam C, Boulware D, Sosenko J, TrialNet and Diabetes Prevention Trial-Type 1 Study Groups. The Influence of
the DQB1*0602 Allele on Predictors of Type 1 Diabetes (T1D) in the TrialNet Natural History Study TNNHS). Diabetes 2014; 63: (Suppl 1):
Abstract 26-OR
205) Sosenko J, Skyler J, Beam C, Boulware D, Mahon J, Krischer J, Greenbaum C, Rafkin L, Matheson D, Palmer J, TrialNet and Diabetes
Prevention Trial Type 1 Study Groups. A Progression Scale for Assessing the Change in Glucose over 6 Months in Individuals at Risk for Type 1
Diabetes (T1D). Diabetes 2014; 63: (Suppl 1): Abstract 1221-P
206) DiMeglio LA, Cheng P, Beck R, Kollman C, Ruedy K, Buckingham B, Weinzimer S, Slover R, Bremer A, Aye T for the DirecNet and TrialNet
Study Groups. Early Predictors of Stimulated C-peptide in Persons with Type 1 Diabetes (T1D). Diabetes 2014; 63: (Suppl 1): Abstract 1503-P
207) Buckingham B, Cheng P, Beck R, Kollman C, Ruedy K, Weinzimer S, Slover R, Bremer A, Tamborlane W, Fuqua J for the DirecNet and
TrialNet Study Groups. Relationship of Glycemic Control and C-peptide Levels 2 Years Following Diagnosis of T1D. Diabetes 2014; 63: (Suppl 1):
Abstract 1504-P
208) Chaudhry ZZ, Watkins RA, Beam C, Guindon L, Mirmira RG, Blum J, DiMeglio L, Evans-Molina C, and the Type 1 Diabetes TrialNet Study
Group. The Proinsulin/C-peptide Ratio and HSP90: Potential Biomarkers for Early Detection of Type 1 Diabetes. American Diabetes Association
74th Annual Meeting 2014; Late Breaking Abstract 149-LB.
209) Pugliese A, Boulware D, Beam C, Babu S, Marks J, Schatz D, DiMeglio L, Evans-Molina C, Harrison L, Greenbaum C, Becker D, Steck A,
Rodriguez H, and the Type 1 Diabetes TrialNet Study Group. HLA-DRB1-DQB1 Haplotypes/Genotypes Influence Progression to Type 1 Diabetes
(T1D) in Autoantibody-Positive Relatives. Diabetes 2014; 63: (Suppl 1): Abstract 271-OR
210) Skyler JS, Fonseca V, Rosenstock J, for the MSB-DM003 Investigators. Effects of Allogeneic Mesenchymal Precursor Cells in Type 2 Diabetes:
A Randomized, Placebo-Controlled Study. American Diabetes Association 74th Annual Meeting 2014; Late Breaking Abstract 123-LB.
211) Skyler JS, Bode B, Hirsch IH, Buse JB, Garg SK, Vaughn DE, Wu XY, Muchmore DB. Recombinant human hyaluronidase pretreatment of CSII
cannula sites provides comparable glycaemic control with reduced hypoglycaemia in T1DM compared to usual CSII. Diabetologia 2014; 57:
Supplement: S70 (abstract 149).
212) Bizzotto R, Hurwitz BE, Schneiderman N, Marks JB, Mendez AJ, Gonzalez A, Gonzalez N, Llabre MM, Santini E, Skyler JS, Mari A, Ferrannini
E. Adaptation of beta cell response to carbohydrate loading: influence of insulin resistance. Diabetologia 2014; 57: Supplement: S210 (abstract 504).
213) Sosenko JM, Skyler JS, Pugliese A, Krischer JP, Greenbaum CJ, Boulware D, Rafkin L, Palmer JP, Type 1 Diabetes Trialnet Study Group.
Abnormal Glucose Tolerance in Young, Non-Obese Autoantibody Negative Relatives of Patients with Type 1 Diabetes (T1D). Diabetes 2015;
64(Suppl 1):Abstract 358-OR, page A93.
214) Davies JD, Robertson HK, Moya R, Koziol J and the TrialNet Type 1 Diabetes Study Group. CD25 Expression on Non-Treg CD4+ T Cells is
Associated with Duration of the Honeymoon Period in Children with Type 1 Diabetes. Diabetes 2015; 64(Suppl 1):Abstract 229-O, page A60.
215) Bayer AL, Lanzoni G, Umland O, Agostini L, Skyler JS, Matheson D, Inverardi L, Fraker C. Innate Immunity Inhibition in Type 1 Diabetes:
Latent Viral Hypothesis in he Etiology of Autoimmunity. Diabetes 2015; 64(Suppl 1):Abstract 1836-P, page A474.
216) Jossan P, Zaitlen N, Sanda S; for the Type 1 Diabetes TrialNet Study Group. Clinical and Genetic Predictors of Residual Insulin Secretion
in New-Onset Type 1 Diabetes. Diabetes 2015; 64(Suppl 1):Abstract 1741-P, page A452.
217) Fouts A, Pyle L, Yu L, Miao D, Michels A, Krischer J, Sosenko J, Gottlieb P, Steck AK and the Type 1 Diabetes TrialNet Study Group. Factors
Involved in Predicting Time to Type 1 Diabetes in Antibody Positive TrialNet Subjects. Diabetes 2015; 64(Suppl 1):Abstract 1722-P, page
A447.
218) Sosenko JM, Yu L, Skyler JS,Steck A, Gottlieb PA, Boulware D, Palmer JP, Diabetes Type 1TrialNet Study Group.
Electrochemiluminescence (ECL) Assays for Predicting Progression to Type 1 Diabetes (T1D) in Single-Autoantibody-Positive Individuals.
Diabetes 2015; 64(Suppl 1):Abstract 2649-PO, page A669.
219) DiMeglio L. Who is not Returning? Retention of Recruited Subjects in the Type 1 Diabetes TrialNet Pathway to Prevention (PTP).
American Diabetes Association 75th Annual Meeting 2015; Late Breaking Abstract 187-LB.
Jay S. Skyler
Page 69
Curriculum Vitae
220) Meah F, Xu P, DiMeglio LA, Sosenko JM, Geyer S, Evans-Molina C, and the Type 1 Diabetes TrialNet Study Group. HOMA2beta is
Predictive of the Development of Type 1 Diabetes in TrialNet Pathway to Prevention Participants. American Diabetes Association 75th Annual
Meeting 2015; Late Breaking Abstract 145-LB.